geneid;symbol;diseaseid;disease_name;score;association_type;original_source;sentence;pmid;pmid_year
3606;IL18;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"This study shows for the first time an association between <span class=""gene"" id=""17688413-9-59-64"">IL-18</span> gene promoter -137 G/C polymorphism and <span class=""disease"" id=""17688413-9-105-120"">prostate cancer</span> in a Chinese population.";17688413;2007
4846;NOS3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The present study aimed at evaluating the <span class=""gene"" id=""16458450-3-42-47"">ecNOS</span> Glu-298-Asp polymorphism by the PCR-RFLP technique, associating genotypes with gene expression levels and the tumor biomarker, <span class=""disease"" id=""16458450-3-175-190"">Prostate Cancer</span> Antigen (DD3), through semi-quantitative RT-PCR.";16458450;2006
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results suggest that in a European-American population, CDKN1A and <span class=""gene"" id=""12727815-11-73-79"">CDKN1B</span> variants are associated with advanced <span class=""disease"" id=""12727815-11-118-133"">prostate cancer</span>.";12727815;2003
2192;FBLN1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Expression of <span class=""gene"" id=""17929269-3-14-19"">FBLN1</span> (major splice forms C and D), FBLN4, FBLN5, SPOCK1, and TENC was compared between 47 <span class=""disease"" id=""17929269-3-105-120"">prostate cancer</span> samples and 13 benign prostatic tissues by quantitative RT-PCR.";17929269;2008
3728;JUP;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1317;SLC31A1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Furthermore, we determined that <span class=""disease"" id=""25320179-8-32-47"">prostate cancer</span> cells express high levels of <span class=""gene"" id=""25320179-8-77-81"">CTR1</span>, the primary copper transporter, and additional chaperones that are required to maintain intracellular copper homeostasis.";25320179;2014
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We identified hypermethylation of the ssDNA-binding protein 2 (<span class=""gene"" id=""18559593-2-63-68"">SSBP2</span>) promoter as a potential DNA marker for human <span class=""disease"" id=""18559593-2-115-130"">prostate cancer</span> based on previous bioinformatics results and pharmacologic unmasking microarray.";18559593;2008
1636;ACE;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The risk of <span class=""disease"" id=""17465223-8-12-27"">prostate cancer</span> development, the PSA level and tumor metastasis may be associated with genetic variation in the <span class=""gene"" id=""17465223-8-124-129"">ACE I</span>/D genotypes which may be used as an important biomarker for further studies.";17465223;2007
2115;ETV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Here we explore the mechanism of <span class=""gene"" id=""17671502-3-33-37"">ETV1</span> outlier expression in human prostate tumours and <span class=""disease"" id=""17671502-3-87-102"">prostate cancer</span> cell lines.";17671502;2007
4878;NPPA;C0376358;Malignant neoplasm of prostate;0,3;Therapeutic;CTD_human;Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells.;18225537;2008
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Herein, we examined single nucleotide polymorphic variants in the 3'-untranslated region of CDKN1A (p21(cip1)) and in codon 109 of <span class=""gene"" id=""12727815-3-131-137"">CDKN1B</span> (p27(kip1)) for association with advanced <span class=""disease"" id=""12727815-3-180-195"">prostate cancer</span> in a European-American population.";12727815;2003
4824;NKX3-1;C0376358;Malignant neoplasm of prostate;0,54;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
6715;SRD5A1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;[Dutasteride in the treatment of hormone refractory prostate cancer].;18500220;2008
23411;SIRT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"We recently demonstrated that <span class=""gene"" id=""21062352-1-30-35"">Sirt1</span>, a NAD(+) -dependent histone deacetylase, was overexpressed in <span class=""disease"" id=""21062352-1-99-114"">prostate cancer</span> (<span class=""disease"" id=""21062352-1-116-119"">PCa</span>) and its inhibition resulted in a significant antiproliferative response in human <span class=""disease"" id=""21062352-1-202-205"">PCa</span> cells.";21062352;2011
8644;AKR1C3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"For <span class=""disease"" id=""18306354-11-4-19"">prostate cancer</span>, the best two-gene interaction included genotypes SRD5A2 V89L GG and <span class=""gene"" id=""18306354-11-89-95"">AKR1C3</span> Q5H CC with OR 1.30, 95% CI 1.01-1.66.";18306354;2008
8000;PSCA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our data demonstrate that CAA for <span class=""disease"" id=""16015594-12-34-49"">prostate cancer</span> can suppress <span class=""gene"" id=""16015594-12-63-67"">PSCA</span> mRNA expression with a tumor grade dependence and the increased expression of <span class=""gene"" id=""16015594-12-146-150"">PSCA</span> mRNA after CAA may be a clinically adverse predictor for tumor recurrences or distant metastases.";16015594;2006
148327;CREB3L4;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
1775;DNASE1L2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
7432;VIP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""19189304-0-0-29"">Vasoactive intestinal peptide</span> behaves as a pro-metastatic factor in human <span class=""disease"" id=""19189304-0-74-89"">prostate cancer</span> cells.";19189304;2009
4193;MDM2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association between polymorphisms of TP53 and <span class=""gene"" id=""20875869-0-46-50"">MDM2</span> and <span class=""disease"" id=""20875869-0-55-70"">prostate cancer</span> risk in southern Chinese.";20875869;2010
6820;SULT2B1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens.;2260966;1991
8829;NRP1;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"In patients bearing the <span class=""gene"" id=""18670643-4-24-30"">FGFR-4</span> Gly(388) variant, expression of Huntingtin-interacting protein 1 (HIP1), which occurs in more than half of human <span class=""disease"" id=""18670643-4-144-160"">prostate cancers</span>, also results in <span class=""gene"" id=""18670643-4-178-184"">FGFR-4</span> stabilization.";18670643;2008
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Androgen-dependent <span class=""disease"" id=""14633711-5-19-34"">prostate cancer</span> cell lines (LNCaP) and non-prostate origin tumor cell lines (SNU449, MCF-7, HCT116, OVCAR-3, and Panc-1) were infected with the viral constructs, and perchlorate-sensitive (125)I uptake and <span class=""gene"" id=""14633711-5-225-228"">NIS</span> protein expression were measured.";14633711;2004
81567;TXNDC5;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as <span class=""gene"" id=""17199135-3-98-129"">thioredoxin domain containing 5</span> , tumor necrosis factor receptor superfamily, member 10a , ribosomal protein S19 and Janus kinase 2 upregulated in AI <span class=""disease"" id=""17199135-3-248-263"">prostate cancer</span>, could play important roles in the transition from AD to AI and could be biomarkers of prognosis.";17199135;2007
8086;AAAS;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
7113;TMPRSS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.;28783165;2017
9687;GREB1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;GREB1 is a novel androgen-regulated gene required for prostate cancer growth.;16496412;2006
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Serum <span class=""gene"" id=""16984552-4-6-10"">HER2</span> levels were assessed in the <span class=""disease"" id=""16984552-4-39-54"">prostate cancer</span> patients prior to treatment as well as in a control group of 100 patients with histologically confirmed non-cancer.";16984552;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Niclosamide has the potential to target the <span class=""gene"" id=""25970160-13-44-47"">IL6</span>-Stat3-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced <span class=""disease"" id=""25970160-13-148-163"">prostate cancer</span>.";25970160;2015
3557;IL1RN;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.;16284379;2006
55256;ADI1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We found that the gene, aci-reductone dioxygenase 1 (<span class=""gene"" id=""17786183-2-53-57"">ADI1</span>), was downregulated in <span class=""disease"" id=""17786183-2-81-96"">prostate cancer</span> cells, whereas enforced expression of rat <span class=""gene"" id=""17786183-2-139-143"">Adi1</span> in these cells caused apoptosis.";17786183;2007
8932;MBD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""19240160-0-0-13"">Interleukin-6</span> increases <span class=""disease"" id=""19240160-0-24-39"">prostate cancer</span> cells resistance to bicalutamide via TIF2.";19240160;2009
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In the present study, we investigated the expression of MLN64 in <span class=""disease"" id=""17592021-3-65-80"">prostate cancer</span>, another hormone-dependent tumor, and compared its expression with that of <span class=""gene"" id=""17592021-3-156-161"">CYP17</span>, the gene encoding for the key enzyme of androgen synthesis.";17592021;2007
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;Regulation of phosphatase homologue of tensin protein expression by bone morphogenetic proteins in prostate epithelial cells.;21456062;2011
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
10013;HDAC6;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"We integrated the RNA-Seq results with DNA-binding sites of BRD4 generated by chromatin immunoprecipitations, correlated these with gene expressions from human <span class=""disease"" id=""24763052-3-160-176"">prostate cancers</span> and identified 21 top BRD4 candidate genes among which the oxidative stress pathway genes KEAP1, SESN3 and <span class=""gene"" id=""24763052-3-284-289"">HDAC6</span> are represented.";24763052;2015
8702;B4GALT4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Our results define a new link between two critical proteins in <span class=""disease"" id=""23704919-10-63-78"">prostate cancer</span> - <span class=""gene"" id=""23704919-10-81-83"">AR</span> and c-Myc - and demonstrate the potential of <span class=""gene"" id=""23704919-10-129-131"">AR</span> and c-Myc-directed therapies to improve <span class=""disease"" id=""23704919-10-172-187"">prostate cancer</span> control.";23704919;2013
1789;DNMT3B;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"A trend toward an increase in MI was detected for the <span class=""gene"" id=""16012746-10-54-60"">DNMT3b</span> polymorphisms in <span class=""disease"" id=""16012746-10-78-93"">prostate cancer</span> patients but not for BPH subjects (mean MI 2.6, 2.9, 3.1 for CC, CT, and TT genotype in <span class=""disease"" id=""16012746-10-182-197"">prostate cancer</span>; 0.8, 0.8, 0.7 for CC, CT, and TT genotype in BPH subjects).";16012746;2005
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"<span class=""disease"" id=""14633711-1-0-15"">Prostate cancer</span> is one of the most promising candidates for <span class=""gene"" id=""14633711-1-60-83"">sodium iodide symporter</span> (<span class=""gene"" id=""14633711-1-85-88"">NIS</span>)-mediated gene therapy.";14633711;2004
8000;PSCA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Prior data in <span class=""disease"" id=""16015594-2-14-30"">prostate cancers</span> indicated that <span class=""gene"" id=""16015594-2-46-50"">PSCA</span> is directly regulated by androgens and <span class=""gene"" id=""16015594-2-90-94"">PSCA</span> expression increases with high-tumor grade, advanced stage, extracapsular invasion, and androgen-independent progression.";16015594;2006
222546;RFX6;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Suppression of <span class=""gene"" id=""24390282-5-15-19"">RFX6</span> diminishes <span class=""disease"" id=""24390282-5-31-46"">prostate cancer</span> cell proliferation, migration and invasion.";24390282;2014
7153;TOP2A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Eighteen (31%) advanced <span class=""disease"" id=""17363613-8-24-40"">prostate cancers</span> showed topoIIalpha overexpression; 12 (26%) showed <span class=""gene"" id=""17363613-8-92-97"">TOP2A</span> low-level amplification; 9 (16%) expressed HER2; and 6 (13%) showed HER2 low-level amplification.";17363613;2007
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Increased <span class=""gene"" id=""11222871-0-10-16"">ErbB-2</span> tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the <span class=""disease"" id=""11222871-0-95-110"">prostate cancer</span> cell line LNCaP following treatment by select pesticides.";11222871;2001
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We found inverse associations between PhIP, MeIQx, or DiMeIQx intake and <span class=""disease"" id=""22564066-7-73-76"">PCa</span> risk when having &lt;2 deletions of the GSTT1 and <span class=""gene"" id=""22564066-7-124-129"">GSTM1</span> genes (<span class=""gene"" id=""22564066-7-137-150"">P(interaction</span>): 0.03, 0.01, and 0.03, respectively), which is supported by analysis of darkly browned meat consumption data.";22564066;2012
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.;20729295;2011
56616;DIABLO;C0376358;Malignant neoplasm of prostate;0,31;Therapeutic;CTD_human;Sensitization of TRAIL-resistant LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic potential.;17718901;2011
4193;MDM2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Alterations in the TP53 and <span class=""gene"" id=""20875869-1-28-32"">MDM2</span> genes appear to be important in the development of many human tumors, but evidence is conflicting on associations between polymorphisms in these genes and risk of <span class=""disease"" id=""20875869-1-196-211"">prostate cancer</span> (<span class=""disease"" id=""20875869-1-213-216"">PCa</span>).";20875869;2010
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Animal and in vitro models of <span class=""disease"" id=""17999153-1-30-45"">prostate cancer</span> demonstrate high <span class=""gene"" id=""17999153-1-63-68"">IL-10</span> levels result in smaller tumors, fewer metastases, and reduced angiogenesis compared to controls.";17999153;2008
2952;GSTT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.;16998812;2007
4849;CNOT3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
196;AHR;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"beta-TrCP inhibition reduces <span class=""disease"" id=""20140206-0-29-44"">prostate cancer</span> cell growth via upregulation of the <span class=""gene"" id=""20140206-0-81-106"">aryl hydrocarbon receptor</span>.";20140206;2010
472;ATM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The <span class=""gene"" id=""17502119-9-4-7"">ATM</span> missense variant P1054R confers an about twofold increased risk for <span class=""disease"" id=""17502119-9-76-91"">prostate cancer</span> in our series.";17502119;2008
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Osteoblasts induce <span class=""disease"" id=""15672864-0-19-34"">prostate cancer</span> proliferation and PSA expression through <span class=""gene"" id=""15672864-0-76-89"">interleukin-6</span>-mediated activation of the androgen receptor.";15672864;2005
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
9985;REC8;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2878;GPX3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"<span class=""gene"" id=""17804715-0-0-24"">Glutathione peroxidase 3</span>, deleted or methylated in <span class=""disease"" id=""17804715-0-51-66"">prostate cancer</span>, suppresses <span class=""disease"" id=""17804715-0-79-94"">prostate cancer</span> growth and metastasis.";17804715;2007
11009;IL24;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"The ASC-<span class=""gene"" id=""21671747-9-8-12"">MDA7</span> only reduced tumor growth in the TRAMP-C2-Ras (TC2Ras) <span class=""disease"" id=""21671747-9-68-83"">prostate cancer</span> model.";21671747;2012
7422;VEGFA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""12893367-0-0-34"">Vascular endothelial growth factor</span> gene-460 C/T polymorphism is a biomarker for <span class=""disease"" id=""12893367-0-80-95"">prostate cancer</span>.";12893367;2003
2650;GCNT1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"An A/G polymorphism of <span class=""gene"" id=""15882971-0-23-46"">core 2 branching enzyme</span> gene is associated with <span class=""disease"" id=""15882971-0-71-86"">prostate cancer</span>.";15882971;2005
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Here we show that the most common <span class=""disease"" id=""27223260-4-34-37"">PCa</span>-associated truncated <span class=""gene"" id=""27223260-4-59-62"">ERG</span> T1-E4 (<span class=""gene"" id=""27223260-4-70-73"">ERG</span>Δ39), encoded by fusion between TMPRSS2 exon 1 and <span class=""gene"" id=""27223260-4-124-127"">ERG</span> exon 4, binds to bromodomain-1 (BD1) of bromodomain containing protein 4 (BRD4), a member of the bromodomain and extraterminal domain (BET) family.";27223260;2016
2650;GCNT1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"These results demonstrate that <span class=""gene"" id=""15882971-7-31-36"">C2GnT</span> A/G polymorphism is associated with the susceptibility to <span class=""disease"" id=""15882971-7-95-110"">prostate cancer</span> in a Japanese population.";15882971;2005
2048;EPHB2;C0376358;Malignant neoplasm of prostate;0,4;GeneticVariation;UNIPROT;"A common nonsense mutation in <span class=""gene"" id=""16155194-0-30-35"">EphB2</span> is associated with <span class=""disease"" id=""16155194-0-55-70"">prostate cancer</span> risk in African American men with a positive family history.";16155194;2006
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Iodide accumulation in LNCaP cells infected with <span class=""disease"" id=""14633711-7-49-57"">Ad-ARR(2</span>)PB/h<span class=""gene"" id=""14633711-7-62-65"">NIS</span>, followed by incubation with synthetic androgen, was 5.3-fold increased compared with those coincubated with perchlorate (15,184 +/- 1,173 cpm versus 2,837 +/- 187 cpm).";14633711;2004
23036;ZNF292;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
861;RUNX1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.";17909013;2007
2255;FGF10;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.;21743467;2011
8754;ADAM9;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"<span class=""gene"" id=""17018608-10-0-5"">ADAM9</span> could be responsible for supporting <span class=""disease"" id=""17018608-10-42-57"">prostate cancer</span> cell survival and progression.";17018608;2007
673;BRAF;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
10951;CBX1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We previously demonstrated that the inhibition of the <span class=""gene"" id=""17914592-1-54-86"">epidermal growth factor receptor</span> (EGFR) signalling affects the endocrine therapy responses of <span class=""disease"" id=""17914592-1-148-163"">prostate cancer</span> (<span class=""disease"" id=""17914592-1-165-168"">PCa</span>) cells and that bicalutamide (BCLT) is able to reinforce PI3K activity through mechanisms involving PTEN decrement and <span class=""gene"" id=""17914592-1-288-292"">EGFR</span> and Her2 activities.";17914592;2007
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Moreover, forced expression of <span class=""gene"" id=""18559593-9-31-36"">SSBP2</span> inhibited <span class=""disease"" id=""18559593-9-47-62"">prostate cancer</span> cell proliferation in the colony formation assay and caused cell cycle arrest.";18559593;2008
2068;ERCC2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Polymorphic variants of <span class=""gene"" id=""17695467-2-24-27"">XPD</span>, at codon 312, 751, and other sites, have been associated with cancer susceptibility, but few studies have investigated their effect on <span class=""disease"" id=""17695467-2-164-179"">prostate cancer</span> risk.";17695467;2007
8720;MBTPS1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4193;MDM2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These findings suggest that TP53 and <span class=""gene"" id=""20875869-6-37-41"">MDM2</span> polymorphisms play a role in <span class=""disease"" id=""20875869-6-71-74"">PCa</span> susceptibility in southern Chinese Han population.";20875869;2010
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"Our results provide biochemical and cellular biologic evidence that NKX3.1 is down-regulated by <span class=""gene"" id=""17202838-7-96-99"">p53</span> over-expression in <span class=""disease"" id=""17202838-7-119-134"">prostate cancer</span> cells.";17202838;2007
3169;FOXA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"A novel <span class=""gene"" id=""19244107-0-8-25"">androgen receptor</span> splice variant is up-regulated during <span class=""disease"" id=""19244107-0-64-79"">prostate cancer</span> progression and promotes androgen depletion-resistant growth.";19244107;2009
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Two mutations identified in the <span class=""gene"" id=""10569618-0-32-49"">androgen receptor</span> of the new human <span class=""disease"" id=""10569618-0-67-82"">prostate cancer</span> cell line MDA PCa 2a.";10569618;2000
3383;ICAM1;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.;16606632;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.;22666205;2012
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"Homozygosity for the <span class=""gene"" id=""15448004-7-21-27"">FGFR-4</span> Arg388 allele is strongly associated with the occurrence of <span class=""disease"" id=""15448004-7-88-103"">prostate cancer</span> in white men.";15448004;2005
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"We observed an association of the slow acetylator genotype, <span class=""gene"" id=""15717312-6-60-65"">NAT 2</span>*6/<span class=""gene"" id=""15717312-6-68-72"">NAT2</span>*6 with <span class=""disease"" id=""15717312-6-80-95"">prostate cancer</span> protection (P=0.017; OR=0.31, 95% CI 0.11--0.84).";15717312;2005
4849;CNOT3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We then did quantitative methylation-specific PCR in primary <span class=""disease"" id=""18559593-3-61-76"">prostate cancer</span> tissues to confirm hypermethylation of the <span class=""gene"" id=""18559593-3-120-125"">SSBP2</span> promoter, and analyzed its correlation with clinicopathologic data.";18559593;2008
328;APEX1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Our results suggest that inherited variability in DNA repair capacity, as reflected by polymorphisms in XRCC1 and <span class=""gene"" id=""16406883-10-114-118"">APE1</span>, is a risk factor for <span class=""disease"" id=""16406883-10-141-156"">prostate cancer</span>.";16406883;2006
5520;PPP2R2A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.;18829485;2008
23411;SIRT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"Our data identified melatonin as a novel inhibitor of <span class=""gene"" id=""21062352-10-54-59"">Sirt1</span> and suggest that melatonin can inhibit <span class=""disease"" id=""21062352-10-99-102"">PCa</span> growth via <span class=""gene"" id=""21062352-10-114-119"">Sirt1</span> inhibition.";21062352;2011
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the enzymatic activity of <span class=""gene"" id=""17609663-3-80-84"">COX2</span> and long-term use of NSAIDs appears to modestly lower the risk of <span class=""disease"" id=""17609663-3-151-166"">prostate cancer</span>.";17609663;2007
4322;MMP13;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Further study of <span class=""gene"" id=""15138554-10-17-23"">MMP-13</span> in <span class=""disease"" id=""15138554-10-27-42"">prostate cancer</span> may help us to understand the progression of the cancer and can lead to new therapeutic options.";15138554;2004
6757;SSX2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"We then further evaluated the expression of one antigen, <span class=""gene"" id=""17929270-5-57-62"">SSX-2</span>, in <span class=""disease"" id=""17929270-5-67-82"">prostate cancer</span> cell lines and tissues.";17929270;2008
1576;CYP3A4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Two epidemiologic studies of breast cancer and five of <span class=""disease"" id=""15496535-7-55-70"">prostate cancer</span> examined <span class=""gene"" id=""15496535-7-80-86"">CYP3A4</span> genotypes.";15496535;2004
23671;TMEFF2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Expression of <span class=""gene"" id=""23405127-2-14-20"">TMEFF2</span> is deregulated in <span class=""disease"" id=""23405127-2-39-54"">prostate cancer</span>, suggesting a role in this disease, but the molecular mechanism(s) involved in this effect are not clear.";23405127;2013
4502;MT2A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.;16574721;2006
858;CAV2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Analysis of candidate genes for prostate cancer.;15583422;2005
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We have recently developed a replication-deficient adenovirus carrying the human <span class=""gene"" id=""14633711-3-81-84"">NIS</span> cDNA linked to a composite probasin promoter, ARR(2)PB, aiming toward specific expression of the human NIS gene (h-NIS) in prostate tissue for targeted radioactive iodide therapy of <span class=""disease"" id=""14633711-3-267-282"">prostate cancer</span> (<span class=""disease"" id=""14633711-3-284-292"">Ad-ARR(2</span>)PB/h<span class=""gene"" id=""14633711-3-297-300"">NIS</span>).";14633711;2004
196;AHR;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"This phenomenon could be ligand independent, as the <span class=""gene"" id=""20140206-7-52-55"">AhR</span> ligand 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) did not alter <span class=""disease"" id=""20140206-7-120-135"">prostate cancer</span> cell growth.";20140206;2010
43;ACHE;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"Amphiphilic dimers and monomers and hydrophilic dimers of <span class=""gene"" id=""20356562-7-58-62"">AChE</span> were identified in BHP and <span class=""disease"" id=""20356562-7-90-92"">PC</span> tissues.";20356562;2010
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"The <span class=""gene"" id=""15448004-10-4-10"">FGFR-4</span> Arg388 allele is associated with both an increased incidence and clinical aggressiveness of <span class=""disease"" id=""15448004-10-103-118"">prostate cancer</span> and results in changes in cellular motility and invasiveness in immortalized prostate epithelial cells consistent with the promotion of metastasis.";15448004;2005
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"New experimental therapies for <span class=""disease"" id=""12237244-12-31-46"">prostate cancer</span> are aimed to down-regulate <span class=""gene"" id=""12237244-12-74-76"">AR</span> expression and to overcome difficulties which occur because of the acquisition of agonistic properties of commonly used antiandrogens.";12237244;2003
2115;ETV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
4846;NOS3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The involvement of <span class=""gene"" id=""12445681-1-19-52"">endothelial nitric oxide synthase</span> (<span class=""gene"" id=""12445681-1-54-59"">ecNOS</span>) gene polymorphisms (ecNOS4a/b and Glu-Asp298) on the shedding of tumor cells in the blood of 61 patients with <span class=""disease"" id=""12445681-1-171-186"">prostate cancer</span> (<span class=""disease"" id=""12445681-1-188-191"">PCa</span>), was analyzed.";12445681;2003
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"This study demonstrated the <span class=""gene"" id=""25970160-12-28-31"">IL6</span>-Stat3-AR axis in <span class=""disease"" id=""25970160-12-49-64"">prostate cancer</span> is one of the crucial mechanisms of enzalutamide resistance.";25970160;2015
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"<span class=""gene"" id=""21349172-0-0-5"">FGFR4</span> Gly388Arg polymorphism contributes to <span class=""disease"" id=""21349172-0-44-59"">prostate cancer</span> development and progression: a meta-analysis of 2618 cases and 2305 controls.";21349172;2011
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These data demonstrate genotypes correlated with low <span class=""gene"" id=""17999153-8-53-58"">IL-10</span> production are associated with increased risk of <span class=""disease"" id=""17999153-8-108-123"">prostate cancer</span> and with high-grade disease in this population.";17999153;2008
4804;NGFR;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.;17409433;2007
3952;LEP;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"We found an overrepresentation of the <span class=""gene"" id=""15042602-4-38-46"">A-allele</span> in <span class=""disease"" id=""15042602-4-50-52"">PC</span> patients and that there is a significantly higher risk for <span class=""disease"" id=""15042602-4-112-114"">PC</span> among A carriers (OR = 1.60; confidence interval (CI), 1.13-2.28, P = 0.008).";15042602;2004
4846;NOS3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Outcome in <span class=""disease"" id=""12429631-0-11-26"">prostate cancer</span>: association with <span class=""gene"" id=""12429631-0-45-78"">endothelial nitric oxide synthase</span> Glu-Asp298 polymorphism at exon 7.";12429631;2003
4477;MSMB;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"Loci on chromosome 10 include <span class=""gene"" id=""18264096-4-30-34"">MSMB</span>, which encodes <span class=""gene"" id=""18264096-4-50-73"">beta-microseminoprotein</span>, a primary constituent of semen and a proposed <span class=""disease"" id=""18264096-4-121-136"">prostate cancer</span> biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.";18264096;2008
5172;SLC26A4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3606;IL18;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Genetic polymorphisms of the <span class=""gene"" id=""17688413-0-29-43"">interleukin-18</span> gene and risk of <span class=""disease"" id=""17688413-0-61-76"">prostate cancer</span>.";17688413;2007
3292;HSD17B1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Our results provide suggestive findings for an association with either familial or sporadic <span class=""disease"" id=""17507624-8-92-107"">prostate cancer</span> with polymorphisms in four genes: AKR1C3, <span class=""gene"" id=""17507624-8-150-157"">HSD17B1</span>, NQO1, and GSTT1.";17507624;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"One of the most interesting but still unsolved issues in <span class=""disease"" id=""7511268-1-57-72"">prostate cancer</span> is the role of androgens, the <span class=""gene"" id=""7511268-1-103-120"">androgen receptor</span> (<span class=""gene"" id=""7511268-1-122-124"">AR</span>) and the p53 tumor suppressor gene in the development and/or progression of prostatic neoplasia.";7511268;1994
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Furthermore, we found that expression of <span class=""gene"" id=""18559593-6-41-46"">SSBP2</span> was down-regulated in primary <span class=""disease"" id=""18559593-6-77-93"">prostate cancers</span> and cancer cell lines.";18559593;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;Structural basis for accommodation of nonsteroidal ligands in the androgen receptor.;16129672;2006
2690;GHR;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"These results suggest that whereas genetic variation in the <span class=""gene"" id=""17220348-6-60-63"">GHR</span> gene does not seem to play a major role in <span class=""disease"" id=""17220348-6-107-122"">prostate cancer</span> etiology, one haplotype in the 3' region may be potentially relevant to cases with later onset of <span class=""disease"" id=""17220348-6-221-236"">prostate cancer</span>.";17220348;2007
10863;ADAM28;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our findings reveal that <span class=""disease"" id=""27223260-9-25-28"">PCa</span>-associated <span class=""gene"" id=""27223260-9-40-43"">ERG</span> can interact and co-occupy with BRD4 in the genome, and suggest this druggable interaction is critical for <span class=""gene"" id=""27223260-9-151-154"">ERG</span>-mediated cell invasion and <span class=""disease"" id=""27223260-9-182-185"">PCa</span> progression.";27223260;2016
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Polymorphisms of three xenobiotic genes (<span class=""gene"" id=""15538743-3-41-46"">CYP17</span>, GSTP1, PON1) were characterized in 384 patients with untreated <span class=""disease"" id=""15538743-3-111-114"">PCa</span> and 360 age-matched control patients with benign prostatic hyperplasia (BPH).";15538743;2005
675;BRCA2;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;GENOMICS_ENGLAND;;;
5100;PCDH8;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
3482;IGF2R;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
55577;NAGK;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6462;SHBG;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Using DNA extracted from blood specimens, we initially genotyped 14 single nucleotide polymorphisms in genes involved in hormone regulation or metabolism (AKR1C3, CYP1A1, CYP1B1, CYP3A4, ESR1, GNRH1, HSD173B, HSD3B2, <span class=""gene"" id=""17220347-3-217-221"">SHBG</span>, and SRD5A2) in 488 <span class=""disease"" id=""17220347-3-242-257"">prostate cancer</span> cases and 617 matched controls.";17220347;2007
7431;VIM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Although systemic androgen deprivation prolongs life in advanced <span class=""disease"" id=""18676866-1-65-80"">prostate cancer</span>, remissions are temporary because patients almost uniformly progress to a state of a castration-resistant prostate cancer (CRPC) as indicated by recurring <span class=""gene"" id=""18676866-1-236-239"">PSA</span>.";18676866;2008
7298;TYMS;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Expression of <span class=""gene"" id=""15999119-0-14-34"">thymidylate synthase</span>, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in <span class=""disease"" id=""15999119-0-136-151"">prostate cancer</span>.";15999119;2005
5273;SERPINB10;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"A case-control study involving 292 <span class=""disease"" id=""16172807-4-35-50"">prostate-cancer</span> patients and 384 controls revealed significant differences in regard to distribution of four missense variations in genes encoding plasminogen activator inhibitor 2 (PAI2) and <span class=""gene"" id=""16172807-4-227-236"">SERPINB10</span>.";16172807;2006
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Association of CYP17, GSTP1, and <span class=""gene"" id=""15538743-0-33-37"">PON1</span> polymorphisms with the risk of <span class=""disease"" id=""15538743-0-69-84"">prostate cancer</span>.";15538743;2005
1571;CYP2E1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Association between <span class=""gene"" id=""12771559-0-20-26"">CYP2E1</span> polymorphisms and susceptibility to <span class=""disease"" id=""12771559-0-63-78"">prostate cancer</span>.";12771559;2004
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Odds ratios for the association between the <span class=""gene"" id=""17999153-5-44-49"">IL-10</span> genotypes and risk of <span class=""disease"" id=""17999153-5-72-87"">prostate cancer</span> or, among cases only, high-grade disease were calculated using logistic regression.";17999153;2008
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.;17639508;2007
55312;RFK;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We investigated the involvement of <span class=""gene"" id=""21308351-3-35-38"">RFK</span> in cisplatin resistance using human <span class=""disease"" id=""21308351-3-75-90"">prostate cancer</span> PC3 cells.";21308351;2011
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Genetic polymorphism of the <span class=""gene"" id=""16083506-0-28-49"">N-acetyltransferase 2</span> gene, and susceptibility to <span class=""disease"" id=""16083506-0-78-93"">prostate cancer</span>: a pilot study in north Indian population.";16083506;2006
6594;SMARCA1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7421;VDR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Tumor progression in the LPB-Tag transgenic model of <span class=""disease"" id=""20347977-0-53-68"">prostate cancer</span> is altered by <span class=""gene"" id=""20347977-0-83-101"">vitamin D receptor</span> and serum testosterone status.";20347977;2010
3284;HSD3B2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Carriage of at least one <span class=""gene"" id=""17823934-7-25-31"">HSD3B2</span> intron 3 intron 3 short allele was associated with a significant increased risk for <span class=""disease"" id=""17823934-7-116-131"">prostate cancer</span> among all subjects (OR = 2.07, 95% CI = 1.08-3.95, P = 0.03) and Caucasians (OR = 2.80, CI = 2.80-7.43, P = 0.04), but not in African Americans (OR = 1.50, CI = 0.62-3.60, P = 0.37).";17823934;2007
81037;CLPTM1L;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.;19151717;2009
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"A mechanism in <span class=""disease"" id=""15525515-5-15-30"">prostate cancer</span> is suggested by a functional <span class=""gene"" id=""15525515-5-60-62"">AR</span> mutation at a specificity-determining residue that recovers coactivator LXXLL motif binding.";15525515;2004
3293;HSD17B3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Association of the G289S single nucleotide polymorphism in the <span class=""gene"" id=""12210481-0-63-70"">HSD17B3</span> gene with <span class=""disease"" id=""12210481-0-81-96"">prostate cancer</span> in Italian men.";12210481;2002
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"We have characterized the <span class=""gene"" id=""10569618-1-26-43"">androgen receptor</span> (<span class=""gene"" id=""10569618-1-45-47"">AR</span>) in a new human <span class=""disease"" id=""10569618-1-64-79"">prostate cancer</span> cell line, MDA PCa 2a, that has recently been established from a bone metastasis of a patient whose cancer exhibited androgen-independent growth.";10569618;2000
2346;FOLH1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"1alpha,25-Dihydroxyvitamin D3 down-regulates expression of <span class=""gene"" id=""18247401-0-59-93"">prostate specific membrane antigen</span> in <span class=""disease"" id=""18247401-0-97-112"">prostate cancer</span> cells.";18247401;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2950;GSTP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.;22581815;2012
2048;EPHB2;C0376358;Malignant neoplasm of prostate;0,4;GeneticVariation;UNIPROT;"Our data show that the K1019X mutation in the <span class=""gene"" id=""16155194-10-46-51"">EphB2</span> gene differs in frequency between AA and EA, is associated with increased risk for <span class=""disease"" id=""16155194-10-135-137"">PC</span> in AA men with a positive family history, and may be an important genetic risk factor for <span class=""disease"" id=""16155194-10-228-243"">prostate cancer</span> in AA.";16155194;2006
51135;IRAK4;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Although the single-nucleotide polymorphisms in IRAK1 and <span class=""gene"" id=""16537705-7-58-63"">IRAK4</span> alone were not significantly associated with <span class=""disease"" id=""16537705-7-109-124"">prostate cancer</span> risk, one single-nucleotide polymorphism in <span class=""gene"" id=""16537705-7-169-174"">IRAK4</span>, when combined with the high-risk genotype at TLR6-1-10, conferred a significant excess risk of <span class=""disease"" id=""16537705-7-271-286"">prostate cancer</span>.";16537705;2006
201294;UNC13D;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
5144;PDE4D;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4.;16740699;2006
26137;ZBTB20;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We validated <span class=""gene"" id=""28319090-5-13-19"">ZBTB20</span>, CELF2, PARD3, AKAP13 and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in <span class=""disease"" id=""28319090-5-147-162"">prostate cancer</span>.";28319090;2017
3558;IL2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Our aim was to investigate whether C/T polymorphisms of the <span class=""gene"" id=""17115417-2-60-73"">interleukin-2</span> (<span class=""gene"" id=""17115417-2-75-79"">IL-2</span>) gene and <span class=""gene"" id=""17115417-2-90-94"">IL-2</span> receptor beta (IL-2RB) gene are associated with <span class=""disease"" id=""17115417-2-143-158"">prostate cancer</span>.";17115417;2007
3479;IGF1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Genetic polymorphisms in <span class=""gene"" id=""24586243-0-25-30"">IGF-I</span> and IGFBP-3 are associated with <span class=""disease"" id=""24586243-0-63-78"">prostate cancer</span> in the Chinese population.";24586243;2015
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"When <span class=""gene"" id=""20875869-4-5-9"">TP53</span> and MDM2 polymorphisms were combined based on the numbers of variant risk alleles (i.e., G-allele of <span class=""gene"" id=""20875869-4-111-115"">TP53</span> codon 72, G-allele of MDM2 SNP309, and G-allele of MDM2 C1797G), individuals with 3-5 variants had a 1.56-fold greater risk of <span class=""disease"" id=""20875869-4-243-246"">PCa</span> than those with 0-2 variants (95% CI = 1.07-2.26).";20875869;2010
4609;MYC;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation.;23704919;2013
3925;STMN1;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Increased expression and differential phosphorylation of <span class=""gene"" id=""17455228-0-57-65"">stathmin</span> may promote <span class=""disease"" id=""17455228-0-78-93"">prostate cancer</span> progression.";17455228;2007
207;AKT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
23671;TMEFF2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Androgen signaling promotes translation of <span class=""gene"" id=""23405127-0-43-49"">TMEFF2</span> in <span class=""disease"" id=""23405127-0-53-68"">prostate cancer</span> cells via phosphorylation of the α subunit of the translation initiation factor 2.";23405127;2013
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"These data demonstrate that the <span class=""gene"" id=""12622714-8-32-36"">NAT2</span> slow acetylator genotype plays an important role in determining the risk of developing <span class=""disease"" id=""12622714-8-124-139"">prostate cancer</span> in Japanese men and is also associated with more clinically advanced and pathologically aggressive disease.";12622714;2003
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Further analysis and data mining for two genes, the <span class=""gene"" id=""15318950-9-52-96"">Insulin like Growth Factor Binding protein 3</span>, and Retinoic X Receptor alpha, demonstrates an association with <span class=""disease"" id=""15318950-9-162-177"">prostate cancer</span>, functional pathway links, and protein-protein interactions that make these genes prime candidates for explaining the mechanism of Selenium's chemopreventive effect in <span class=""disease"" id=""15318950-9-346-361"">prostate cancer</span>.";15318950;2005
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Variants of the hK2 protein gene (<span class=""gene"" id=""17085659-0-34-38"">KLK2</span>) are associated with serum hK2 levels and predict the presence of <span class=""disease"" id=""17085659-0-105-120"">prostate cancer</span> at biopsy.";17085659;2007
142;PARP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study is the first to provide evidence that the ADPRT V762A-genetic variant contributes to <span class=""disease"" id=""15342424-8-96-99"">CaP</span> susceptibility and altered ADPRT/<span class=""gene"" id=""15342424-8-133-139"">PARP-1</span> enzyme function in response to oxidative damage.";15342424;2004
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"Thus, ERG has a distinct role in <span class=""disease"" id=""19396168-7-33-48"">prostate cancer</span> progression and cooperates with <span class=""gene"" id=""19396168-7-81-85"">PTEN</span> haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma.";19396168;2009
2115;ETV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To study aberrant activation of <span class=""gene"" id=""17671502-5-32-36"">ETV1</span>, we identified two <span class=""disease"" id=""17671502-5-56-71"">prostate cancer</span> cell lines, LNCaP and MDA-PCa 2B, that had <span class=""gene"" id=""17671502-5-115-119"">ETV1</span> outlier expression.";17671502;2007
8365;HIST1H4H;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
2068;ERCC2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Association of <span class=""gene"" id=""17695467-0-15-18"">XPD</span> polymorphisms with <span class=""disease"" id=""17695467-0-38-53"">prostate cancer</span> in Taiwanese patients.";17695467;2007
6657;SOX2;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
6715;SRD5A1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.;20564326;2010
2923;PDIA3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results show that overexpression of <span class=""gene"" id=""19240160-11-42-46"">IL-6</span> increases the resistance of <span class=""disease"" id=""19240160-11-75-90"">prostate cancer</span> cells to bicalutamide via TIF2.";19240160;2009
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Importantly, 16 of 18 unique <span class=""gene"" id=""12533788-7-29-34"">CHEK2</span> mutations identified in both sporadic and familial cases were not detected among 423 unaffected men, suggesting a pathological effect of <span class=""gene"" id=""12533788-7-172-177"">CHEK2</span> mutations in <span class=""disease"" id=""12533788-7-191-206"">prostate cancer</span> development.";12533788;2003
9203;ZMYM3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The aim of this study was to evaluate whether pretreatment serum <span class=""gene"" id=""16984552-2-65-69"">HER2</span> levels can be used to predict biochemical recurrence-free survival in <span class=""disease"" id=""16984552-2-140-155"">prostate cancer</span> patients about to undergo endocrine therapy.";16984552;2007
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Reactivation of <span class=""gene"" id=""18559593-8-16-21"">SSBP2</span> expression by the demethylating agent 5-aza-2'-deoxycytidine in <span class=""disease"" id=""18559593-8-86-101"">prostate cancer</span> cell lines confirmed epigenetic inactivation as one major mechanism of <span class=""gene"" id=""18559593-8-173-178"">SSBP2</span> regulation.";18559593;2008
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Importantly, 16 of 18 unique <span class=""gene"" id=""12533788-7-29-34"">CHEK2</span> mutations identified in both sporadic and familial cases were not detected among 423 unaffected men, suggesting a pathological effect of <span class=""gene"" id=""12533788-7-172-177"">CHEK2</span> mutations in <span class=""disease"" id=""12533788-7-191-206"">prostate cancer</span> development.";12533788;2003
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Apigenin suppresses cancer cell growth through ERbeta.;17132221;2007
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"We find that <span class=""disease"" id=""19396168-3-13-28"">prostate cancer</span> specimens containing the TMPRSS2-ERG rearrangement are significantly enriched for loss of the tumor suppressor <span class=""gene"" id=""19396168-3-140-144"">PTEN</span>.";19396168;2009
64374;SIL1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
7763;ZFAND5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We investigated whether common genetic variation in <span class=""gene"" id=""17609663-4-52-56"">COX2</span> influences the risk of advanced <span class=""disease"" id=""17609663-4-89-104"">prostate cancer</span>.";17609663;2007
3558;IL2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"<span class=""gene"" id=""17115417-0-0-4"">IL-2</span> gene C/T polymorphism is associated with <span class=""disease"" id=""17115417-0-46-61"">prostate cancer</span>.";17115417;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The epidemiological impact of <span class=""gene"" id=""26468117-1-30-34"">SOD2</span> imbalance on <span class=""disease"" id=""26468117-1-48-63"">prostate cancer</span> (<span class=""disease"" id=""26468117-1-65-67"">PC</span>) risk associated with genetic variations has previously been studied.";26468117;2016
567;B2M;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"<span class=""gene"" id=""17404077-0-0-20"">Beta-2-microglobulin</span> is an androgen-regulated secreted protein elevated in serum of patients with advanced <span class=""disease"" id=""17404077-0-107-122"">prostate cancer</span>.";17404077;2007
27232;GNMT;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Immunohistochemical staining was used to analyze <span class=""gene"" id=""17332283-7-49-53"">GNMT</span> expression in tissue specimens collected from 5 normal individuals, 33 benign prostatic hyperplasia patients, and 45 <span class=""disease"" id=""17332283-7-171-186"">prostate cancer</span> patients.";17332283;2007
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.;16998812;2007
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Expression of the Bcl-2 protein <span class=""gene"" id=""19593445-0-32-35"">BAD</span> promotes <span class=""disease"" id=""19593445-0-45-60"">prostate cancer</span> growth.";19593445;2009
56288;PARD3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"We validated ZBTB20, CELF2, <span class=""gene"" id=""28319090-5-28-33"">PARD3</span>, AKAP13 and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in <span class=""disease"" id=""28319090-5-147-162"">prostate cancer</span>.";28319090;2017
79784;MYH14;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Our study provides strong evidence that high intake of phytoestrogens substantially reduce <span class=""disease"" id=""16921512-11-91-106"">prostate cancer</span> risk among men with specific polymorphic variation in the promoter region of the <span class=""gene"" id=""16921512-11-188-210"">estrogen receptor-beta</span> gene.";16921512;2006
857;CAV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We determined serum <span class=""gene"" id=""22159333-6-20-25"">Cav-1</span> and serum markers of antioxidant activity-glutathione             (GSH), 2,2-diphenyl-1-picrylhydrazyl (DPPH), Trolox equivalent antioxidant capacity             (TEAC), ferric-reducing antioxidant power (FRAP), N,N-dimethyl-1,4-diaminobenzene             (DMPD), free radicals method (FRK) and blue chromium peroxide (Cro) in 97 serum             samples (82 <span class=""disease"" id=""22159333-6-386-401"">prostate cancer</span> patients and 15 controls).";22159333;2012
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"The <span class=""gene"" id=""12622714-4-4-8"">NAT2</span> slow acetylator genotype was statistically higher among <span class=""disease"" id=""12622714-4-65-80"">prostate cancer</span> patients (17.1%) compared with controls (8.6%) (Odds ration (OR) = 2.21; 95% confidence interval (CI), 1.04-4.69; P = 0.0289).";12622714;2003
7113;TMPRSS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.;17136230;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide.;16934689;2006
51135;IRAK4;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We analyzed 11 single nucleotide polymorphisms (four in IRAK1 and seven in <span class=""gene"" id=""16537705-6-75-80"">IRAK4</span>) among 1,383 newly diagnosed <span class=""disease"" id=""16537705-6-110-125"">prostate cancer</span> patients and 780 population controls in Sweden.";16537705;2006
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Men homozygous for SEPP1-Ala234 who were also <span class=""gene"" id=""19074884-11-46-50"">SOD2</span>-Ala16+ had a higher risk of prostate cancer (OR, 1.43; 95% CI, 1.17-1.76) and aggressive <span class=""disease"" id=""19074884-11-140-155"">prostate cancer</span> (OR, 1.60; 95% CI, 1.22-2.09) than those who were <span class=""gene"" id=""19074884-11-206-210"">SOD2</span>-Val16 homozygotes (interaction, <span class=""disease"" id=""19074884-11-243-258"">prostate cancer</span> P = 0.05; aggressive <span class=""disease"" id=""19074884-11-280-295"">prostate cancer</span> P = 0.01).";19074884;2009
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"In a case-control study of Finnish men, the association of <span class=""disease"" id=""12783936-7-59-74"">prostate cancer</span> with the <span class=""gene"" id=""12783936-7-84-88"">PON1</span> mutation identified in the cohort study was investigated in 69 case patients with familial prostate cancer and 69 unmatched healthy control subjects.";12783936;2003
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Polymorphisms of <span class=""gene"" id=""18304461-0-17-22"">GSTM1</span> and CYP1A1 genes and their genetic susceptibility to <span class=""disease"" id=""18304461-0-76-91"">prostate cancer</span> in Chinese men.";18304461;2008
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;Spatial genomic heterogeneity within localized, multifocal prostate cancer.;26005866;2015
55256;ADI1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Collectively, these observations argue that <span class=""gene"" id=""17786183-9-44-48"">ADI1</span> may check <span class=""disease"" id=""17786183-9-59-74"">prostate cancer</span> progression through apoptosis and that this activity does not require metal binding.";17786183;2007
3667;IRS1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"<span class=""disease"" id=""15678496-0-0-15"">Prostate cancer</span> risk and <span class=""gene"" id=""15678496-0-25-29"">IRS1</span>, IRS2, IGF1, and INS polymorphisms: strong association of <span class=""gene"" id=""15678496-0-88-92"">IRS1</span> G972R variant and cancer risk.";15678496;2005
2065;ERBB3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""17634423-1-0-6"">ErbB-3</span>, an ErbB receptor tyrosine kinase, has been implicated in the pathogenesis of several malignancies, including <span class=""disease"" id=""17634423-1-117-132"">prostate cancer</span>.";17634423;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Furthermore, resveratrol, a phytoalexin enriched in red grapes, strawberries and peanuts, has been shown to inhibit <span class=""gene"" id=""20729295-6-116-118"">AR</span> transcriptional activity in <span class=""disease"" id=""20729295-6-147-162"">prostate cancer</span> cells.";20729295;2011
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"African-Americans with the <span class=""gene"" id=""18174250-6-27-31"">IL10</span>-819TT genotype had a lower <span class=""disease"" id=""18174250-6-59-62"">CaP</span> risk [odds ratio (OR) = 0.27, 95% confidence interval (CI) = 0.07-1.01], but subjects with the genotype combination of IL1B-511CT/TT and <span class=""gene"" id=""18174250-6-200-204"">IL10</span>-592CC had a higher <span class=""disease"" id=""18174250-6-224-227"">CaP</span> risk (OR = 2.56, 95% CI = 1.09-6.02).";18174250;2008
1488;CTBP2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed <span class=""disease"" id=""18264096-4-121-136"">prostate cancer</span> biomarker, and <span class=""gene"" id=""18264096-4-152-157"">CTBP2</span>, a gene with antiapoptotic activity; the locus on chromosome 7 is at JAZF1, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.";18264096;2008
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The mean level of <span class=""gene"" id=""16984552-6-18-22"">HER2</span> in serum was significantly higher in <span class=""disease"" id=""16984552-6-60-75"">prostate cancer</span> patients than non-<span class=""disease"" id=""16984552-6-94-109"">prostate cancer</span> patients (P = 0.006).";16984552;2007
540;ATP7B;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Copper signaling axis as a target for prostate cancer therapeutics.;25320179;2014
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To investigate the association among <span class=""gene"" id=""17486273-1-37-42"">XRCC1</span> polymorphisms, smoking, drinking and the risk of <span class=""disease"" id=""17486273-1-92-107"">prostate cancer</span> (<span class=""disease"" id=""17486273-1-109-112"">PCa</span>) in men from Han, Southern China.";17486273;2007
3399;ID3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
7185;TRAF1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
210;ALAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Case-only gene-environment interaction between <span class=""gene"" id=""24500903-0-47-51"">ALAD</span> tagSNPs and occupational lead exposure in <span class=""disease"" id=""24500903-0-94-109"">prostate cancer</span>.";24500903;2014
6387;CXCL12;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This is the first report showing that <span class=""gene"" id=""17785557-14-38-44"">CXCL12</span> G801A polymorphism may be a risk factor for <span class=""disease"" id=""17785557-14-89-91"">PC</span>.";17785557;2007
1588;CYP19A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The VV (high activity) genotype of the V432L polymorphism from CYP1B1 (odds ratio [OR] = 1.36; 95% CI, 1.03 to 1.79; P = .031), and the long allele (&gt; 175 bp) of the TTTA repeat from <span class=""gene"" id=""17704407-4-183-188"">CYP19</span> (OR, 1.26; 95% CI, 1.08 to 1.47; P = .003) were significantly associated with the risk of <span class=""disease"" id=""17704407-4-279-294"">prostate cancer</span>.";17704407;2007
10207;PATJ;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
101669767;SCHLAP1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Here we characterize a long noncoding RNA termed <span class=""gene"" id=""24076601-3-49-56"">SChLAP1</span> (<span class=""gene"" id=""24076601-3-58-108"">second chromosome locus associated with prostate-1</span>; also called <span class=""gene"" id=""24076601-3-122-131"">LINC00913</span>) that is overexpressed in a subset of <span class=""disease"" id=""24076601-3-170-186"">prostate cancers</span>.";24076601;2014
2048;EPHB2;C0376358;Malignant neoplasm of prostate;0,4;GeneticVariation;UNIPROT;"We evaluated the contribution of <span class=""gene"" id=""16155194-2-33-38"">EphB2</span> to inherited <span class=""disease"" id=""16155194-2-52-54"">PC</span> susceptibility in African Americans (AA) by screening the gene for germline polymorphisms.";16155194;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Additionally, recent pre-clinical studies suggested enzalutamide might have the potential adverse effect of inducing metastasis of <span class=""disease"" id=""25970160-2-131-146"">prostate cancer</span> cells via <span class=""gene"" id=""25970160-2-157-162"">Stat3</span> activation.";25970160;2015
149628;PYHIN1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
23451;SF3B1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
596;BCL2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Additionally, common <span class=""gene"" id=""16733517-4-21-26"">BCL-2</span> haplotypes appeared to influence <span class=""disease"" id=""16733517-4-60-75"">prostate cancer</span> risk; however, studies in larger data sets are needed to confirm our findings.";16733517;2007
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
3925;STMN1;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"<span class=""gene"" id=""17455228-4-0-8"">Stathmin</span> expression and phosphorylation patterns were analyzed in mouse and human <span class=""disease"" id=""17455228-4-82-85"">PCa</span> cell lines as well as in human <span class=""disease"" id=""17455228-4-117-120"">PCa</span> tissue arrays.";17455228;2007
6817;SULT1A1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"This study compares a polymorphism in the <span class=""gene"" id=""14973106-3-42-49"">SULT1A1</span> gene, <span class=""gene"" id=""14973106-3-56-63"">SULT1A1</span> enzyme activity, meat consumption, and the risk of <span class=""disease"" id=""14973106-3-115-130"">prostate cancer</span> in a population based case-control study.";14973106;2004
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We evaluated the association of <span class=""disease"" id=""17646272-2-32-47"">prostate cancer</span> with genetic polymorphisms in SOD1 (CuZn-SOD; IVS3-251A&gt;G), <span class=""gene"" id=""17646272-2-108-112"">SOD2</span> [<span class=""gene"" id=""17646272-2-114-119"">MnSOD</span>; Ex2+24T&gt;C (V16A)], and SOD3 (EC-SOD; IVS1+186C&gt;T, Ex3-631C&gt;G, Ex3-516C&gt;T, and Ex3-489C&gt;T), the three main isoforms of SOD.";17646272;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Knock down of Stat3 abrogated enzalutamide resistance resulting in reduced recruitment of AR to the PSA promoter in <span class=""disease"" id=""25970160-10-116-131"">prostate cancer</span> cells expressing <span class=""gene"" id=""25970160-10-149-152"">IL6</span>.";25970160;2015
1200;TPP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3630;INS;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Polymorphism of the insulin gene is associated with increased prostate cancer risk.;12610512;2003
6387;CXCL12;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Although we did not find a significant relationship between the frequency of the Arg/Pro + Pro/Pro genotype of p53 Arg72Pro and susceptibility in <span class=""disease"" id=""17785557-12-146-148"">PC</span>, there was a combined effect of <span class=""gene"" id=""17785557-12-181-187"">CXCL12</span> GA + AA genotype and the p53 72Arg/Pro + Pro/Pro genotype on the frequency of <span class=""disease"" id=""17785557-12-266-268"">PC</span>.";17785557;2007
1499;CTNNB1;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1636;ACE;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The aim was to substantiate the putative significance of <span class=""gene"" id=""17465223-1-57-86"">angiotensin-converting enzyme</span> (<span class=""gene"" id=""17465223-1-88-91"">ACE</span>) (insertion/deletion) I/D polymorphism on <span class=""disease"" id=""17465223-1-134-149"">prostate cancer</span> risk, BTPSA-A TPSA (before treatment-after treatment prostate-specific antigen) levels and tumor development.";17465223;2007
2065;ERBB3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Despite being a plasma membrane protein, <span class=""gene"" id=""17634423-3-41-47"">ErbB-3</span> was also detected in the nuclei of the <span class=""disease"" id=""17634423-3-87-102"">prostate cancer</span> cells in the metastatic specimens.";17634423;2007
4669;NAGLU;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5621;PRNP;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
3576;CXCL8;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We demonstrate that treatment of human <span class=""disease"" id=""16606632-9-39-54"">prostate cancer</span> cell lines with zinc reduces expression of VEGF, IL-6, <span class=""gene"" id=""16606632-9-110-114"">IL-8</span> and MMP-9.";16606632;2006
2118;ETV4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
3169;FOXA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.;26457646;2016
5224;PGAM2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1107;CHD3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6092;ROBO2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Using tissue microarrays, we did immunohistochemistry and fluorescence in situ hybridization for <span class=""gene"" id=""17363613-4-97-101"">HER2</span> and TOP2A in 100 <span class=""disease"" id=""17363613-4-119-135"">prostate cancers</span> (41 localized and 59 advanced) and 42 cases of benign prostatic hyperplasia (BPH).";17363613;2007
5295;PIK3R1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
8409;UXT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Genome-wide impact of <span class=""gene"" id=""19318562-0-22-56"">androgen receptor trapped clone-27</span> loss on androgen-regulated transcription in <span class=""disease"" id=""19318562-0-101-116"">prostate cancer</span> cells.";19318562;2009
9446;GSTO1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
324;APC;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;Inactivation of Apc in the mouse prostate causes prostate carcinoma.;17363566;2007
5590;PRKCZ;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells.;16931574;2007
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Our results indicate that the <span class=""gene"" id=""18756523-7-30-35"">FGFR4</span> Arg allele of the Gly388Arg polymorphism and the G allele of the rs2011077 polymorphism have a significant impact on the development of <span class=""disease"" id=""18756523-7-172-187"">prostate cancer</span> and BPH, and the progression of prostate cancer in a Japanese population.";18756523;2008
7984;ARHGEF5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
143686;SESN3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We integrated the RNA-Seq results with DNA-binding sites of BRD4 generated by chromatin immunoprecipitations, correlated these with gene expressions from human <span class=""disease"" id=""24763052-3-160-176"">prostate cancers</span> and identified 21 top BRD4 candidate genes among which the oxidative stress pathway genes KEAP1, <span class=""gene"" id=""24763052-3-274-279"">SESN3</span> and HDAC6 are represented.";24763052;2015
7546;ZIC2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
7367;UGT2B17;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association between polymorphisms in HSD3B1 and <span class=""gene"" id=""17826523-0-48-55"">UGT2B17</span> and <span class=""disease"" id=""17826523-0-60-75"">prostate cancer</span> risk.";17826523;2007
1306;COL15A1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1588;CYP19A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In conclusion, our results suggest that several SNPs along the androgen pathway, especially in <span class=""gene"" id=""16424004-8-95-102"">CYP19A1</span> and CYP17A1, may influence <span class=""disease"" id=""16424004-8-130-145"">prostate cancer</span> development and progression.";16424004;2006
2048;EPHB2;C0376358;Malignant neoplasm of prostate;0,4;GeneticVariation;UNIPROT;"Taken together with studies indicating that <span class=""gene"" id=""15300251-7-44-49"">EphB2</span> may have an essential role in cell migration and maintenance of normal tissue architecture, our findings suggest that mutational inactivation of <span class=""gene"" id=""15300251-7-195-200"">EPHB2</span> may be important in the progression and metastasis of <span class=""disease"" id=""15300251-7-255-270"">prostate cancer</span>.";15300251;2004
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""15672864-2-0-13"">Interleukin-6</span> (<span class=""gene"" id=""15672864-2-15-19"">IL-6</span>) is considered to contribute to <span class=""disease"" id=""15672864-2-52-55"">CaP</span> progression and is produced at high levels in osteoblasts.";15672864;2005
328;APEX1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We determined whether polymorphisms in XRCC1 and <span class=""gene"" id=""16406883-2-49-53"">APE1</span> increase the risk of <span class=""disease"" id=""16406883-2-75-90"">prostate cancer</span>.";16406883;2006
55210;ATAD3A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"<span class=""gene"" id=""21584487-0-0-38"">ATPase family AAA domain containing 3A</span> is an anti-apoptotic factor and a secretion regulator of PSA in <span class=""disease"" id=""21584487-0-103-118"">prostate cancer</span>.";21584487;2011
25932;CLIC4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
842;CASP9;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
2878;GPX3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"In this report, we found that the expression of <span class=""gene"" id=""17804715-2-48-72"">glutathione peroxidase 3</span> (<span class=""gene"" id=""17804715-2-74-78"">GPx3</span>) was widely inactivated in <span class=""disease"" id=""17804715-2-106-122"">prostate cancers</span>.";17804715;2007
7163;TPD52;C0376358;Malignant neoplasm of prostate;0,38;Therapeutic;CTD_human;"PC-1/<span class=""gene"" id=""17875733-1-5-9"">PrLZ</span> gene overexpression has been identified to be associated with <span class=""disease"" id=""17875733-1-72-87"">prostate cancer</span> progression.";17875733;2007
55210;ATAD3A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"In vitro, silencing of <span class=""gene"" id=""21584487-5-23-29"">ATAD3A</span> expression reduced PSA secretion and cisplatin resistance, suggesting that <span class=""gene"" id=""21584487-5-105-111"">ATAD3A</span> was associated with PSA secretion and drug resistance in <span class=""disease"" id=""21584487-5-169-172"">PCa</span>.";21584487;2011
11095;ADAMTS8;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"The <span class=""gene"" id=""23704919-1-4-21"">androgen receptor</span> (<span class=""gene"" id=""23704919-1-23-25"">AR</span>) is the principal therapeutic target in <span class=""disease"" id=""23704919-1-66-81"">prostate cancer</span>.";23704919;2013
3303;HSPA1A;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer.;15764345;2005
55256;ADI1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We generated point mutations at key residues in the metal-binding site of <span class=""gene"" id=""17786183-8-74-78"">ADI1</span> to disrupt <span class=""gene"" id=""17786183-8-90-93"">ARD</span> function, and we found that these mutations did not affect intracellular localization, apoptosis, or colony formation suppression in human <span class=""disease"" id=""17786183-8-233-248"">prostate cancer</span> cells.";17786183;2007
30008;EFEMP2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Expression of FBLN1 (major splice forms C and D), <span class=""gene"" id=""17929269-3-50-55"">FBLN4</span>, FBLN5, SPOCK1, and TENC was compared between 47 <span class=""disease"" id=""17929269-3-105-120"">prostate cancer</span> samples and 13 benign prostatic tissues by quantitative RT-PCR.";17929269;2008
23476;BRD4;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"We integrated the RNA-Seq results with DNA-binding sites of <span class=""gene"" id=""24763052-3-60-64"">BRD4</span> generated by chromatin immunoprecipitations, correlated these with gene expressions from human <span class=""disease"" id=""24763052-3-160-176"">prostate cancers</span> and identified 21 top <span class=""gene"" id=""24763052-3-199-203"">BRD4</span> candidate genes among which the oxidative stress pathway genes KEAP1, SESN3 and HDAC6 are represented.";24763052;2015
5378;PMS1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7163;TPD52;C0376358;Malignant neoplasm of prostate;0,38;Therapeutic;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
2952;GSTT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Associations between genetic polymorphisms of CYP1A1, CYP1A2, CYP2E1, GSTM1 and <span class=""gene"" id=""11275366-1-80-85"">GSTT1</span> and <span class=""disease"" id=""11275366-1-90-105"">prostate cancer</span> (<span class=""disease"" id=""11275366-1-107-110"">PCa</span>) were analyzed in a case-control study of 315 individuals.";11275366;2001
7040;TGFB1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association of polymorphisms in <span class=""gene"" id=""18082198-0-32-37"">TGFB1</span> and <span class=""disease"" id=""18082198-0-42-57"">prostate cancer</span> prognosis.";18082198;2008
2296;FOXC1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
79728;PALB2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"We screened human <span class=""disease"" id=""1631125-1-18-33"">prostate cancer</span> tissues for the presence of somatic mutations in the hormone binding domain of the <span class=""gene"" id=""1631125-1-117-134"">androgen receptor</span> (<span class=""gene"" id=""1631125-1-136-138"">AR</span>) gene.";1631125;1992
7099;TLR4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Two recent publications reported that variants in <span class=""gene"" id=""17301271-2-50-54"">TLR4</span> were associated with risk of <span class=""disease"" id=""17301271-2-84-99"">prostate cancer</span>.";17301271;2007
84818;IL17RC;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Furthermore, immunohistochemical staining of prostate tissue microarrays showed that <span class=""gene"" id=""17603628-7-85-92"">IL-17RC</span> protein expression was significantly higher in androgen-independent <span class=""disease"" id=""17603628-7-161-177"">prostate cancers</span> than in androgen-dependent ones when anti-ICD was used, whereas the trend was reversed using anti-ECD.";17603628;2007
7153;TOP2A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Using tissue microarrays, we did immunohistochemistry and fluorescence in situ hybridization for HER2 and <span class=""gene"" id=""17363613-4-106-111"">TOP2A</span> in 100 <span class=""disease"" id=""17363613-4-119-135"">prostate cancers</span> (41 localized and 59 advanced) and 42 cases of benign prostatic hyperplasia (BPH).";17363613;2007
467;ATF3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We found that <span class=""gene"" id=""16516039-3-14-18"">ATF3</span> was differently expressed in an in vitro <span class=""disease"" id=""16516039-3-60-75"">prostate cancer</span> tumor progression model and we investigated the possible role of <span class=""gene"" id=""16516039-3-141-145"">ATF3</span> in <span class=""disease"" id=""16516039-3-149-164"">prostate cancer</span>.";16516039;2006
1576;CYP3A4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Two Scottish prospective studies showed <span class=""gene"" id=""15496535-10-40-46"">CYP3A4</span>*1B to be a risk factor for <span class=""disease"" id=""15496535-10-74-89"">prostate cancer</span> among men with benign prostatic hyperplasia.";15496535;2004
3284;HSD3B2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"SRD5A2 and <span class=""gene"" id=""17823934-0-11-17"">HSD3B2</span> polymorphisms are associated with <span class=""disease"" id=""17823934-0-52-67"">prostate cancer</span> risk and aggressiveness.";17823934;2007
4601;MXI1;C0376358;Malignant neoplasm of prostate;0,66;Biomarker;CTD_human;;;
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;GeneticVariation;UNIPROT;"<span class=""gene"" id=""9072974-0-0-4"">PTEN</span>, a putative <span class=""gene"" id=""9072974-0-17-45"">protein tyrosine phosphatase</span> gene mutated in human brain, breast, and <span class=""disease"" id=""9072974-0-87-102"">prostate cancer</span>.";9072974;1997
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"The purpose of this study was to determine the frequency of a polymorphism of the candidate metabolic enzyme <span class=""gene"" id=""12622714-1-109-130"">N-acetyltransferase-2</span> (<span class=""gene"" id=""12622714-1-132-136"">NAT2</span>) in Japanese <span class=""disease"" id=""12622714-1-150-165"">prostate cancer</span> patients and Japanese non-cancer controls, in order to determine if an association exists between <span class=""gene"" id=""12622714-1-264-268"">NAT2</span> genotype and the occurrence, clinical stage and grade of <span class=""disease"" id=""12622714-1-326-341"">prostate cancer</span>.";12622714;2003
4601;MXI1;C0376358;Malignant neoplasm of prostate;0,66;GeneticVariation;UNIPROT;"<span class=""gene"" id=""7773287-2-0-4"">MXI1</span> maps to chromosome 10q24-q25, a region that is deleted in some cases of <span class=""disease"" id=""7773287-2-77-92"">prostate cancer</span>.";7773287;1995
6522;SLC4A2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"The <span class=""gene"" id=""23704919-1-4-21"">androgen receptor</span> (<span class=""gene"" id=""23704919-1-23-25"">AR</span>) is the principal therapeutic target in <span class=""disease"" id=""23704919-1-66-81"">prostate cancer</span>.";23704919;2013
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in prostate cancer therapy.;16368536;2006
6387;CXCL12;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To investigate the effect of the <span class=""gene"" id=""17785557-6-33-39"">CXCL12</span> G801A polymorphism on <span class=""gene"" id=""17785557-6-62-68"">CXCL12</span> and CXCR4 expression, immunohistochemistry was done in genotyped <span class=""disease"" id=""17785557-6-134-136"">PC</span> tissues.";17785557;2007
4846;NOS3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""12445681-0-0-33"">Endothelial nitric oxide synthase</span> gene polymorphisms and the shedding of circulating tumour cells in the blood of <span class=""disease"" id=""12445681-0-114-129"">prostate cancer</span> patients.";12445681;2003
6462;SHBG;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Overall, <span class=""gene"" id=""17220347-7-9-13"">SHBG</span> D356N heterozygotes were found to have an increased risk of <span class=""disease"" id=""17220347-7-74-89"">prostate cancer</span> among whites (odds ratio, 1.34; 95% confidence interval, 1.10-1.63; P = 0.0007).";17220347;2007
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Herein, we examined single nucleotide polymorphic variants in the 3'-untranslated region of CDKN1A (p21(cip1)) and in codon 109 of <span class=""gene"" id=""12727815-3-131-137"">CDKN1B</span> (p27(kip1)) for association with advanced <span class=""disease"" id=""12727815-3-180-195"">prostate cancer</span> in a European-American population.";12727815;2003
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The prevalence of <span class=""gene"" id=""14634453-4-18-23"">hOGG1</span> Ser326Cys polymorphism was compared between white patients cases and controls using polymerase chain reaction restriction fragment length polymorphism analysis of genomic DNA isolated from 84 incident patients with primary <span class=""disease"" id=""14634453-4-247-262"">prostate cancer</span> and 252 individually matched controls (1:3 ratio) by age (+/- 5 years at diagnosis) in white men.";14634453;2004
5788;PTPRC;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Interleukin-6 stimulation of growth of <span class=""disease"" id=""19011039-0-39-54"">prostate cancer</span> in vitro and in vivo through activation of the <span class=""gene"" id=""19011039-0-102-119"">androgen receptor</span>.";19011039;2009
60526;LDAH;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"In addition, we report here five new loci for <span class=""disease"" id=""20676098-5-46-61"">prostate cancer</span> susceptibility, at 5p15 (lambda-corrected probability P(GC) = 3.9 x 10(-18)), GPRC6A/RFX6 (P(GC) = 1.6 x 10(-12)), 13q22 (P(GC) = 2.8 x 10(-9)), <span class=""gene"" id=""20676098-5-207-214"">C2orf43</span> (P(GC) = 7.5 x 10(-8)) and FOXP4 (P(GC) = 7.6 x 10(-8)).";20676098;2010
9203;ZMYM3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
672;BRCA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The strongest evidence for <span class=""disease"" id=""17585057-5-27-42"">prostate cancer</span> association was for a glutamine-to-arginine substitution at codon 356 (Gln(356)Arg) in exon 11 of the <span class=""gene"" id=""17585057-5-145-150"">BRCA1</span> gene.";17585057;2007
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Eighteen (31%) advanced <span class=""disease"" id=""17363613-8-24-40"">prostate cancers</span> showed topoIIalpha overexpression; 12 (26%) showed TOP2A low-level amplification; 9 (16%) expressed <span class=""gene"" id=""17363613-8-141-145"">HER2</span>; and 6 (13%) showed <span class=""gene"" id=""17363613-8-166-170"">HER2</span> low-level amplification.";17363613;2007
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"We also report results for a previously described <span class=""gene"" id=""23104005-7-50-56"">HOXB13</span> variant (rs138213197[T]), confirming it as a <span class=""disease"" id=""23104005-7-102-117"">prostate cancer</span> risk variant in populations from across Europe.";23104005;2013
4804;NGFR;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells.;17409433;2007
3606;IL18;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"We analyzed two single nucleotide polymorphisms of <span class=""gene"" id=""17688413-5-51-56"">IL-18</span> gene promoter -137 G/C and -607 C/A in 265 patients with <span class=""disease"" id=""17688413-5-114-129"">prostate cancer</span> and 280 age- and sex-matched controls, using sequence-specific primers-polymerase chain reaction strategy.";17688413;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"<span class=""gene"" id=""23704919-0-0-17"">Androgen receptor</span> promotes ligand-independent <span class=""disease"" id=""23704919-0-46-61"">prostate cancer</span> progression through c-Myc upregulation.";23704919;2013
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"The germline mutation G84E of <span class=""gene"" id=""22714738-10-30-36"">HOXB13</span> is a rare but recurrent mutation associated with elevated risk of <span class=""disease"" id=""22714738-10-103-118"">prostate cancer</span> in men of European descent, with an effect size that is greater than observed for previously validated risk variants of genome wide association studies.";22714738;2013
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Relationship between <span class=""gene"" id=""17486273-0-21-26"">XRCC1</span> polymorphisms and susceptibility to <span class=""disease"" id=""17486273-0-63-78"">prostate cancer</span> in men from Han, Southern China.";17486273;2007
11187;PKP3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"Here we find that the <span class=""disease"" id=""24390282-3-22-37"">prostate cancer</span> risk-associated SNP rs339331 at 6q22 lies within a functional <span class=""gene"" id=""24390282-3-100-106"">HOXB13</span>-binding site.";24390282;2014
3283;HSD3B1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"However, among white men with family history of <span class=""disease"" id=""17826523-6-48-63"">prostate cancer</span>, the <span class=""gene"" id=""17826523-6-69-75"">HSD3B1</span> 367Thr allele was positively associated with <span class=""disease"" id=""17826523-6-121-136"">prostate cancer</span> (odds ratio 3.0, 95% confidence interval 1.0 to 9.2).";17826523;2007
3283;HSD3B1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Association between polymorphisms in <span class=""gene"" id=""17826523-0-37-43"">HSD3B1</span> and UGT2B17 and <span class=""disease"" id=""17826523-0-60-75"">prostate cancer</span> risk.";17826523;2007
894;CCND2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"<span class=""gene"" id=""17016690-4-0-9"">Cyclin D2</span> promoter methylation was found in 117/118 <span class=""disease"" id=""17016690-4-52-55"">PCa</span>, 38/38 HGPIN, 24/30 BPH, 11/11 NPT, and 4/4 cell lines.";17016690;2007
2952;GSTT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We found inverse associations between PhIP, MeIQx, or DiMeIQx intake and <span class=""disease"" id=""22564066-7-73-76"">PCa</span> risk when having &lt;2 deletions of the <span class=""gene"" id=""22564066-7-114-119"">GSTT1</span> and GSTM1 genes (P(interaction): 0.03, 0.01, and 0.03, respectively), which is supported by analysis of darkly browned meat consumption data.";22564066;2012
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Here, we knocked down <span class=""gene"" id=""18829485-5-22-26"">SOD2</span> expression in AR-expressing LNCaP <span class=""disease"" id=""18829485-5-61-76"">prostate cancer</span> cells and determined gene expression changes, transcription factor binding, and AR transcription activity in <span class=""gene"" id=""18829485-5-186-190"">SOD2</span> knockdown cells.";18829485;2008
2787;GNG5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;The rat sodium iodide symporter gene permits more effective radioisotope concentration than the human sodium iodide symporter gene in human and rodent cancer cells.;12489024;2003
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Despite limitations due to study size, we conclude that the association between HCA intake and <span class=""disease"" id=""22564066-9-95-98"">PCa</span> risk could be modified by polymorphisms of GSTT1, GSTM1, and <span class=""gene"" id=""22564066-9-160-165"">MnSOD</span>.";22564066;2012
6757;SSX2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Our findings suggest that <span class=""gene"" id=""17929270-10-26-31"">SSX-2</span> could be further pursued as an immunotherapeutic target in <span class=""disease"" id=""17929270-10-91-106"">prostate cancer</span>, and that treatment with 5-aza-2'-deoxycytidine could be exploited to modulate antigen expression in combination with immunotherapeutic approaches.";17929270;2008
3284;HSD3B2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Two polymorphisms, a valine (V) for leucine (L) substitution at the 89 codon of the SRD5A2 gene and a (TG)n,(TA)n,(CA)n repeat polymorphism within the third intron of the <span class=""gene"" id=""17823934-3-171-177"">HSD3B2</span> gene were evaluated with regard to <span class=""disease"" id=""17823934-3-213-228"">prostate cancer</span> risk.";17823934;2007
10333;TLR6;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"In particular, Toll-like receptors (TLR), especially the <span class=""gene"" id=""16537705-3-57-61"">TLR6</span>-1-10 gene cluster, are involved in <span class=""disease"" id=""16537705-3-97-112"">prostate cancer</span> development.";16537705;2006
50509;COL5A3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
4683;NBN;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"<span class=""gene"" id=""25415046-0-0-3"">NBN</span> gain is predictive for adverse outcome following image-guided radiotherapy for localized <span class=""disease"" id=""25415046-0-93-108"">prostate cancer</span>.";25415046;2015
5926;ARID4A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"The <span class=""gene"" id=""15448004-0-4-39"">fibroblast growth factor receptor-4</span> Arg388 allele is associated with <span class=""disease"" id=""15448004-0-73-88"">prostate cancer</span> initiation and progression.";15448004;2005
7367;UGT2B17;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The purpose of this study was to determine whether polymorphisms in HSD3B1 and <span class=""gene"" id=""17826523-3-79-86"">UGT2B17</span> increase the risk of <span class=""disease"" id=""17826523-3-108-123"">prostate cancer</span>.";17826523;2007
26227;PHGDH;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2690;GHR;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Haplotype-based analysis of common variation in the <span class=""gene"" id=""17220348-0-52-75"">growth hormone receptor</span> gene and <span class=""disease"" id=""17220348-0-85-100"">prostate cancer</span> risk.";17220348;2007
2115;ETV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.;27783944;2016
996;CDC27;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.;17003774;2007
928;CD9;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1647;GADD45A;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"We examined the mechanism of regulation of <span class=""gene"" id=""19190346-3-43-54"">GADD45alpha</span> in <span class=""disease"" id=""19190346-3-58-73"">prostate cancer</span> cells and the effect of its up-regulation on sensitivity to docetaxel chemotherapy.";19190346;2009
4502;MT2A;C0376358;Malignant neoplasm of prostate;0,33;Therapeutic;CTD_human;Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions.;16574721;2006
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Stratification by quartiles of dietary and supplemental vitamin E intake (IU/d) showed risks of <span class=""disease"" id=""17646272-6-96-111"">prostate cancer</span> tended to be increased among <span class=""gene"" id=""17646272-6-141-145"">SOD2</span> Ala allele carriers, except at the highest quartile of vitamin E intake (&gt;222; P(interaction) = 0.06, Q1-Q3 versus Q4).";17646272;2007
8405;SPOP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6926;TBX3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Frequent detection of codon 877 mutation in the <span class=""gene"" id=""8187068-0-48-65"">androgen receptor</span> gene in advanced <span class=""disease"" id=""8187068-0-83-99"">prostate cancers</span>.";8187068;1994
2065;ERBB3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We speculate that nuclear localization of <span class=""gene"" id=""17634423-9-42-48"">ErbB-3</span> may aid <span class=""disease"" id=""17634423-9-57-72"">prostate cancer</span> cell survival during androgen ablation and progression of prostate cancer in bone.";17634423;2007
55256;ADI1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Androgens induced <span class=""gene"" id=""17786183-4-18-22"">ADI1</span> expression in human <span class=""disease"" id=""17786183-4-43-58"">prostate cancer</span> LNCaP cells, which was not blocked by cycloheximide, indicating that <span class=""gene"" id=""17786183-4-128-132"">ADI1</span> is a primary androgen-responsive gene.";17786183;2007
5744;PTHLH;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""disease"" id=""16243370-0-0-15"">Prostate cancer</span> cell type-specific involvement of the VDR and RXR in regulation of the human <span class=""gene"" id=""16243370-0-93-98"">PTHrP</span> gene via a negative VDRE.";16243370;2006
632;BGLAP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Formalin-fixed paraffin-embedded <span class=""disease"" id=""14666681-9-33-35"">PC</span> before H/T and HRPC for each patient were stained for <span class=""gene"" id=""14666681-9-90-101"">osteocalcin</span>.";14666681;2004
23411;SIRT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"This anti-<span class=""disease"" id=""21062352-9-10-13"">PCa</span> response was accompanied with a significant decrease in <span class=""gene"" id=""21062352-9-70-75"">Sirt1</span> in TRAMP prostate.";21062352;2011
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.;17003774;2007
632;BGLAP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""14666681-10-0-11"">Osteocalcin</span> immunohistochemical stain was detected in 18 of 20 <span class=""disease"" id=""14666681-10-63-65"">PC</span> before H/T and 19 of 20 of HRPC.";14666681;2004
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.;16284379;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.;17311914;2007
1465;CSRP1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
5371;PML;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Here we found that <span class=""gene"" id=""29335545-2-19-22"">PML</span> is frequently co-deleted with PTEN in metastatic human <span class=""disease"" id=""29335545-2-78-93"">prostate cancer</span> (<span class=""disease"" id=""29335545-2-95-98"">CaP</span>).";29335545;2018
3479;IGF1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""16465378-2-0-5"">IGF-I</span> has been shown to exert a potent mitogenic action on <span class=""disease"" id=""16465378-2-59-74"">prostate cancer</span>.";16465378;2006
8615;USO1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
54809;SAMD9;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7367;UGT2B17;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A significant association was observed between the <span class=""gene"" id=""17826523-7-51-58"">UGT2B17</span> null polymorphism and <span class=""disease"" id=""17826523-7-81-96"">prostate cancer</span> risk (odds ratio 1.7, 95% confidence interval 1.03 to 2.9).";17826523;2007
4524;MTHFR;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;Association between polymorphisms of folate-metabolizing enzymes and risk of prostate cancer.;17967524;2008
3925;STMN1;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Furthermore, modulation of <span class=""gene"" id=""17455228-11-27-35"">stathmin</span> phosphorylation may correlate with the development of androgen-independent <span class=""disease"" id=""17455228-11-111-114"">PCa</span>.";17455228;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.;1562539;1992
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Increased levels of serum human kallikrein-2 (hK2) and an <span class=""gene"" id=""17085659-1-58-61"">hK2</span> gene (<span class=""gene"" id=""17085659-1-68-72"">KLK2</span>) variant are positively associated for <span class=""disease"" id=""17085659-1-112-127"">prostate cancer</span>, but the relationships between them remain unclear.";17085659;2007
4214;MAP3K1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
7367;UGT2B17;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results suggest that the HSD3B1 N367T and <span class=""gene"" id=""17826523-9-48-55"">UGT2B17</span> null polymorphisms may modify the risk of <span class=""disease"" id=""17826523-9-98-113"">prostate cancer</span>, particularly among men with a family history of the disease.";17826523;2007
2690;GHR;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The <span class=""gene"" id=""17220348-1-4-27"">growth hormone receptor</span> (<span class=""gene"" id=""17220348-1-29-32"">GHR</span>) is potentially involved in <span class=""disease"" id=""17220348-1-61-76"">prostate cancer</span> through its role in stimulating insulin-like growth factor I production and its cellular effects on prostate epithelium.";17220348;2007
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our results suggest that the C allele of the functional C748T polymorphism of <span class=""gene"" id=""15643194-12-78-82"">KLK2</span> may increase the risk of <span class=""disease"" id=""15643194-12-108-111"">PCa</span>.";15643194;2005
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Human glandular kallikrein, which is encoded by the human <span class=""gene"" id=""15643194-1-58-70"">kallikrein-2</span> (<span class=""gene"" id=""15643194-1-72-76"">KLK2</span>) gene, is significantly associated with the occurrence of <span class=""disease"" id=""15643194-1-135-150"">prostate cancer</span> (<span class=""disease"" id=""15643194-1-152-155"">PCa</span>).";15643194;2005
2068;ERCC2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"We found a significant difference in the frequency of the <span class=""gene"" id=""17695467-5-58-61"">XPD</span> codon 312 genotype, but not the <span class=""gene"" id=""17695467-5-94-97"">XPD</span> codon 751 or promoter-114 genotypes, between the <span class=""disease"" id=""17695467-5-147-162"">prostate cancer</span> and control groups.";17695467;2007
3576;CXCL8;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study provides a molecular basis to support the correlation of <span class=""gene"" id=""17606477-7-68-72"">IL-8</span> expression with that of cyclin D1 in human <span class=""disease"" id=""17606477-7-116-131"">prostate cancer</span> and suggests a mechanism by which this chemokine promotes cell proliferation.";17606477;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).;25062956;2015
5328;PLAU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Increased expression of <span class=""gene"" id=""11454671-4-24-27"">uPA</span> has been reported in various malignancies including <span class=""disease"" id=""11454671-4-80-95"">prostate cancer</span>.";11454671;2001
9420;CYP7B1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Expression of the <span class=""gene"" id=""17639508-4-18-24"">CYP7B1</span> gene and protein in clinical prostate tissues and <span class=""disease"" id=""17639508-4-75-90"">prostate cancer</span> cell lines were investigated using real-time PCR and immunohistochemistry.";17639508;2007
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our findings concerning MLN64 and <span class=""gene"" id=""17592021-10-34-39"">CYP17</span> gene expression and their significant positive correlation in human <span class=""disease"" id=""17592021-10-108-123"">prostate cancer</span> may suggest their possible role in intraneoplastic autonomous steroidogenesis.";17592021;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Interactions between phytoestrogen intake and <span class=""gene"" id=""16921512-7-46-68"">estrogen receptor-beta</span> SNPs on <span class=""disease"" id=""16921512-7-77-92"">prostate cancer</span> risk were evaluated considering both multiplicative and additive effect scales.";16921512;2006
4023;LPL;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We herein analyzed the association of <span class=""gene"" id=""15386377-2-38-41"">LPL</span> gene polymorphisms with the risk of <span class=""disease"" id=""15386377-2-78-93"">prostate cancer</span> in a Japanese population.";15386377;2004
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.;21946351;2011
9203;ZMYM3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1312;COMT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4193;MDM2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"When TP53 and <span class=""gene"" id=""20875869-4-14-18"">MDM2</span> polymorphisms were combined based on the numbers of variant risk alleles (i.e., G-allele of TP53 codon 72, G-allele of <span class=""gene"" id=""20875869-4-138-142"">MDM2</span> SNP309, and G-allele of <span class=""gene"" id=""20875869-4-167-171"">MDM2</span> C1797G), individuals with 3-5 variants had a 1.56-fold greater risk of <span class=""disease"" id=""20875869-4-243-246"">PCa</span> than those with 0-2 variants (95% CI = 1.07-2.26).";20875869;2010
1316;KLF6;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;;;
5291;PIK3CB;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
10809;STARD10;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our study provides strong evidence that high intake of phytoestrogens substantially reduce <span class=""disease"" id=""16921512-11-91-106"">prostate cancer</span> risk among men with specific polymorphic variation in the promoter region of the <span class=""gene"" id=""16921512-11-188-210"">estrogen receptor-beta</span> gene.";16921512;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.;16998812;2007
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Further analysis and data mining for two genes, the <span class=""gene"" id=""15318950-9-52-96"">Insulin like Growth Factor Binding protein 3</span>, and Retinoic X Receptor alpha, demonstrates an association with <span class=""disease"" id=""15318950-9-162-177"">prostate cancer</span>, functional pathway links, and protein-protein interactions that make these genes prime candidates for explaining the mechanism of Selenium's chemopreventive effect in <span class=""disease"" id=""15318950-9-346-361"">prostate cancer</span>.";15318950;2005
7178;TPT1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
10451;VAV3;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.";17909013;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Interactions between phytoestrogen intake and <span class=""gene"" id=""16921512-7-46-68"">estrogen receptor-beta</span> SNPs on <span class=""disease"" id=""16921512-7-77-92"">prostate cancer</span> risk were evaluated considering both multiplicative and additive effect scales.";16921512;2006
4158;MC2R;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Multivariable analysis was used to investigate the association of known and new <span class=""gene"" id=""12783936-6-80-84"">PON1</span> mutations with incident <span class=""disease"" id=""12783936-6-109-124"">prostate cancer</span> in 1569 cancer-free men in the cohort followed for 9-14 years.";12783936;2003
658;BMPR1B;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We previously demonstrated that the inhibition of the <span class=""gene"" id=""17914592-1-54-86"">epidermal growth factor receptor</span> (EGFR) signalling affects the endocrine therapy responses of <span class=""disease"" id=""17914592-1-148-163"">prostate cancer</span> (<span class=""disease"" id=""17914592-1-165-168"">PCa</span>) cells and that bicalutamide (BCLT) is able to reinforce PI3K activity through mechanisms involving PTEN decrement and <span class=""gene"" id=""17914592-1-288-292"">EGFR</span> and Her2 activities.";17914592;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The results of our study of Turkish <span class=""disease"" id=""17465268-10-36-51"">prostate cancer</span> patients suggest that mutation of the <span class=""gene"" id=""17465268-10-90-95"">MnSOD</span> gene may be an important risk factor for <span class=""disease"" id=""17465268-10-137-152"">prostate cancer</span>.";17465268;2007
826;CAPNS1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
567;B2M;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Human <span class=""gene"" id=""17404077-9-6-9"">B2M</span> is identified in the serum of mice bearing human <span class=""disease"" id=""17404077-9-59-74"">prostate cancer</span> xenograft.";17404077;2007
27232;GNMT;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Immunohistochemical staining results showed abundant <span class=""gene"" id=""17332283-12-53-57"">GNMT</span> expression in normal prostatic and benign prostatic hyperplasia tissues, whereas it was diminished in 82.2% (37 of 45) of the <span class=""disease"" id=""17332283-12-184-199"">prostate cancer</span> tissues.";17332283;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Knock down of Stat3 abrogated enzalutamide resistance resulting in reduced recruitment of AR to the PSA promoter in <span class=""disease"" id=""25970160-10-116-131"">prostate cancer</span> cells expressing <span class=""gene"" id=""25970160-10-149-152"">IL6</span>.";25970160;2015
6041;RNASEL;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"Relevant studies were selected by searching PubMed from January 1996 to August 2005 using keywords ""<span class=""gene"" id=""17020975-2-100-106"">RNASEL</span> gene AND <span class=""disease"" id=""17020975-2-116-131"">prostate cancer</span>.""";17020975;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"<span class=""gene"" id=""16877366-0-0-17"">Androgen receptor</span> remains critical for cell-cycle progression in androgen-independent CWR22 <span class=""disease"" id=""16877366-0-92-107"">prostate cancer</span> cells.";16877366;2006
59084;ENPP5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6387;CXCL12;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We genotyped <span class=""gene"" id=""17785557-4-13-19"">CXCL12</span> G801A and p53Arg72Pro in 167 <span class=""disease"" id=""17785557-4-49-51"">PC</span> patients and 167 age-matched healthy subjects.";17785557;2007
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Polymorphisms of <span class=""gene"" id=""18756523-0-17-52"">fibroblast growth factor receptor 4</span> have association with the development of <span class=""disease"" id=""18756523-0-94-109"">prostate cancer</span> and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population.";18756523;2008
894;CCND2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Hypermethylation of <span class=""gene"" id=""17016690-0-20-29"">Cyclin D2</span> is associated with loss of mRNA expression and tumor development in <span class=""disease"" id=""17016690-0-98-113"">prostate cancer</span>.";17016690;2007
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We hypothesized that the functional polymorphisms in IGF-I and <span class=""gene"" id=""24586243-2-63-70"">IGFBP-3</span> may be associated with the risk of <span class=""disease"" id=""24586243-2-106-121"">prostate cancer</span> (<span class=""disease"" id=""24586243-2-123-126"">PCa</span>) in the Chinese population.";24586243;2015
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"The ability of resveratrol to inhibit tumor growth, metastasis and angiogenesis, and enhance the therapeutic potential of <span class=""gene"" id=""21209944-11-122-127"">TRAIL</span> suggests that resveratrol alone or in combination with <span class=""gene"" id=""21209944-11-183-188"">TRAIL</span> can be used for the management of <span class=""disease"" id=""21209944-11-223-238"">prostate cancer</span>.";21209944;2011
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"To study the functional importance of <span class=""gene"" id=""16877366-2-38-40"">AR</span> in these tumors, we derived androgen-independent CWR22 <span class=""disease"" id=""16877366-2-96-99"">PCa</span> xenografts in castrated mice and generated a cell line from one of these xenografts (CWR22R3).";16877366;2006
1902;LPAR1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Expression and function of lysophosphatidic acid <span class=""gene"" id=""16809448-0-49-53"">LPA1</span> receptor in <span class=""disease"" id=""16809448-0-66-81"">prostate cancer</span> cells.";16809448;2006
2938;GSTA1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"In this study, 190 Japanese male patients with <span class=""disease"" id=""15616829-4-47-62"">prostate cancer</span> and 294 healthy controls, frequency-matched for age, were compared for frequencies of <span class=""gene"" id=""15616829-4-149-154"">GSTA1</span>, GSTT1, GSTM1, and GSTP1 genotypes.";15616829;2005
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"We investigated the association between the Gly388Arg polymorphism or the G or A polymorphism at intron 11 (rs2011077) of <span class=""gene"" id=""18756523-3-122-127"">FGFR4</span>, which was located 1,213 base pairs apart from the Gly388Arg polymorphism, and the risk of <span class=""disease"" id=""18756523-3-219-234"">prostate cancer</span> or benign prostate hyperplasia (BPH), and the <span class=""disease"" id=""18756523-3-281-296"">prostate cancer</span> disease status in Japanese men.";18756523;2008
54756;IL17RD;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer.;16474841;2006
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;Association between gene polymorphism of manganese superoxide dismutase and prostate cancer risk.;23315858;2013
1026;CDKN1A;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results suggest that in a European-American population, <span class=""gene"" id=""12727815-11-62-68"">CDKN1A</span> and CDKN1B variants are associated with advanced <span class=""disease"" id=""12727815-11-118-133"">prostate cancer</span>.";12727815;2003
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Overall, our data suggest that mutations in <span class=""gene"" id=""12533788-9-44-49"">CHEK2</span> may contribute to <span class=""disease"" id=""12533788-9-68-83"">prostate cancer</span> risk and that the DNA-damage-signaling pathway may play an important role in the development of <span class=""disease"" id=""12533788-9-180-195"">prostate cancer</span>.";12533788;2003
7113;TMPRSS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
285704;RGMB;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
1672;DEFB1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
10587;TXNRD2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Among men carrying the variant allele for <span class=""gene"" id=""21716162-6-42-65"">thioredoxin reductase 2</span> (<span class=""gene"" id=""21716162-6-67-73"">TXNRD2</span>) rs4485648, microsomal epoxide hydrolase 1 (EPHX1) rs17309872, or myeloperoxidase (MPO) rs11079344, an increased <span class=""disease"" id=""21716162-6-187-202"">prostate cancer</span> risk was observed with high, compared with no, petroleum oil/petroleum distillate (OR=1.9, 95% CI: 1.1-3.2, P interaction=0.01; OR=2.1, 95% CI: 1.1-4.0, P interaction=0.01), or terbufos (OR=3.0, 95% CI: 1.5-6.0, P interaction=2.0×10(-3)) use, respectively.";21716162;2012
306;ANXA3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
83259;PCDH11Y;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Protocadherin-PC promotes androgen-independent prostate cancer cell growth.;16637074;2006
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"Association between polymorphisms of <span class=""gene"" id=""20875869-0-37-41"">TP53</span> and MDM2 and <span class=""disease"" id=""20875869-0-55-70"">prostate cancer</span> risk in southern Chinese.";20875869;2010
2272;FHIT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Taken together, the consistently significant but flipped association between single nucleotide polymorphism rs760317 and <span class=""disease"" id=""17548701-8-121-136"">prostate cancer</span> in three independent samples suggests that rs760317 may be in linkage disequilibrium with one or more <span class=""disease"" id=""17548701-8-239-254"">prostate cancer</span> susceptibility variants in or near <span class=""gene"" id=""17548701-8-290-294"">FHIT</span>.";17548701;2007
1543;CYP1A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study suggests that the <span class=""gene"" id=""11275366-5-29-35"">CYP1A1</span> polymorphism and its combination with GSTM1 may be associated with <span class=""disease"" id=""11275366-5-103-106"">PCa</span> susceptibility in the Japanese population.";11275366;2001
3945;LDHB;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"The <span class=""gene"" id=""27424772-1-4-10"">HOXB13</span> p.G84E mutation has been firmly established as a <span class=""disease"" id=""27424772-1-60-75"">prostate cancer</span> susceptibility allele.";27424772;2016
153090;DAB2IP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A genetic variant in <span class=""gene"" id=""18073375-9-21-27"">DAB2IP</span> may be associated with the risk of aggressive <span class=""disease"" id=""18073375-9-74-89"">prostate cancer</span> and should be evaluated further.";18073375;2007
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We found that men with the <span class=""gene"" id=""15538743-5-27-32"">CYP17</span>/A1A1-A1A2 genotypes, GSTP1/IleVal genotype, PON192/QR and PON55/LM-MM genotypes had a significantly higher risk of <span class=""disease"" id=""15538743-5-148-151"">PCa</span> compared with the others genotypes.";15538743;2005
7079;TIMP4;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1508;CTSB;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.;19503093;2009
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To determine whether <span class=""gene"" id=""14634453-2-21-26"">hOGG1</span> has a role in the risk of <span class=""disease"" id=""14634453-2-53-68"">prostate cancer</span> we screened normal prostate tissue specimens for <span class=""gene"" id=""14634453-2-118-123"">hOGG1</span> expression and assessed the role of <span class=""gene"" id=""14634453-2-160-165"">hOGG1</span> Ser326Cys polymorphism in the risk of <span class=""disease"" id=""14634453-2-204-219"">prostate cancer</span>.";14634453;2004
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"CDNA expression array analysis revealed increased manganese superoxide dismutase (<span class=""gene"" id=""12592389-2-82-87"">SOD-2</span>) expression in the mac25/IGFBP-rP1-transfected M12 human <span class=""disease"" id=""12592389-2-145-160"">prostate cancer</span> cell line compared to M12 control cells.";12592389;2003
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In vitro, <span class=""gene"" id=""16000583-3-10-17"">IGFBP-3</span> and VTP194204 individually induced apoptosis, and suppressed cell growth in <span class=""disease"" id=""16000583-3-94-109"">prostate cancer</span> cell lines in an additive manner.";16000583;2005
4782;NFIC;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"<span class=""gene"" id=""19240160-0-0-13"">Interleukin-6</span> increases <span class=""disease"" id=""19240160-0-24-39"">prostate cancer</span> cells resistance to bicalutamide via TIF2.";19240160;2009
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Recently, some reports demonstrated that <span class=""gene"" id=""8827083-2-41-43"">AR</span> gene mutations were detected in human <span class=""disease"" id=""8827083-2-82-97"">prostate cancer</span> tissues.";8827083;1996
9;NAT1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The results provide mechanistic support for a role of <span class=""gene"" id=""12618593-11-54-58"">NAT1</span> and/or NAT2 acetylator polymorphism(s) in human <span class=""disease"" id=""12618593-11-107-122"">prostate cancer</span> risk related to aromatic and/or heterocyclic amine carcinogens.";12618593;2003
10945;KDELR1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2878;GPX3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The rate of methylation of the <span class=""gene"" id=""17804715-5-31-35"">GPx3</span> exon 1 region in <span class=""disease"" id=""17804715-5-53-68"">prostate cancer</span> samples reaches 90%.";17804715;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Cellular changes in prostate cancer cells induced by intermittent androgen suppression.;17141945;2007
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"There is contradictory evidence of the effects that environmental factors-dietary habits (ingestion rates of red meat, soy products, fish, etc.) and work environment (exposure to metals, pesticides, several toxic products, etc.)-and <span class=""gene"" id=""27318894-1-233-237"">KLK3</span>, AR, RNASEL, MSR1, and ELAC2 expression patterns have on <span class=""disease"" id=""27318894-1-295-310"">prostate cancer</span> (<span class=""disease"" id=""27318894-1-312-315"">PCa</span>).";27318894;2016
8405;SPOP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Thus, <span class=""gene"" id=""22610119-9-6-10"">SPOP</span> mutations may define a new molecular subtype of <span class=""disease"" id=""22610119-9-59-74"">prostate cancer</span>.";22610119;2012
7040;TGFB1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Because of the role of <span class=""gene"" id=""18082198-1-23-28"">TGFB1</span> in <span class=""disease"" id=""18082198-1-32-47"">prostate cancer</span> and progression, we hypothesized that polymorphisms of <span class=""gene"" id=""18082198-1-103-108"">TGFB1</span> at C-509T may be associated with <span class=""disease"" id=""18082198-1-142-157"">prostate cancer</span> risk and/or more aggressive tumors.";18082198;2008
93611;FBXO44;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
1588;CYP19A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Stratification by age at onset showed that the associations of CYP1B1 and <span class=""gene"" id=""17704407-7-74-79"">CYP19</span> variants were largely confined to the younger <span class=""disease"" id=""17704407-7-126-141"">prostate cancer</span> patients.";17704407;2007
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Statistically significant effect modification of both HCA (DiMeIQx) and darkly browned meat intake and <span class=""disease"" id=""22564066-8-103-106"">PCa</span> risk was observed for allelic variants of MnSOD (rs4880) (<span class=""gene"" id=""22564066-8-165-178"">P(interaction</span>): 0.02).";22564066;2012
7422;VEGFA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The <span class=""gene"" id=""16908180-8-4-8"">VEGF</span> -634C allele was associated with the aggressive phenotype of <span class=""disease"" id=""16908180-8-70-85"">prostate cancer</span> as defined by the high histological grade (OR=3.48; P=0.007).";16908180;2006
55256;ADI1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Here we report the characterization of human <span class=""gene"" id=""17786183-3-45-49"">ADI1</span> in <span class=""disease"" id=""17786183-3-53-68"">prostate cancer</span>.";17786183;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Common genetic alterations in <span class=""disease"" id=""22610119-3-30-45"">prostate cancer</span> include losses of NKX3.1 (8p21) and PTEN (10q23), gains of AR (the <span class=""gene"" id=""22610119-3-113-130"">androgen receptor</span> gene) and fusion of ETS family transcription factor genes with androgen-responsive promoters.";22610119;2012
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We sought to examine the hypothesis that genotypes correlated with low <span class=""gene"" id=""17999153-2-71-76"">IL-10</span> production may be associated with increased <span class=""disease"" id=""17999153-2-121-136"">prostate cancer</span> risk among Finnish male participants from the Alpha-tocopherol Beta-carotene Cancer Prevention Study.";17999153;2008
10955;SERINC3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
79689;STEAP4;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Copper signaling axis as a target for prostate cancer therapeutics.;25320179;2014
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;[Dutasteride in the treatment of hormone refractory prostate cancer].;18500220;2008
324;APC;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2947;GSTM3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Metabolic susceptibility genes and <span class=""disease"" id=""14968442-0-35-50"">prostate cancer</span> risk in a southern European population: the role of glutathione S-transferases GSTM1, <span class=""gene"" id=""14968442-0-137-142"">GSTM3</span>, and GSTT1 genetic polymorphisms.";14968442;2004
64816;CYP3A43;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"When all subjects were considered, there was a 3-fold increase in risk of <span class=""disease"" id=""15894682-5-74-89"">prostate cancer</span> among individuals with the <span class=""gene"" id=""15894682-5-117-124"">CYP3A43</span>-Ala/Ala genotype (odds ratio, 3.0; 95% confidence interval, 1.2-7.2) compared with those with the <span class=""gene"" id=""15894682-5-223-230"">CYP3A43</span>-Pro/Pro genotype after adjusting for age, race, and smoking.";15894682;2005
23204;ARL6IP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7.;16434975;2006
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Anti-<span class=""gene"" id=""15672864-9-5-9"">IL-6</span> antibody added to HOBIT or POB CM dose-dependently inhibited the CM-induced cell proliferation and PSA expression in these <span class=""disease"" id=""15672864-9-133-136"">CaP</span> cell lines.";15672864;2005
472;ATM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
894;CCND2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"To assess <span class=""gene"" id=""17016690-2-10-19"">Cyclin D2</span> promoter methylation status and expression levels in prostate tissues, quantitative methylation-specific PCR and quantitative reverse transcription PCR assays were performed in a large series of prostate carcinomas, high-grade prostatic intraepithelial neoplasias (HGPIN), benign prostate hyperplasias (BPH), normal prostate tissue (NPT) samples, and <span class=""disease"" id=""17016690-2-371-386"">prostate cancer</span> (<span class=""disease"" id=""17016690-2-388-391"">PCa</span>) cell lines (before and after demethylating treatment).";17016690;2007
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In the human <span class=""disease"" id=""11222871-3-13-28"">prostate cancer</span> cell lines LNCaP and PC-3, <span class=""gene"" id=""11222871-3-56-62"">erbB-2</span> kinase was activated by pesticides of different chemical classes: (1) the organochlorine insecticides beta-hexa-chlorocyclohexane (beta-HCH), o,p'-dichlorodiphenyltrichloroethane (o,p'-DDT), and heptachlor epoxide; (2) the pyrethroid insecticide trans-permethrin, and (3) the fungicide chlorothalonil. o,p'-DDT also causes phosphorylation of mitogen-activated protein kinase (MAPK) and cellular proliferation of the androgen-dependent LNCaP line.";11222871;2001
6822;SULT2A1;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"The <span class=""gene"" id=""12237244-1-4-21"">androgen receptor</span> (<span class=""gene"" id=""12237244-1-23-25"">AR</span>), a transcription factor that mediates the action of androgens in target tissues, is expressed in nearly all <span class=""disease"" id=""12237244-1-135-151"">prostate cancers</span>.";12237244;2003
4477;MSMB;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
8289;ARID1A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
7153;TOP2A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Low-level <span class=""gene"" id=""17363613-0-10-15"">TOP2A</span> amplification in <span class=""disease"" id=""17363613-0-33-48"">prostate cancer</span> is associated with HER2 duplication, androgen resistance, and decreased survival.";17363613;2007
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Taken together, these observations suggest that combination therapy with <span class=""gene"" id=""16000583-8-73-80"">IGFBP-3</span> and RXR ligands may have therapeutic potential for <span class=""disease"" id=""16000583-8-132-147"">prostate cancer</span> treatment.";16000583;2005
301;ANXA1;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
8289;ARID1A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Interferon-gamma-induced dephosphorylation of STAT3 and apoptosis are dependent on the mTOR pathway.;16427044;2006
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"In vitro, <span class=""gene"" id=""16000583-3-10-17"">IGFBP-3</span> and VTP194204 individually induced apoptosis, and suppressed cell growth in <span class=""disease"" id=""16000583-3-94-109"">prostate cancer</span> cell lines in an additive manner.";16000583;2005
55829;SELENOS;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
9518;GDF15;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""16775185-0-0-32"">Macrophage inhibitory cytokine-1</span> H6D polymorphism, <span class=""disease"" id=""16775185-0-51-66"">prostate cancer</span> risk, and survival.";16775185;2006
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Combination therapy of <span class=""gene"" id=""16000583-0-23-67"">insulin-like growth factor binding protein-3</span> and retinoid X receptor ligands synergize on <span class=""disease"" id=""16000583-0-113-128"">prostate cancer</span> cell apoptosis in vitro and in vivo.";16000583;2005
55210;ATAD3A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"The effect of <span class=""gene"" id=""21584487-2-14-20"">ATAD3A</span> on the expression of prostate specific antigen (PSA) and drug resistance in <span class=""disease"" id=""21584487-2-97-100"">PCa</span> cell lines was determined by in vitro experiments.";21584487;2011
7162;TPBG;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Genetic polymorphisms in IGF-I and <span class=""gene"" id=""24586243-0-35-42"">IGFBP-3</span> are associated with <span class=""disease"" id=""24586243-0-63-78"">prostate cancer</span> in the Chinese population.";24586243;2015
7163;TPD52;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"PC-1/<span class=""gene"" id=""17875733-1-5-9"">PrLZ</span> gene overexpression has been identified to be associated with <span class=""disease"" id=""17875733-1-72-87"">prostate cancer</span> progression.";17875733;2007
3606;IL18;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Variations in the DNA sequence in the <span class=""gene"" id=""17688413-3-38-43"">IL-18</span> gene promoter may lead to altered <span class=""gene"" id=""17688413-3-78-83"">IL-18</span> production and/or activity, and so this can modulate an individual's susceptibility to <span class=""disease"" id=""17688413-3-171-186"">prostate cancer</span>.";17688413;2007
8000;PSCA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""16015594-5-0-4"">PSCA</span> in situ hybridization (ISH) was performed on the cancerous pretreatment biopsy or transurethral resection of prostate (TURP) tissue of 42 men with primarily organ-confined <span class=""disease"" id=""16015594-5-177-192"">prostate cancer</span> before CAA, and on their tumor tissue from radical retropubic prostatectomy after CAA with bicalutamide and goserelin acetate for 3 months prior to undergoing radical prostatectomy.";16015594;2006
7040;TGFB1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The TT genotype of <span class=""gene"" id=""18082198-15-19-24"">TGFB1</span> at C-509T demonstrates a protective effect against high grade <span class=""disease"" id=""18082198-15-87-102"">prostate cancer</span> and cases with poor prognosis.";18082198;2008
6223;RPS19;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as thioredoxin domain containing 5 , tumor necrosis factor receptor superfamily, member 10a , <span class=""gene"" id=""17199135-3-189-210"">ribosomal protein S19</span> and Janus kinase 2 upregulated in AI <span class=""disease"" id=""17199135-3-248-263"">prostate cancer</span>, could play important roles in the transition from AD to AI and could be biomarkers of prognosis.";17199135;2007
1571;CYP2E1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"In this study, the association between RsaI and DraI polymorphisms of <span class=""gene"" id=""12771559-2-70-76"">CYP2E1</span> and <span class=""disease"" id=""12771559-2-81-84"">PCa</span> risk was analysed in a case-control study of 227 individuals using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).";12771559;2004
796;CALCA;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Since <span class=""gene"" id=""16222118-12-6-8"">CT</span>/CTR expression in <span class=""disease"" id=""16222118-12-27-43"">prostate cancers</span> increases with tumor progression, the suppression of ""<span class=""gene"" id=""16222118-12-98-100"">CT</span> System"" may enhance the effectiveness of chemotherapy.";16222118;2006
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In summary, this is an initial description of the successful therapeutic use of <span class=""gene"" id=""16000583-7-80-87"">IGFBP-3</span> as a cancer therapy in vivo, and shows that combination treatment of <span class=""gene"" id=""16000583-7-157-164"">IGFBP-3</span> and RXR ligand has a synergistic effect on apoptosis induction leading to substantial inhibition of <span class=""disease"" id=""16000583-7-265-280"">prostate cancer</span> xenograft growth.";16000583;2005
7164;TPD52L1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3667;IRS1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The <span class=""gene"" id=""15678496-7-4-8"">IRS1</span> G972R GR/RR genotypes were associated with a significant 2.8-fold increased risk for <span class=""disease"" id=""15678496-7-94-109"">prostate cancer</span> (95% CI 1.5-5.1, P = 0.0007).";15678496;2005
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Resveratrol enhances antitumor activity of <span class=""gene"" id=""21209944-0-43-48"">TRAIL</span> in <span class=""disease"" id=""21209944-0-52-67"">prostate cancer</span> xenografts through activation of FOXO transcription factor.";21209944;2011
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with <span class=""gene"" id=""17636462-0-95-132"">TNF-related apoptosis inducing ligand</span> (<span class=""gene"" id=""17636462-0-134-139"">TRAIL</span>) in androgen-insensitive <span class=""disease"" id=""17636462-0-165-180"">prostate cancer</span> cells.";17636462;2008
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"Both NKX3.1 and <span class=""gene"" id=""17202838-2-16-19"">p53</span> are related to <span class=""disease"" id=""17202838-2-35-50"">prostate cancer</span> and play crucial roles in <span class=""disease"" id=""17202838-2-77-92"">prostate cancer</span> progression.";17202838;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Synthesis and biological evaluation of a nonsteroidal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide.;16934689;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Overall, this study demonstrates that <span class=""gene"" id=""25908785-8-38-40"">AR</span>-Vs broadly restore <span class=""gene"" id=""25908785-8-60-62"">AR</span> chromatin binding events that are otherwise suppressed during endocrine therapy, and provides pre-clinical rationale for BET inhibition as a strategy for inhibiting expression and chromatin binding of <span class=""gene"" id=""25908785-8-264-266"">AR</span>-Vs in <span class=""disease"" id=""25908785-8-273-276"">PCa</span>.";25908785;2015
1548;CYP2A6;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
2130;EWSR1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"An Interaction with Ewing's Sarcoma Breakpoint Protein <span class=""gene"" id=""27783944-0-55-58"">EWS</span> Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in <span class=""disease"" id=""27783944-0-127-142"">Prostate Cancer</span>.";27783944;2016
4609;MYC;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"These results suggest that increased expression of <span class=""gene"" id=""19593445-7-51-54"">BAD</span> provides a proliferative advantage to prostate tumors, while <span class=""gene"" id=""19593445-7-116-119"">BAD</span> dephosphorylation increases sensitivity of <span class=""disease"" id=""19593445-7-163-178"">prostate cancer</span> cells to apoptosis.";19593445;2009
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.;20876804;2010
8648;NCOA1;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"The three coactivators, TIF-2, <span class=""gene"" id=""12237244-11-31-36"">SRC-1</span> and RAC3, are up-regulated in relapsed <span class=""disease"" id=""12237244-11-76-91"">prostate cancer</span>.";12237244;2003
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.;27783944;2016
2591;GALNT3;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3326;HSP90AB1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
8202;NCOA3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Androgen receptors in prostate cancer.;12237244;2003
51755;CDK12;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
100750225;PCAT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer.;26752646;2016
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Using PC-3 and DU145 human <span class=""disease"" id=""17196171-4-27-42"">prostate cancer</span> cells, we analyzed the role of SAPKs in <span class=""gene"" id=""17196171-4-83-87"">IL-6</span> mediated cell growth and found that the p38MAPK and JNK are involved in androgen-independent cancer cell growth.";17196171;2007
3690;ITGB3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"[Prognostic implications of <span class=""gene"" id=""16158739-0-28-32"">GP3a</span> glucoprotein gene PLA1/PLA2 allele in <span class=""disease"" id=""16158739-0-71-87"">prostatic cancer</span>: pilot results of the study].";16158739;2005
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Gly388Arg polymorphism in <span class=""gene"" id=""21349172-2-26-31"">FGFR4</span> gene has been reported to be involved in <span class=""disease"" id=""21349172-2-73-88"">prostate cancer</span> incidence and aggressiveness in several studies.";21349172;2011
11178;LZTS1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Germline sequence variants of the <span class=""gene"" id=""12377406-0-34-39"">LZTS1</span> gene are associated with <span class=""disease"" id=""12377406-0-65-80"">prostate cancer</span> risk.";12377406;2002
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"DNA from 584 <span class=""disease"" id=""17999153-3-13-28"">prostate cancer</span> cases and 584 controls was genotyped for four <span class=""gene"" id=""17999153-3-75-80"">IL-10</span> alleles, -1082, -819, -592, and 210.";17999153;2008
57646;USP28;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
8661;EIF3A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1474;CST6;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Treatment of metastatic prostate cell lines with the histone deacetylase inhibitor trichostatin A resulted in significant induction of <span class=""gene"" id=""19503093-5-135-139"">CST6</span> mRNA levels and increased <span class=""gene"" id=""19503093-5-166-170"">CST6</span> protein expression, indicating that epigenetic silencing may play a role in the loss of <span class=""gene"" id=""19503093-5-259-263"">CST6</span> expression observed in <span class=""disease"" id=""19503093-5-287-302"">prostate cancer</span>.";19503093;2009
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Cellular changes in prostate cancer cells induced by intermittent androgen suppression.;17141945;2007
3293;HSD17B3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"We have investigated the G289S (glycine at codon 289 replaced by serine) polymorphism at the <span class=""gene"" id=""12210481-4-93-100"">HSD17B3</span> locus as a candidate single nucleotide polymorphism (SNP) for <span class=""disease"" id=""12210481-4-163-178"">prostate cancer</span> risk in constitutional DNA from 103 Italian <span class=""disease"" id=""12210481-4-223-238"">prostate cancer</span> patients and 109 Italian disease-free centenarians to assess the role of this SNP in susceptibility to <span class=""disease"" id=""12210481-4-342-357"">prostate cancer</span>.";12210481;2002
857;CAV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This is the first report providing evidence for <span class=""gene"" id=""15948133-9-48-53"">CAV-1</span> being involved in predisposition to aggressive <span class=""disease"" id=""15948133-9-101-116"">prostate cancer</span>.";15948133;2005
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"A recent study of familial and early onset <span class=""disease"" id=""22714738-1-43-58"">prostate cancer</span> reported a recurrent rare germline mutation of <span class=""gene"" id=""22714738-1-106-112"">HOXB13</span> among men of European descent.";22714738;2013
10551;AGR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Here we investigated whether <span class=""gene"" id=""25237833-3-29-33"">AGR2</span> transcript levels can be used as a biomarker to detect <span class=""disease"" id=""25237833-3-89-104"">prostate cancer</span> (<span class=""disease"" id=""25237833-3-106-109"">PCa</span>).";25237833;2015
307;ANXA4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"To examine this finding in a large international sample of <span class=""disease"" id=""23064873-4-59-74"">prostate cancer</span> families, we genotyped this mutation and 14 other SNPs in or flanking <span class=""gene"" id=""23064873-4-145-151"">HOXB13</span> in 2,443 <span class=""disease"" id=""23064873-4-161-176"">prostate cancer</span> families recruited by the International Consortium for Prostate Cancer Genetics (ICPCG).";23064873;2013
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Our study confirmed the association between the G84E mutation of <span class=""gene"" id=""22714738-5-65-71"">HOXB13</span> and risk of <span class=""disease"" id=""22714738-5-84-99"">prostate cancer</span> among subjects of European descent.";22714738;2013
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"New <span class=""gene"" id=""12783936-0-4-17"">paraoxonase 1</span> polymorphism I102V and the risk of <span class=""disease"" id=""12783936-0-53-68"">prostate cancer</span> in Finnish men.";12783936;2003
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;Human HOX gene disorders.;24239177;2014
8667;EIF3H;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Expression and copy number analysis of TRPS1, <span class=""gene"" id=""14997205-0-46-52"">EIF3S3</span> and MYC genes in breast and <span class=""disease"" id=""14997205-0-81-96"">prostate cancer</span>.";14997205;2004
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Using PC-3 and DU145 human <span class=""disease"" id=""17196171-4-27-42"">prostate cancer</span> cells, we analyzed the role of SAPKs in <span class=""gene"" id=""17196171-4-83-87"">IL-6</span> mediated cell growth and found that the p38MAPK and JNK are involved in androgen-independent cancer cell growth.";17196171;2007
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association of <span class=""gene"" id=""15538743-0-15-20"">CYP17</span>, GSTP1, and PON1 polymorphisms with the risk of <span class=""disease"" id=""15538743-0-69-84"">prostate cancer</span>.";15538743;2005
23382;AHCYL2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Recently, a rare, recurrent mutation (G84E) in <span class=""gene"" id=""23064873-2-47-53"">HOXB13</span> was reported to be associated with <span class=""disease"" id=""23064873-2-89-104"">prostate cancer</span> risk.";23064873;2013
283131;NEAT1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
9380;GRHPR;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5295;PIK3R1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Among the three polymorphisms, we found that the <span class=""gene"" id=""17486273-3-49-54"">XRCC1</span> Arg399Gln variant allele was associated with increased <span class=""disease"" id=""17486273-3-110-113"">PCa</span> risk (adjusted odd ratio [OR]: 1.67, 95% confident interval [CI]: 1.11-2.51), but the <span class=""gene"" id=""17486273-3-200-205"">XRCC1</span> Arg194Trp variant allele had a 38% reduction in risk of <span class=""disease"" id=""17486273-3-262-265"">PCa</span> (adjusted OR: 0.62, 95% CI: 0.41-0.93).";17486273;2007
3489;IGFBP6;C0376358;Malignant neoplasm of prostate;0,31;Therapeutic;CTD_human;"<span class=""gene"" id=""15846301-0-0-44"">Insulin-like growth factor binding protein-6</span> inhibits <span class=""disease"" id=""15846301-0-54-69"">prostate cancer</span> cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer.";15846301;2005
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;The pace of prostatic intraepithelial neoplasia development is determined by the timing of Pten tumor suppressor gene excision.;19081794;2009
6296;ACSM3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Although the <span class=""gene"" id=""16266977-3-13-30"">androgen receptor</span> (<span class=""gene"" id=""16266977-3-32-34"">AR</span>) is suggested to play an important role in <span class=""disease"" id=""16266977-3-78-93"">prostate cancer</span> progression even after the androgen ablation, limited tissue availability for molecular studies and small numbers of human <span class=""disease"" id=""16266977-3-217-232"">prostate cancer</span> cell lines have restricted <span class=""disease"" id=""16266977-3-260-275"">prostate cancer</span> research.";16266977;2005
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Palliative treatment for non-organ-confined <span class=""disease"" id=""12237244-3-44-59"">prostate cancer</span> aims to down-regulate the concentration of circulating androgen or to block the transcription activation function of the <span class=""gene"" id=""12237244-3-181-183"">AR</span>.";12237244;2003
3558;IL2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"We compared the frequency of the polymorphisms of the <span class=""gene"" id=""17115417-3-54-58"">IL-2</span> gene and the IL-2RB gene between 96 patients with <span class=""disease"" id=""17115417-3-109-124"">prostate cancer</span> and 105 healthy male volunteers from the same area (age &gt;60 years).";17115417;2007
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"In addition, there was a statistically increased risk of <span class=""disease"" id=""12622714-5-57-72"">prostate cancer</span> among smokers with the <span class=""gene"" id=""12622714-5-96-100"">NAT2</span> slow genotype (OR = 3.78: 95% CI, 1.48-9.66; P = 0.0041).";12622714;2003
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"The <span class=""gene"" id=""15525515-1-4-21"">androgen receptor</span> (<span class=""gene"" id=""15525515-1-23-25"">AR</span>) is required for male sex development and contributes to <span class=""disease"" id=""15525515-1-83-98"">prostate cancer</span> cell survival.";15525515;2004
10948;STARD3;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We hypothesized that osteoblast-derived <span class=""gene"" id=""15672864-3-40-44"">IL-6</span> in the bone microenvironment contributes to the fertile soil for <span class=""disease"" id=""15672864-3-110-113"">CaP</span> growth.";15672864;2005
10333;TLR6;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Although the single-nucleotide polymorphisms in IRAK1 and IRAK4 alone were not significantly associated with <span class=""disease"" id=""16537705-7-109-124"">prostate cancer</span> risk, one single-nucleotide polymorphism in IRAK4, when combined with the high-risk genotype at <span class=""gene"" id=""16537705-7-221-225"">TLR6</span>-1-10, conferred a significant excess risk of <span class=""disease"" id=""16537705-7-271-286"">prostate cancer</span>.";16537705;2006
5887;RAD23B;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
1026;CDKN1A;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Herein, we examined single nucleotide polymorphic variants in the 3'-untranslated region of <span class=""gene"" id=""12727815-3-92-98"">CDKN1A</span> (p21(cip1)) and in codon 109 of CDKN1B (p27(kip1)) for association with advanced <span class=""disease"" id=""12727815-3-180-195"">prostate cancer</span> in a European-American population.";12727815;2003
9;NAT1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"<span class=""gene"" id=""12618593-3-0-4"">NAT1</span> and NAT2 are both subject to genetic polymorphism in humans, and molecular epidemiological investigations suggest that <span class=""gene"" id=""12618593-3-124-128"">NAT1</span> and/or NAT2 acetylator genotype modifies risk for <span class=""disease"" id=""12618593-3-179-195"">prostate cancers</span>.";12618593;2003
2065;ERBB3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We found that <span class=""gene"" id=""17634423-2-14-20"">ErbB-3</span> expression was up-regulated in <span class=""disease"" id=""17634423-2-52-67"">prostate cancer</span> cells within lymph node and bone metastases.";17634423;2007
3169;FOXA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Exome sequencing identifies recurrent SPOP, <span class=""gene"" id=""22610119-0-44-49"">FOXA1</span> and MED12 mutations in <span class=""disease"" id=""22610119-0-73-88"">prostate cancer</span>.";22610119;2012
3558;IL2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"There was a significant difference in distribution of the genotype of the <span class=""gene"" id=""17115417-5-74-78"">IL-2</span> gene polymorphism between the <span class=""disease"" id=""17115417-5-109-124"">prostate cancer</span> group and the control group (P = 0.017).";17115417;2007
2077;ERF;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
5080;PAX6;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
23338;JADE2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6928;HNF1B;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We carried out a fine-mapping study in the <span class=""gene"" id=""18758462-1-43-48"">HNF1B</span> gene at 17q12 in two study populations and identified a second locus associated with <span class=""disease"" id=""18758462-1-134-149"">prostate cancer</span> risk, approximately 26 kb centromeric to the first known locus (rs4430796); these loci are separated by a recombination hot spot.";18758462;2008
2064;ERBB2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Low-level TOP2A amplification in <span class=""disease"" id=""17363613-0-33-48"">prostate cancer</span> is associated with <span class=""gene"" id=""17363613-0-68-72"">HER2</span> duplication, androgen resistance, and decreased survival.";17363613;2007
23301;EHBP1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Among men carrying two T alleles at rs2710647 in <span class=""gene"" id=""23593118-6-49-76"">EH domain binding protein 1</span> (<span class=""gene"" id=""23593118-6-78-83"">EHBP1</span>) SNP, the risk of <span class=""disease"" id=""23593118-6-102-117"">prostate cancer</span> in those with high malathion use was 3.43 times those with no use (95% CI: 1.44-8.15) (P-interaction= 0.003).";23593118;2013
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study demonstrated the <span class=""gene"" id=""25970160-12-28-31"">IL6</span>-Stat3-AR axis in <span class=""disease"" id=""25970160-12-49-64"">prostate cancer</span> is one of the crucial mechanisms of enzalutamide resistance.";25970160;2015
595;CCND1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study provides a molecular basis to support the correlation of IL-8 expression with that of <span class=""gene"" id=""17606477-7-97-106"">cyclin D1</span> in human <span class=""disease"" id=""17606477-7-116-131"">prostate cancer</span> and suggests a mechanism by which this chemokine promotes cell proliferation.";17606477;2007
3249;HPN;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Analysis of candidate genes for prostate cancer.;15583422;2005
632;BGLAP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our data suggest the expression of <span class=""gene"" id=""14666681-12-35-37"">OC</span> in <span class=""disease"" id=""14666681-12-41-43"">PC</span> is not correlated to the response of H/T.";14666681;2004
7015;TERT;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Sequence variants at the TERT-CLPTM1L locus associate with many cancer types.;19151717;2009
7403;KDM6A;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"Common genetic alterations in <span class=""disease"" id=""22610119-3-30-45"">prostate cancer</span> include losses of NKX3.1 (8p21) and <span class=""gene"" id=""22610119-3-82-86"">PTEN</span> (10q23), gains of AR (the androgen receptor gene) and fusion of ETS family transcription factor genes with androgen-responsive promoters.";22610119;2012
246778;IL27;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"We applied the <span class=""gene"" id=""24028178-5-15-20"">IL-27</span> gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of <span class=""disease"" id=""24028178-5-143-158"">prostate cancer</span> at a bone metastatic site in vivo.";24028178;2014
5493;PPL;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1789;DNMT3B;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"In this study, we examined the C/T polymorphism of the <span class=""gene"" id=""16012746-4-55-61"">DNMT3b</span> gene in specimens from 81 patients with <span class=""disease"" id=""16012746-4-102-117"">prostate cancer</span> and 42 controls selected from patients with benign prostatic hypertrophy (BPH).";16012746;2005
23411;SIRT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"Melatonin, a novel <span class=""gene"" id=""21062352-0-19-24"">Sirt1</span> inhibitor, imparts antiproliferative effects against <span class=""disease"" id=""21062352-0-78-93"">prostate cancer</span> in vitro in culture and in vivo in TRAMP model.";21062352;2011
7153;TOP2A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Both genes have not been compared in a single <span class=""disease"" id=""17363613-3-46-61"">prostate cancer</span> study and the frequency of <span class=""gene"" id=""17363613-3-89-94"">TOP2A</span> amplifications in <span class=""disease"" id=""17363613-3-113-128"">prostate cancer</span> is unknown.";17363613;2007
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"In this study, we analyzed <span class=""gene"" id=""12533788-3-27-32"">CHEK2</span>, the upstream regulator of p53 in the DNA-damage-signaling pathway, in several groups of patients with <span class=""disease"" id=""12533788-3-136-151"">prostate cancer</span>.";12533788;2003
27232;GNMT;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Here, we report on our efforts to characterize the haplotypes, loss of heterozygosity (LOH), and expression levels of the <span class=""gene"" id=""17332283-3-122-126"">GNMT</span> in <span class=""disease"" id=""17332283-3-130-145"">prostate cancer</span>.";17332283;2007
596;BCL2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Here, we explored the effect of DNA sequence variation within the <span class=""gene"" id=""16733517-2-66-71"">BCL-2</span> gene on <span class=""disease"" id=""16733517-2-80-95"">prostate cancer</span> susceptibility in three clinical populations, consisting of 428 African Americans, 214 Jamaicans and 218 European Americans.";16733517;2007
5176;SERPINF1;C0376358;Malignant neoplasm of prostate;0,35;Therapeutic;CTD_human;Pigment epithelial-derived factor and melanoma differentiation associated gene-7 cytokine gene therapies delivered by adipose-derived stromal/mesenchymal stem cells are effective in reducing prostate cancer cell growth.;21671747;2012
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Mutations in <span class=""gene"" id=""12533788-0-13-18"">CHEK2</span> associated with <span class=""disease"" id=""12533788-0-35-50"">prostate cancer</span> risk.";12533788;2003
8202;NCOA3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Because AR coactivators enhance transactivation of AR, in this report we evaluated the relationship of a CAG/CAA repeat length polymorphism in the <span class=""gene"" id=""11927493-2-147-151"">AIB1</span>/<span class=""gene"" id=""11927493-2-152-157"">SRC-3</span> gene (amplified in breast cancer gene 1, a steroid receptor coactivator and an AR coactivator) with <span class=""disease"" id=""11927493-2-258-273"">prostate cancer</span> risk in a population-based case-control study in China.";11927493;2002
2068;ERCC2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"As for <span class=""gene"" id=""17695467-7-7-10"">XPD</span> codon 312 or promoter-114, there was no difference in distribution between the <span class=""disease"" id=""17695467-7-90-105"">prostate cancer</span> and control groups.";17695467;2007
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results suggest that <span class=""gene"" id=""14634453-8-27-32"">hOGG1</span> may have a role in the repair of 8-OH-dG adducts in prostate tissue and <span class=""gene"" id=""14634453-8-105-110"">hOGG1</span> Ser326Cys polymorphism is associated with <span class=""disease"" id=""14634453-8-153-168"">prostate cancer</span> risk.";14634453;2004
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"It is known that over expression of <span class=""gene"" id=""25970160-1-36-39"">IL6</span> in <span class=""disease"" id=""25970160-1-43-58"">prostate cancer</span> cells confer enzalutamide resistance and that this may occur through constitutive Stat3 activation.";25970160;2015
4683;NBN;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"If validated independently, <span class=""gene"" id=""25415046-10-28-34"">Nibrin</span> gains may be the first <span class=""disease"" id=""25415046-10-58-61"">PCa</span> predictive biomarker to facilitate local treatment decisions using precision medicine approaches with surgery or radiotherapy.";25415046;2015
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our study provides evidence that the <span class=""gene"" id=""17136762-10-37-43"">SRD5A2</span> A49T A variant is associated with an increased risk of <span class=""disease"" id=""17136762-10-99-114"">prostate cancer</span>, lower levels of circulating 3alpha-diolG and decreased risk of baldness.";17136762;2007
606293;KLKP1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"<span class=""gene"" id=""16541416-0-0-6"">KLK31P</span> is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in <span class=""disease"" id=""16541416-0-116-131"">prostate cancer</span> cells than in normal prostate cells.";16541416;2006
8854;ALDH1A2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Finally, transfection-mediated reexpression of wild-type <span class=""gene"" id=""16166285-7-57-64"">ALDH1a2</span> (but not a presumptive catalytically dead mutant) in the <span class=""disease"" id=""16166285-7-122-137"">prostate cancer</span> cell line DU145 resulted in decreased colony growth (P &lt; 0.0001), comparable with treatment with either 5-aza-dC or RA.";16166285;2005
8754;ADAM9;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Microarray analysis detected elevated <span class=""gene"" id=""17018608-2-38-43"">ADAM9</span> during the transition of human LNCaP <span class=""disease"" id=""17018608-2-81-96"">prostate cancer</span> cells from an androgen-dependent to an androgen-independent and metastatic state.";17018608;2007
5309;PITX3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
5591;PRKDC;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"To test this hypothesis, DNA samples from 165 cases of <span class=""disease"" id=""17196815-3-55-70"">prostate cancer</span> and healthy controls were analyzed by PCR-RFLP to determine the genotypic frequency of three DNA repair genes (XRCC1, XPC and <span class=""gene"" id=""17196815-3-197-202"">XRCC7</span>).";17196815;2007
54790;TET2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Among men carrying two A alleles at rs7679673 in <span class=""gene"" id=""23593118-7-49-53"">TET2</span>, the risk of <span class=""disease"" id=""23593118-7-67-82"">prostate cancer</span> associated with high aldrin use was 3.67 times those with no use (95% CI: 1.43, 9.41) (P-interaction= 0.006).";23593118;2013
207;AKT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In the MNU model, the progressive evolution of dominant tumor cell populations showing an increase in p-<span class=""gene"" id=""15682402-9-104-107"">AKT</span> in parallel with a decline in AR staining suggests that activation of AKT signaling may be one of several mechanisms contributing to androgen insensitivity during <span class=""disease"" id=""15682402-9-271-286"">prostate cancer</span> progression.";15682402;2005
221895;JAZF1;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Loci on chromosome 10 include MSMB, which encodes beta-microseminoprotein, a primary constituent of semen and a proposed <span class=""disease"" id=""18264096-4-121-136"">prostate cancer</span> biomarker, and CTBP2, a gene with antiapoptotic activity; the locus on chromosome 7 is at <span class=""gene"" id=""18264096-4-227-232"">JAZF1</span>, a transcriptional repressor that is fused by chromosome translocation to SUZ12 in endometrial cancer.";18264096;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;Mutant androgen receptors in prostatic tumors distinguish between amino-acid-sequence requirements for transactivation and ligand binding.;7591265;1995
7307;U2AF1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"We confirmed that <span class=""gene"" id=""23704919-8-18-20"">AR</span> directly regulates c-Myc transcription in a ligand-independent manner, that <span class=""gene"" id=""23704919-8-97-99"">AR</span> and c-Myc suppression reduces ligand-independent <span class=""disease"" id=""23704919-8-149-164"">prostate cancer</span> cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of <span class=""gene"" id=""23704919-8-253-255"">AR</span> suppression.";23704919;2013
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.;25970160;2015
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Our findings suggest that mutations of the <span class=""gene"" id=""7511268-6-43-45"">AR</span> gene are relatively frequent in <span class=""disease"" id=""7511268-6-78-93"">prostate cancer</span> and may have therapeutical significance.";7511268;1994
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We find that <span class=""disease"" id=""19396168-3-13-28"">prostate cancer</span> specimens containing the TMPRSS2-<span class=""gene"" id=""19396168-3-62-65"">ERG</span> rearrangement are significantly enriched for loss of the tumor suppressor PTEN.";19396168;2009
5179;PENK;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
1317;SLC31A1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Not surprisingly, robust <span class=""gene"" id=""25320179-10-25-29"">CTR1</span>-dependent uptake of copper into <span class=""disease"" id=""25320179-10-62-77"">prostate cancer</span> cells was observed, an activity that was accentuated by activation of AR.";25320179;2014
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Here, we exposed <span class=""gene"" id=""18798265-5-17-20"">ERG</span>-positive <span class=""disease"" id=""18798265-5-30-45"">prostate cancer</span> cell lines to HDAC inhibitors Trichostatin A (TSA), MS-275 and suberoylanilide hydroxamic acid (SAHA) with or without androgen deprivation.";18798265;2009
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Here, we knocked down <span class=""gene"" id=""18829485-5-22-26"">SOD2</span> expression in AR-expressing LNCaP <span class=""disease"" id=""18829485-5-61-76"">prostate cancer</span> cells and determined gene expression changes, transcription factor binding, and AR transcription activity in <span class=""gene"" id=""18829485-5-186-190"">SOD2</span> knockdown cells.";18829485;2008
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We demonstrated that cultures derived from <span class=""disease"" id=""17914592-3-43-46"">PCa</span> tissues harvested after NHT presented significantly higher <span class=""gene"" id=""17914592-3-106-110"">EGFR</span> and Her2 levels compared to cultures derived from control patients.";17914592;2007
6462;SHBG;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"This study suggests that genetic variation in <span class=""gene"" id=""17220347-8-46-50"">SHBG</span> may influence <span class=""disease"" id=""17220347-8-65-80"">prostate cancer</span> susceptibility.";17220347;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"CDNA expression array analysis revealed increased manganese superoxide dismutase (<span class=""gene"" id=""12592389-2-82-87"">SOD-2</span>) expression in the mac25/IGFBP-rP1-transfected M12 human <span class=""disease"" id=""12592389-2-145-160"">prostate cancer</span> cell line compared to M12 control cells.";12592389;2003
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"We therefore sought to determine whether the <span class=""gene"" id=""15448004-3-45-51"">FGFR-4</span> Arg388 allele was associated with <span class=""disease"" id=""15448004-3-86-101"">prostate cancer</span> incidence and/or the occurrence of aggressive disease.";15448004;2005
6890;TAP1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A significantly increased risk of <span class=""disease"" id=""16406883-6-34-49"">prostate cancer</span> was observed in white men with the <span class=""gene"" id=""16406883-6-85-90"">XRCC1</span>(399Gln) allele (OR 1.6, 95% CI 1.1 to 2.4).";16406883;2006
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"In a low-selenium population, <span class=""gene"" id=""19074884-13-30-34"">SOD2</span>-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of <span class=""disease"" id=""19074884-13-102-117"">prostate cancer</span>/aggressive <span class=""disease"" id=""19074884-13-129-144"">prostate cancer</span> especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.";19074884;2009
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Stratification by quartiles of dietary and supplemental vitamin E intake (IU/d) showed risks of <span class=""disease"" id=""17646272-6-96-111"">prostate cancer</span> tended to be increased among <span class=""gene"" id=""17646272-6-141-145"">SOD2</span> Ala allele carriers, except at the highest quartile of vitamin E intake (&gt;222; P(interaction) = 0.06, Q1-Q3 versus Q4).";17646272;2007
6462;SHBG;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Collectively, our results show a role of <span class=""gene"" id=""23936228-8-41-45"">SHBG</span> in upregulating stemness of <span class=""disease"" id=""23936228-8-74-89"">prostate cancer</span> cells upon DHT exposure in vitro, and <span class=""gene"" id=""23936228-8-128-132"">SHBG</span> expression in <span class=""disease"" id=""23936228-8-147-162"">prostate cancer</span> samples is significantly associated with poor clinicopathological features, indicating a role of <span class=""gene"" id=""23936228-8-260-264"">SHBG</span> in <span class=""disease"" id=""23936228-8-268-283"">prostate cancer</span> progression.";23936228;2014
9968;MED12;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
54431;DNAJC10;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6695;SPOCK1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Expression of FBLN1 (major splice forms C and D), FBLN4, FBLN5, <span class=""gene"" id=""17929269-3-64-70"">SPOCK1</span>, and TENC was compared between 47 <span class=""disease"" id=""17929269-3-105-120"">prostate cancer</span> samples and 13 benign prostatic tissues by quantitative RT-PCR.";17929269;2008
6462;SHBG;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Heterozygotes at <span class=""gene"" id=""17220347-4-17-21"">SHBG</span> D356N were found to be associated with an increased risk of <span class=""disease"" id=""17220347-4-82-97"">prostate cancer</span> compared with the homozygous wild type, particularly among non-Hispanic whites (odds ratio, 1.54; 95% confidence interval, 1.13-2.09; P = 0.006).";17220347;2007
6695;SPOCK1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Three FBLN genes are significantly downregulated in <span class=""disease"" id=""17929269-14-52-67"">prostate cancer</span>, whereas <span class=""gene"" id=""17929269-14-77-83"">SPOCK1</span> is often upregulated.";17929269;2008
23269;MGA;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2938;GSTA1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"These findings suggest that the <span class=""gene"" id=""15616829-9-32-37"">GSTA1</span> and GSTT1 polymorphisms are associated with <span class=""disease"" id=""15616829-9-82-97"">prostate cancer</span> susceptibility, especially among smokers.";15616829;2005
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"However, we found no previous studies clarifying the nature of <span class=""gene"" id=""26468117-2-63-67"">SOD2</span> effects on <span class=""disease"" id=""26468117-2-79-94"">prostate cancer</span>.";26468117;2016
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"The results of our study of Turkish <span class=""disease"" id=""17465268-10-36-51"">prostate cancer</span> patients suggest that mutation of the <span class=""gene"" id=""17465268-10-90-95"">MnSOD</span> gene may be an important risk factor for <span class=""disease"" id=""17465268-10-137-152"">prostate cancer</span>.";17465268;2007
373156;GSTK1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4846;NOS3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The <span class=""gene"" id=""16458450-0-4-37"">endothelial nitric oxide synthase</span> Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with <span class=""disease"" id=""16458450-0-128-143"">prostate cancer</span> and benign prostatic hyperplasia.";16458450;2006
4437;MSH3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"We hypothesized that mismatch repair gene polymorphism could be a risk factor for <span class=""disease"" id=""18355840-4-82-97"">prostate cancer</span> and p53 Pro/Pro genotype carriers could influence <span class=""gene"" id=""18355840-4-148-152"">MSH3</span> and MSH6 polymorphisms.";18355840;2008
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Here, we performed integrated in vivo and in vitro protocols that analyzed the association between Ala16Val-<span class=""gene"" id=""26468117-3-108-112"">SOD2</span> polymorphism and prostate cancer aggressiveness at the time of diagnosis and evaluated the effect of the imbalance on <span class=""disease"" id=""26468117-3-231-233"">PC</span> proliferation using the DU-145 <span class=""disease"" id=""26468117-3-265-267"">PC</span> cell line treated with paraquat and porphyrin.";26468117;2016
6256;RXRA;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.;15318950;2005
4311;MME;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
1474;CST6;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"However, the association of <span class=""gene"" id=""19503093-3-28-32"">CST6</span> with <span class=""disease"" id=""19503093-3-38-53"">prostate cancer</span> invasion and progression remains unclear.";19503093;2009
1474;CST6;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"These results suggest that the downregulation of the <span class=""gene"" id=""19503093-8-53-57"">CST6</span> gene is associated with promoter histone modifications and that this association plays an important role in <span class=""disease"" id=""19503093-8-166-181"">prostate cancer</span> progression during the invasive and metastatic stages of the disease.";19503093;2009
1387;CREBBP;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer.;15378487;2005
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Selenium status also modifies the effect of the mitochondrial superoxide dismutase (<span class=""gene"" id=""19074884-3-84-88"">SOD2</span>) SNP Ala16Val on <span class=""disease"" id=""19074884-3-106-121"">prostate cancer</span> risk.";19074884;2009
10516;FBLN5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"Our recent microarray analysis suggested downregulation of three fibulins, FBLN1, FBLN4, and <span class=""gene"" id=""17929269-6-93-98"">FBLN5</span>, in <span class=""disease"" id=""17929269-6-103-118"">prostate cancer</span>, while two further ECM genes, SPOCK1 (testican) and TENC (tenascin C), appeared upregulated or unchanged.";17929269;2008
2182;ACSL4;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4780;NFE2L2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In addition, inhibition of <span class=""gene"" id=""20124447-9-27-31"">Nrf2</span> greatly suppressed in vitro and in vivo tumor growth of DU-145 <span class=""disease"" id=""20124447-9-95-110"">prostate cancer</span> cells.";20124447;2010
8339;HIST1H2BG;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
2012;EMP1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
153090;DAB2IP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Two genome-wide association studies of aggressive <span class=""disease"" id=""18073375-0-50-65"">prostate cancer</span> implicate putative prostate tumor suppressor gene <span class=""gene"" id=""18073375-0-116-122"">DAB2IP</span>.";18073375;2007
22907;DHX30;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
10551;AGR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""25237833-8-0-4"">AGR2</span> SV-G and SV-H are potential diagnostic biomarkers for the non-invasive detection of <span class=""disease"" id=""25237833-8-89-92"">PCa</span> using urine exosomes.";25237833;2015
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"<span class=""gene"" id=""19011039-0-0-13"">Interleukin-6</span> stimulation of growth of <span class=""disease"" id=""19011039-0-39-54"">prostate cancer</span> in vitro and in vivo through activation of the androgen receptor.";19011039;2009
406991;MIR21;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Resveratrol reduces <span class=""disease"" id=""23272133-0-20-35"">prostate cancer</span> growth and metastasis by inhibiting the Akt/<span class=""gene"" id=""23272133-0-80-91"">MicroRNA-21</span> pathway.";23272133;2013
3283;HSD3B1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"The purpose of this study was to determine whether polymorphisms in <span class=""gene"" id=""17826523-3-68-74"">HSD3B1</span> and UGT2B17 increase the risk of <span class=""disease"" id=""17826523-3-108-123"">prostate cancer</span>.";17826523;2007
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Further analysis demonstrated that the <span class=""disease"" id=""18304461-7-39-54"">prostate cancer</span> patients with a <span class=""gene"" id=""18304461-7-71-76"">GSTM1</span> (0/0) genotype were younger than those with the <span class=""gene"" id=""18304461-7-125-130"">GSTM1</span> (+/+) genotype (P=0.024).";18304461;2008
26054;SENP6;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We evaluated the association between polymorphisms in the cytochrome P-450 CYP1A1 (CYP1A1) and <span class=""gene"" id=""18304461-2-95-123"">glutathione S-transferase M1</span> (<span class=""gene"" id=""18304461-2-125-130"">GSTM1</span>) genes and genetic susceptibility to <span class=""disease"" id=""18304461-2-168-183"">prostate cancer</span> in Chinese men.";18304461;2008
6387;CXCL12;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A significant increase in the GA + AA genotype of the <span class=""gene"" id=""17785557-7-54-60"">CXCL12</span> G801A polymorphism was observed in <span class=""disease"" id=""17785557-7-96-98"">PC</span> patients compared with healthy controls.";17785557;2007
116113;FOXP4;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"In addition, we report here five new loci for <span class=""disease"" id=""20676098-5-46-61"">prostate cancer</span> susceptibility, at 5p15 (lambda-corrected probability P(GC) = 3.9 x 10(-18)), GPRC6A/RFX6 (P(GC) = 1.6 x 10(-12)), 13q22 (P(GC) = 2.8 x 10(-9)), C2orf43 (P(GC) = 7.5 x 10(-8)) and <span class=""gene"" id=""20676098-5-242-247"">FOXP4</span> (P(GC) = 7.6 x 10(-8)).";20676098;2010
3284;HSD3B2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Stratified analyses revealed that most of the <span class=""disease"" id=""17823934-8-46-61"">prostate cancer</span> risk associated with the intron 3 <span class=""gene"" id=""17823934-8-96-102"">HSD3B2</span> short allele was confined to the SRD5A2 89L variant subgroup and indicated that in combination these polymorphisms may be associated with increased risk of aggressive (Gleason &gt;7) disease (Gleason &gt;7).";17823934;2007
2048;EPHB2;C0376358;Malignant neoplasm of prostate;0,4;GeneticVariation;UNIPROT;"Nonsense-mediated decay microarray analysis identifies mutations of <span class=""gene"" id=""15300251-0-68-73"">EPHB2</span> in human <span class=""disease"" id=""15300251-0-83-98"">prostate cancer</span>.";15300251;2004
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"<span class=""gene"" id=""12622714-0-0-21"">N-acetyltransferase-2</span> gene polymorphism as a possible biomarker for <span class=""disease"" id=""12622714-0-68-83"">prostate cancer</span> in Japanese men.";12622714;2003
50508;NOX3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
463;ZFHX3;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
463;ZFHX3;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6185;RPN2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Lastly, the <span class=""gene"" id=""12622714-7-12-16"">NAT2</span> slow acetylator genotype was significantly higher among <span class=""disease"" id=""12622714-7-73-88"">prostate cancer</span> patients with high-grade tumors (31.4%) compared with controls (8.6%) (OR = 4.90; 95% CI, 1.97-12.20; P = 0.0010).";12622714;2003
23036;ZNF292;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Altered <span class=""gene"" id=""18670643-0-8-43"">fibroblast growth factor receptor 4</span> stability promotes <span class=""disease"" id=""18670643-0-63-78"">prostate cancer</span> progression.";18670643;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Effects of manganese superoxide dismutase silencing on androgen receptor function and gene regulation: implications for castration-resistant prostate cancer.;18829485;2008
6817;SULT1A1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"When <span class=""gene"" id=""14973106-9-5-12"">SULT1A1</span> activity was considered, there was a strong association between increased <span class=""gene"" id=""14973106-9-87-94"">SULT1A1</span> activity and <span class=""disease"" id=""14973106-9-108-123"">prostate cancer</span> risk in Caucasians (OR, 3.04; 95% CI, 1.8-5.1 and OR, 4.96; 95% CI, 3.0-8.3, for the second and third tertiles of <span class=""gene"" id=""14973106-9-238-245"">SULT1A1</span> activity, respectively) compared with individuals in the low enzyme activity tertile.";14973106;2004
136991;ASZ1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
7372;UMPS;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Overexpression of orotate phosphoribosyl transferase in hormone-refractory prostate cancer.;19082440;2009
3952;LEP;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"According to our results we hypothesize that the polymorphism in <span class=""gene"" id=""15042602-7-65-68"">LEP</span> gene may be relevant to <span class=""disease"" id=""15042602-7-93-95"">PC</span> risk and progression, supporting the hypothesis for <span class=""gene"" id=""15042602-7-148-154"">leptin</span> involvement in cancer ethiopathogenesis.";15042602;2004
632;BGLAP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Previously, we demonstrated that <span class=""gene"" id=""14666681-2-33-35"">OC</span> immunohistochemical staining was found in primary <span class=""disease"" id=""14666681-2-86-101"">prostate cancer</span> (<span class=""disease"" id=""14666681-2-103-105"">PC</span>) and <span class=""disease"" id=""14666681-2-111-113"">PC</span> metastasis to lymph node and bone.";14666681;2004
2650;GCNT1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"By examining the polymorphism in <span class=""disease"" id=""15882971-3-33-48"">prostate cancer</span> and benign prostatic hyperplasia patients, we found that the <span class=""gene"" id=""15882971-3-110-115"">C2GnT</span> G allele was more frequently observed in the <span class=""disease"" id=""15882971-3-161-176"">prostate cancer</span> group (p=0.015) than the control group.";15882971;2005
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"p38MAPK activation is involved in androgen-independent proliferation of human <span class=""disease"" id=""17196171-0-78-93"">prostate cancer</span> cells by regulating <span class=""gene"" id=""17196171-0-114-118"">IL-6</span> secretion.";17196171;2007
7012;TERC;C0376358;Malignant neoplasm of prostate;0,32;Therapeutic;CTD_human;Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model.;16520278;2006
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The <span class=""gene"" id=""17823934-6-4-10"">SRD5A2</span> V89L polymorphism was not independently associated with <span class=""disease"" id=""17823934-6-67-82"">prostate cancer</span> risk.";17823934;2007
894;CCND2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Conversely, <span class=""gene"" id=""17016690-6-12-21"">Cyclin D2</span> mRNA levels were significantly lower in <span class=""disease"" id=""17016690-6-62-65"">PCa</span> (P&lt;0.01) and a significant inverse correlation between <span class=""gene"" id=""17016690-6-121-130"">Cyclin D2</span> methylation and expression levels was found in prostatic tissues (r=-0.61, P&lt;0.000001).";17016690;2007
1588;CYP19A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We identified a novel single nucleotide polymorphism (SNP) in the <span class=""gene"" id=""16424004-3-66-73"">CYP19A1</span> gene, T201M, with a mild significant association with <span class=""disease"" id=""16424004-3-128-143"">prostate cancer</span> [odds ratio (OR), 2.04; 95% confidence interval (95% CI), 1.03-4.03; P = 0.04].";16424004;2006
1543;CYP1A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In conclusion, our study demonstrated that exon 3 of mEH and <span class=""gene"" id=""17919073-9-61-67"">CYP1A1</span> T/C gene polymorphism are predisposing risk factors for susceptibility of sporadic <span class=""disease"" id=""17919073-9-151-154"">PCa</span> in northern India.";17919073;2008
43;ACHE;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"The <span class=""gene"" id=""20356562-6-4-8"">AChE</span> activity did not vary with cancer, showing 2.46+/-0.45 mU/mg in S1 and 2.70+/-0.53 mU/mg in S2 from <span class=""disease"" id=""20356562-6-109-111"">PC</span> samples.";20356562;2010
8644;AKR1C3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our results provide suggestive findings for an association with either familial or sporadic <span class=""disease"" id=""17507624-8-92-107"">prostate cancer</span> with polymorphisms in four genes: <span class=""gene"" id=""17507624-8-142-148"">AKR1C3</span>, HSD17B1, NQO1, and GSTT1.";17507624;2007
10961;ERP29;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5144;PDE4D;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Taken together, these observations suggest that combination therapy with <span class=""gene"" id=""16000583-8-73-80"">IGFBP-3</span> and RXR ligands may have therapeutic potential for <span class=""disease"" id=""16000583-8-132-147"">prostate cancer</span> treatment.";16000583;2005
3479;IGF1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
5567;PRKACB;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Androgen dependent regulation of protein kinase A subunits in prostate cancer cells.;16949795;2007
11009;IL24;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"These studies present definitive evidence that changes in mitochondrial function and ROS production are key components associated with selective killing of <span class=""disease"" id=""14678967-7-156-171"">prostate cancer</span> cells by <span class=""gene"" id=""14678967-7-181-186"">mda-7</span>/<span class=""gene"" id=""14678967-7-187-192"">IL-24</span>.";14678967;2004
27232;GNMT;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Peripheral blood mononuclear cell DNA collected from 326 <span class=""disease"" id=""17332283-4-57-72"">prostate cancer</span> patients and 327 age-matched controls was used to determine <span class=""gene"" id=""17332283-4-133-137"">GNMT</span> haplotypes.";17332283;2007
3479;IGF1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We investigated whether <span class=""gene"" id=""16465378-3-24-29"">IGF-I</span> might also affect the motility of <span class=""disease"" id=""16465378-3-64-79"">prostate cancer</span> cells and defined the mechanism of action.";16465378;2006
472;ATM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We investigated whether the prevalence of the <span class=""gene"" id=""17502119-3-46-49"">ATM</span> missense substitution P1054R is increased in a hospital-based series of <span class=""disease"" id=""17502119-3-122-137"">prostate cancer</span> patients and whether carriers are at increased risk for treatment-related side effects.";17502119;2008
27232;GNMT;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Haplotypes, loss of heterozygosity, and expression levels of <span class=""gene"" id=""17332283-0-61-88"">glycine N-methyltransferase</span> in <span class=""disease"" id=""17332283-0-92-107"">prostate cancer</span>.";17332283;2007
5925;RB1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2192;FBLN1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Our recent microarray analysis suggested downregulation of three fibulins, <span class=""gene"" id=""17929269-6-75-80"">FBLN1</span>, FBLN4, and FBLN5, in <span class=""disease"" id=""17929269-6-103-118"">prostate cancer</span>, while two further ECM genes, SPOCK1 (testican) and TENC (tenascin C), appeared upregulated or unchanged.";17929269;2008
5396;PRRX1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
467;ATF3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The expression of transcription factor <span class=""gene"" id=""16516039-0-39-72"">activating transcription factor 3</span> in the human prostate and its regulation by androgen in <span class=""disease"" id=""16516039-0-129-144"">prostate cancer</span>.";16516039;2006
6558;SLC12A2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Among the SNPs studied, the A allele of the <span class=""gene"" id=""17085659-6-44-48"">KLK2</span>-SNP1 (G&gt;A, rs2664155) and the T allele of the <span class=""gene"" id=""17085659-6-95-99"">KLK2</span>-SNP5 (C&gt;T, rs198977) polymorphisms showed positive associations with <span class=""disease"" id=""17085659-6-169-184"">prostate cancer</span>, adjusted ORs for <span class=""gene"" id=""17085659-6-203-207"">KLK2</span>-SNP1 AG and AA genotypes being 1.4 [95% confidence interval (95% CI), 1.2-1.8; P=0.002] and for <span class=""gene"" id=""17085659-6-304-308"">KLK2</span>-SNP5 TT or CT genotypes being 1.3 (95% CI, 1.1-1.6; P=0.05).";17085659;2007
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These SNPs were identified from sequencing the <span class=""gene"" id=""17085659-4-47-51"">KLK2</span> gene among 20 patients with aggressive <span class=""disease"" id=""17085659-4-91-106"">prostate cancer</span>.";17085659;2007
672;BRCA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To our knowledge, however, no study has comprehensively assessed the role of other <span class=""gene"" id=""17585057-2-83-88"">BRCA1</span> sequence variations (e.g., missense mutations) in <span class=""disease"" id=""17585057-2-139-154"">prostate cancer</span>.";17585057;2007
384;ARG2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"In contrast to <span class=""disease"" id=""23424623-6-15-30"">prostate cancer</span>, <span class=""gene"" id=""23424623-6-32-36"">ARG2</span> expression was rarely demonstrated in PDC cells by immunohistochemistry, and instead <span class=""gene"" id=""23424623-6-122-126"">ARG2</span> was characteristically expressed in α-smooth muscle actin-positive cancer-associated fibroblasts (CAFs), especially those located within and around necrotic areas in PDC.";23424623;2013
55210;ATAD3A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"In order to investigate the clinical value of <span class=""gene"" id=""21584487-1-46-84"">ATPase family AAA domain containing 3A</span> (<span class=""gene"" id=""21584487-1-86-92"">ATAD3A</span>), a potential anti-apoptotic factor in <span class=""disease"" id=""21584487-1-132-147"">prostate cancer</span> (<span class=""disease"" id=""21584487-1-149-152"">PCa</span>), immunohistochemistry was used to measure <span class=""gene"" id=""21584487-1-196-202"">ATAD3A</span> expression in pathological specimens from 86 Chinese patients and in 183 tissue-array samples from American patients.";21584487;2011
3219;HOXB9;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo.;27182052;2017
6928;HNF1B;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Multiple loci identified in a genome-wide association study of prostate cancer.;18264096;2008
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Individuals carrying both the CYP19A1 and <span class=""gene"" id=""16424004-7-42-46"">KLK3</span> -252A&gt;G variant alleles had a significantly increased risk for <span class=""disease"" id=""16424004-7-110-125"">prostate cancer</span> (OR, 2.87; 95% CI, 1.10-7.49; P = 0.03).";16424004;2006
26499;PLEK2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;Regulation and expression of human CYP7B1 in prostate: overexpression of CYP7B1 during progression of prostatic adenocarcinoma.;17639508;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;[Implications of estrogens and their receptors for the development and progression of prostate cancer].;16220300;2006
8495;PPFIBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We identify two independent susceptibility loci for <span class=""disease"" id=""26443449-4-52-67"">prostate cancer</span> at 11p15.4 (rs12791447, P=3.59 × 10(-8); <span class=""gene"" id=""26443449-4-109-116"">PPFIBP2</span>) and 14q23.2 (rs58262369, P=6.05 × 10(-10); ESR2).";26443449;2016
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Hypermethylation of the <span class=""gene"" id=""18559593-7-24-29"">SSBP2</span> promoter and its expression were closely associated with higher stages of <span class=""disease"" id=""18559593-7-104-119"">prostate cancer</span>.";18559593;2008
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"<span class=""gene"" id=""15672864-2-0-13"">Interleukin-6</span> (<span class=""gene"" id=""15672864-2-15-19"">IL-6</span>) is considered to contribute to <span class=""disease"" id=""15672864-2-52-55"">CaP</span> progression and is produced at high levels in osteoblasts.";15672864;2005
7862;BRPF1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
132671;SPATA18;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"<span class=""gene"" id=""19074884-10-0-4"">SOD2</span>-Ala16+ men were at a greater risk of <span class=""disease"" id=""19074884-10-42-57"">prostate cancer</span> [odds ratios (OR), 1.19; 95% confidence intervals (CI), 1.03-1.37] compared with <span class=""gene"" id=""19074884-10-139-143"">SOD2</span>-Val16 homozygotes.";19074884;2009
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"It is known that over expression of IL6 in <span class=""disease"" id=""25970160-1-43-58"">prostate cancer</span> cells confer enzalutamide resistance and that this may occur through constitutive <span class=""gene"" id=""25970160-1-141-146"">Stat3</span> activation.";25970160;2015
29087;THYN1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
154;ADRB2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Interestingly, <span class=""gene"" id=""18454446-9-15-25"">beta(2)-AR</span> mRNA was strongly down-regulated by androgen ablation therapy of <span class=""disease"" id=""18454446-9-91-106"">prostate cancer</span> patients.";18454446;2008
7422;VEGFA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A significant increased risk of <span class=""disease"" id=""16908180-7-32-47"">prostate cancer</span> was associated with the <span class=""gene"" id=""16908180-7-72-76"">VEGF</span> -634 (GC+CC) combined genotype (OR=1.95; P=0.02).";16908180;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7298;TYMS;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Tissue of <span class=""disease"" id=""15999119-4-10-13"">CaP</span> and BPH tissue samples were obtained from formalin-fixed, paraffin-embedded sections by laser-captured microdissection, and then RNA was extracted. mRNA expression of <span class=""gene"" id=""15999119-4-181-183"">TS</span>, DPD, TP, and OPRT was analyzed by quantitative reverse transcriptase-polymerase chain reaction.";15999119;2005
222546;RFX6;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Clinical data indicate that <span class=""gene"" id=""24390282-6-28-32"">RFX6</span> upregulation in human <span class=""disease"" id=""24390282-6-55-71"">prostate cancers</span> correlates with tumor progression, metastasis and risk of biochemical relapse.";24390282;2014
222546;RFX6;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Together, our results suggest that rs339331 affects <span class=""disease"" id=""24390282-8-52-67"">prostate cancer</span> risk by altering <span class=""gene"" id=""24390282-8-85-89"">RFX6</span> expression through a functional interaction with the <span class=""disease"" id=""24390282-8-143-158"">prostate cancer</span> susceptibility gene HOXB13.";24390282;2014
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Dietary intake of phytoestrogens, <span class=""gene"" id=""16921512-0-34-56"">estrogen receptor-beta</span> polymorphisms and the risk of <span class=""disease"" id=""16921512-0-87-102"">prostate cancer</span>.";16921512;2006
6950;TCP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
2272;FHIT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"In a recent study, linkage and association between germline genetic variation in <span class=""gene"" id=""17548701-3-81-85"">FHIT</span> (specifically single nucleotide polymorphism rs760317) and <span class=""disease"" id=""17548701-3-145-160"">prostate cancer</span> were reported.";17548701;2007
596;BCL2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Germline <span class=""gene"" id=""16733517-0-9-14"">BCL-2</span> sequence variants and inherited predisposition to <span class=""disease"" id=""16733517-0-65-80"">prostate cancer</span>.";16733517;2007
2146;EZH2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
50618;ITSN2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
23071;ERP44;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Over-expression of <span class=""gene"" id=""20729295-3-19-21"">AR</span> and upregulation of <span class=""gene"" id=""20729295-3-42-44"">AR</span> transcriptional activity are often observed in the later stages of <span class=""disease"" id=""20729295-3-112-127"">prostate cancer</span>.";20729295;2011
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Overall, our data suggest that mutations in <span class=""gene"" id=""12533788-9-44-49"">CHEK2</span> may contribute to <span class=""disease"" id=""12533788-9-68-83"">prostate cancer</span> risk and that the DNA-damage-signaling pathway may play an important role in the development of <span class=""disease"" id=""12533788-9-180-195"">prostate cancer</span>.";12533788;2003
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Other <span class=""gene"" id=""12783936-11-6-10"">PON1</span> alleles were not statistically significantly associated with <span class=""disease"" id=""12783936-11-72-87"">prostate cancer</span>.";12783936;2003
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"[<span class=""gene"" id=""7511268-0-1-18"">Androgen receptor</span> gene mutations and p53 gene analysis in advanced <span class=""disease"" id=""7511268-0-68-83"">prostate cancer</span>].";7511268;1994
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In Caucasians, higher <span class=""disease"" id=""18174250-7-22-25"">CaP</span> risk was associated with the <span class=""gene"" id=""18174250-7-55-59"">IL10</span>-1082AG/GG genotype (OR = 3.62, 95% CI = 1.42-9.28), the genotype combination of <span class=""gene"" id=""18174250-7-140-144"">IL10</span>-1082AA plus IL1B-31TT/TC (OR = 2.92, 95% CI = 1.13-7.55) and the genotype combination of TNF-238GG plus <span class=""gene"" id=""18174250-7-249-253"">IL10</span>-592AA (OR = 2.14, 95% CI = 1.05-4.38).";18174250;2008
6387;CXCL12;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Currently, there are no reports investigating the role of <span class=""gene"" id=""17785557-3-58-64"">CXCL12</span> G801A polymorphism in <span class=""disease"" id=""17785557-3-87-102"">prostate cancer</span> (<span class=""disease"" id=""17785557-3-104-106"">PC</span>).";17785557;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"<span class=""gene"" id=""8274409-0-0-17"">Androgen receptor</span> gene mutations in human <span class=""disease"" id=""8274409-0-42-57"">prostate cancer</span>.";8274409;1994
10857;PGRMC1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
3283;HSD3B1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"No evidence was found for a main effect of the <span class=""gene"" id=""17826523-5-47-53"">HSD3B1</span> codon 367 polymorphism on <span class=""disease"" id=""17826523-5-80-95"">prostate cancer</span> risk.";17826523;2007
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process.;20932324;2011
1545;CYP1B1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The VV (high activity) genotype of the V432L polymorphism from <span class=""gene"" id=""17704407-4-63-69"">CYP1B1</span> (odds ratio [OR] = 1.36; 95% CI, 1.03 to 1.79; P = .031), and the long allele (&gt; 175 bp) of the TTTA repeat from CYP19 (OR, 1.26; 95% CI, 1.08 to 1.47; P = .003) were significantly associated with the risk of <span class=""disease"" id=""17704407-4-279-294"">prostate cancer</span>.";17704407;2007
4036;LRP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To test this hypothesis, DNA samples from 165 cases of <span class=""disease"" id=""17196815-3-55-70"">prostate cancer</span> and healthy controls were analyzed by PCR-RFLP to determine the genotypic frequency of three DNA repair genes (<span class=""gene"" id=""17196815-3-182-187"">XRCC1</span>, XPC and XRCC7).";17196815;2007
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Therefore, the present study was designed to validate whether resveratrol can enhance the apoptosis-inducing potential of <span class=""gene"" id=""21209944-3-122-127"">TRAIL</span> in a xenograft model of <span class=""disease"" id=""21209944-3-152-167"">prostate cancer</span>.";21209944;2011
8560;DEGS1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
283237;TTC9C;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1585;CYP11B2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
7113;TMPRSS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Gene fusions between prostate-specific, androgen responsive <span class=""gene"" id=""18798265-1-60-67"">TMPRSS2</span> gene and oncogenic ETS factors, such as ERG, occur in up to 50% of all <span class=""disease"" id=""18798265-1-139-155"">prostate cancers</span>.";18798265;2009
2690;GHR;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"One haplotype in the 3' region of the <span class=""gene"" id=""17220348-3-38-41"">GHR</span> gene was found associated with <span class=""disease"" id=""17220348-3-73-88"">prostate cancer</span> risk in elderly men (&gt;65 years old at the time of diagnosis), with heterozygote haplotype carriers having an odds ratio of 1.65 (95% confidence interval, 1.21-2.16; P = 0.0009, P(corrected) = 0.03).";17220348;2007
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Our results indicate a role of <span class=""gene"" id=""15717312-8-31-35"">NAT2</span> polymorphisms in the carcinogenic pathway of <span class=""disease"" id=""15717312-8-81-96"">prostate cancer</span>, specifically in a population of Southern Europe.";15717312;2005
6817;SULT1A1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Caucasians homozygous for the <span class=""gene"" id=""14973106-7-30-37"">SULT1A1</span>*1 high activity allele were at increased risk for <span class=""disease"" id=""14973106-7-88-103"">prostate cancer</span> [odds ratio (OR), 1.68; 95% confidence interval (CI), 1.05-2.68] compared with individuals homozygous for the low-activity allele.";14973106;2004
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Knock down of <span class=""gene"" id=""25970160-10-14-19"">Stat3</span> abrogated enzalutamide resistance resulting in reduced recruitment of AR to the PSA promoter in <span class=""disease"" id=""25970160-10-116-131"">prostate cancer</span> cells expressing IL6.";25970160;2015
64579;NDST4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
6817;SULT1A1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"The association between <span class=""gene"" id=""14973106-8-24-31"">SULT1A1</span> genotype and <span class=""disease"" id=""14973106-8-45-60"">prostate cancer</span> risk in African-Americans did not reach significance (OR, 1.60; 95% CI, 0.46-5.62).";14973106;2004
6817;SULT1A1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"These results indicate that variations in <span class=""gene"" id=""14973106-13-42-49"">SULT1A1</span> activity contributes to <span class=""disease"" id=""14973106-13-74-89"">prostate cancer</span> risk and the magnitude of the association may differ by ethnicity and be modified by meat consumption.";14973106;2004
1576;CYP3A4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""15496535-0-0-6"">CYP3A4</span> polymorphisms--potential risk factors for breast and <span class=""disease"" id=""15496535-0-60-75"">prostate cancer</span>: a HuGE review.";15496535;2004
6817;SULT1A1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"When <span class=""gene"" id=""14973106-12-5-12"">SULT1A1</span> activity was stratified by tertiles of meat consumption, there was greater risk of <span class=""disease"" id=""14973106-12-96-111"">prostate cancer</span> in the highest tertile of meat consumption.";14973106;2004
10948;STARD3;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Our findings concerning <span class=""gene"" id=""17592021-10-24-29"">MLN64</span> and CYP17 gene expression and their significant positive correlation in human <span class=""disease"" id=""17592021-10-108-123"">prostate cancer</span> may suggest their possible role in intraneoplastic autonomous steroidogenesis.";17592021;2007
10948;STARD3;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"In the present study, we investigated the expression of <span class=""gene"" id=""17592021-3-56-61"">MLN64</span> in <span class=""disease"" id=""17592021-3-65-80"">prostate cancer</span>, another hormone-dependent tumor, and compared its expression with that of CYP17, the gene encoding for the key enzyme of androgen synthesis.";17592021;2007
8085;KMT2D;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
3952;LEP;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"We evaluated DNA samples from 268 (536 alleles) unrelated individuals, 118 healthy controls (HCs) and 150 <span class=""disease"" id=""15042602-3-106-121"">prostate cancer</span> (<span class=""disease"" id=""15042602-3-123-125"">PC</span>) patients, for <span class=""gene"" id=""15042602-3-141-147"">leptin</span> gene (LEP) locus -2548 genotypes.";15042602;2004
563;AZGP1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Similarly to androgen-independent <span class=""disease"" id=""16877366-3-34-37"">PCa</span> in patients, the relapsed xenografts and cell line expressed <span class=""gene"" id=""16877366-3-99-101"">AR</span> and were resistant to treatment with bicalutamide.";16877366;2006
2065;ERBB3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Bone microenvironment and androgen status modulate subcellular localization of <span class=""gene"" id=""17634423-0-79-84"">ErbB3</span> in <span class=""disease"" id=""17634423-0-88-103"">prostate cancer</span> cells.";17634423;2007
7371;UCK2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Endocrine approaches in the therapy of prostate carcinoma.;15790600;2005
7114;TMSB4X;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Downregulation of thymosin beta4 expression by androgen in prostate cancer LNCaP cells.;17916567;2008
3952;LEP;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Overexpressing <span class=""gene"" id=""15042602-0-15-21"">leptin</span> genetic polymorphism (-2548 G/A) is associated with susceptibility to <span class=""disease"" id=""15042602-0-92-107"">prostate cancer</span> and risk of advanced disease.";15042602;2004
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model.;15126378;2004
28;ABO;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""18304461-9-0-5"">GSTM1</span> (0/0) gene polymorphism may be linked to <span class=""disease"" id=""18304461-9-47-62"">prostate cancer</span> risk and early age of onset in Chinese.";18304461;2008
23411;SIRT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"Forced overexpression of <span class=""gene"" id=""21062352-7-25-30"">Sirt1</span> partially rescued the <span class=""disease"" id=""21062352-7-53-56"">PCa</span> cells from melatonin's antiproliferative effects, suggesting that <span class=""gene"" id=""21062352-7-123-128"">Sirt1</span> is a direct target of melatonin.";21062352;2011
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.;16998812;2007
356;FASLG;C0376358;Malignant neoplasm of prostate;0,33;Therapeutic;CTD_human;Fas ligand delivery by a prostate-restricted replicative adenovirus enhances safety and antitumor efficacy.;17875776;2007
328;APEX1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Association between polymorphisms in the DNA repair genes XRCC1 and <span class=""gene"" id=""16406883-0-68-72"">APE1</span>, and the risk of <span class=""disease"" id=""16406883-0-90-105"">prostate cancer</span> in white and black Americans.";16406883;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Resveratrol regulates the PTEN/AKT pathway through <span class=""gene"" id=""20729295-0-51-68"">androgen receptor</span>-dependent and -independent mechanisms in <span class=""disease"" id=""20729295-0-110-125"">prostate cancer</span> cell lines.";20729295;2011
4824;NKX3-1;C0376358;Malignant neoplasm of prostate;0,54;Biomarker;CTD_human;Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.;22610119;2012
8409;UXT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Our studies show that reduction of <span class=""gene"" id=""19318562-11-35-41"">ART-27</span> protein levels in <span class=""disease"" id=""19318562-11-60-75"">prostate cancer</span> may facilitate antiandrogen-resistant disease.";19318562;2009
27294;DHDH;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
1499;CTNNB1;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;Inactivation of Apc in the mouse prostate causes prostate carcinoma.;17363566;2007
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Two polymorphisms, a valine (V) for leucine (L) substitution at the 89 codon of the <span class=""gene"" id=""17823934-3-84-90"">SRD5A2</span> gene and a (TG)n,(TA)n,(CA)n repeat polymorphism within the third intron of the HSD3B2 gene were evaluated with regard to <span class=""disease"" id=""17823934-3-213-228"">prostate cancer</span> risk.";17823934;2007
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Iodide uptake in a panel of non-prostate tumor cell lines infected with <span class=""disease"" id=""14633711-9-72-80"">Ad-ARR(2</span>)PB/h<span class=""gene"" id=""14633711-9-85-88"">NIS</span> was no more than 2,500 cpm, demonstrating the tissue specificity of this construct.";14633711;2004
6916;TBXAS1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
54535;CCHCR1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.;21743467;2011
7015;TERT;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We also identified a SNP in <span class=""gene"" id=""21743467-6-28-32"">TERT</span> more strongly associated with <span class=""disease"" id=""21743467-6-63-67"">PrCa</span> than that previously reported.";21743467;2011
10257;ABCC4;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Androgen induces expression of the multidrug resistance protein gene <span class=""gene"" id=""17003774-0-69-73"">MRP4</span> in <span class=""disease"" id=""17003774-0-77-92"">prostate cancer</span> cells.";17003774;2007
8379;MAD1L1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;;;
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"However, supportive evidence is limited to the effect of HER-2/neu that stimulates <span class=""disease"" id=""19011039-2-83-98"">prostate cancer</span> progression through activation of the <span class=""gene"" id=""19011039-2-137-154"">androgen receptor</span>.";19011039;2009
1191;CLU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This androgen regulation of <span class=""gene"" id=""17148459-13-28-37"">clusterin</span> may underline the cytoprotective role of androgens in normal prostate physiology as well as play an antiapoptotic role in <span class=""disease"" id=""17148459-13-160-175"">prostate cancer</span> progression.";17148459;2007
29893;PSMC3IP;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
55827;DCAF6;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
4193;MDM2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In the comparison of genotype distributions of TP53 codon 72 between cases and controls, the adjusted odds ratios for <span class=""disease"" id=""20875869-3-118-121"">PCa</span> associated with the Pro/Pro, Arg/Pro, and Arg/Arg genotypes were 1.00, 1.89 (95% CI = 1.20-2.97), and 2.01 (95% CI = 1.11-3.64), respectively; however, <span class=""gene"" id=""20875869-3-274-278"">MDM2</span> SNP309 and C1797G did not show any significant difference between cases and controls.";20875869;2010
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We have recently shown that resveratrol can enhance the apoptosis-inducing potential of <span class=""gene"" id=""21209944-2-88-93"">TRAIL</span> in <span class=""disease"" id=""21209944-2-97-112"">prostate cancer</span> cells through multiple mechanisms in vitro.";21209944;2011
3171;FOXA3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
55072;RNF31;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
4023;LPL;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"A high fat intake has been associated with <span class=""disease"" id=""15386377-1-43-58"">prostate cancer</span> risk, and gene polymorphisms of <span class=""gene"" id=""15386377-1-91-109"">lipoprotein lipase</span> (<span class=""gene"" id=""15386377-1-111-114"">LPL</span>) play an important role in plasma lipoprotein metabolism.";15386377;2004
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Treatment with the bromodomain and extraterminal (BET) inhibitor JQ1 resulted in inhibition of <span class=""gene"" id=""25908785-6-95-97"">AR</span>-V chromatin binding and impaired <span class=""gene"" id=""25908785-6-131-133"">AR</span>-V driven <span class=""disease"" id=""25908785-6-143-146"">PCa</span> cell growth in vitro and in vivo.";25908785;2015
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"<span class=""gene"" id=""25908785-1-0-17"">Androgen receptor</span> (<span class=""gene"" id=""25908785-1-19-21"">AR</span>) variants (<span class=""gene"" id=""25908785-1-33-35"">AR</span>-Vs) expressed in <span class=""disease"" id=""25908785-1-53-68"">prostate cancer</span> (<span class=""disease"" id=""25908785-1-70-73"">PCa</span>) lack the <span class=""gene"" id=""25908785-1-84-86"">AR</span> ligand binding domain (LBD) and function as constitutively active transcription factors.";25908785;2015
7163;TPD52;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
9709;HERPUD1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6768;ST14;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3915;LAMC1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
5530;PPP3CA;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
7422;VEGFA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We demonstrate that treatment of human <span class=""disease"" id=""16606632-9-39-54"">prostate cancer</span> cell lines with zinc reduces expression of <span class=""gene"" id=""16606632-9-98-102"">VEGF</span>, IL-6, IL-8 and MMP-9.";16606632;2006
10810;WASF3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
5328;PLAU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Sixty-three locally recurrent hormone-refractory tumours and 78 hormone-refractory metastases from 29 patients who died from <span class=""disease"" id=""16430655-2-125-140"">prostate cancer</span> were analysed for <span class=""gene"" id=""16430655-2-159-162"">uPA</span> gene-copy number using fluorescence in situ hybridization.";16430655;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Similarly to androgen-independent <span class=""disease"" id=""16877366-3-34-37"">PCa</span> in patients, the relapsed xenografts and cell line expressed <span class=""gene"" id=""16877366-3-99-101"">AR</span> and were resistant to treatment with bicalutamide.";16877366;2006
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"The epidemiological impact of <span class=""gene"" id=""26468117-1-30-34"">SOD2</span> imbalance on <span class=""disease"" id=""26468117-1-48-63"">prostate cancer</span> (<span class=""disease"" id=""26468117-1-65-67"">PC</span>) risk associated with genetic variations has previously been studied.";26468117;2016
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""19074884-10-0-4"">SOD2</span>-Ala16+ men were at a greater risk of <span class=""disease"" id=""19074884-10-42-57"">prostate cancer</span> [odds ratios (OR), 1.19; 95% confidence intervals (CI), 1.03-1.37] compared with <span class=""gene"" id=""19074884-10-139-143"">SOD2</span>-Val16 homozygotes.";19074884;2009
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Combination therapy of <span class=""gene"" id=""16000583-0-23-67"">insulin-like growth factor binding protein-3</span> and retinoid X receptor ligands synergize on <span class=""disease"" id=""16000583-0-113-128"">prostate cancer</span> cell apoptosis in vitro and in vivo.";16000583;2005
2908;NR3C1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"The <span class=""gene"" id=""19244107-1-4-21"">androgen receptor</span> (<span class=""gene"" id=""19244107-1-23-25"">AR</span>) plays a key role in progression to incurable androgen ablation-resistant <span class=""disease"" id=""19244107-1-100-115"">prostate cancer</span> (PCA).";19244107;2009
9518;GDF15;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A recent study (JNCI 2004, 96:1248-1254) found marginal evidence of an association between the presence of the mature <span class=""gene"" id=""16775185-3-118-123"">MIC-1</span> protein nonsynonymous polymorphism H6D C-to-G (rs1058587) with reduced <span class=""disease"" id=""16775185-3-195-210"">prostate cancer</span> risk [odds ratio, 0.83; 95% confidence interval (95% CI), 0.69-0.99].";16775185;2006
84818;IL17RC;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Differential expression of <span class=""gene"" id=""17603628-0-27-34"">IL-17RC</span> isoforms in androgen-dependent and androgen-independent <span class=""disease"" id=""17603628-0-91-107"">prostate cancers</span>.";17603628;2007
472;ATM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""17502119-0-0-3"">ATM</span> missense variant P1054R predisposes to <span class=""disease"" id=""17502119-0-43-58"">prostate cancer</span>.";17502119;2008
8804;CREG1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"NAT1 and <span class=""gene"" id=""12618593-3-9-13"">NAT2</span> are both subject to genetic polymorphism in humans, and molecular epidemiological investigations suggest that NAT1 and/or <span class=""gene"" id=""12618593-3-136-140"">NAT2</span> acetylator genotype modifies risk for <span class=""disease"" id=""12618593-3-179-195"">prostate cancers</span>.";12618593;2003
27242;TNFRSF21;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Tumor necrosis factor-alpha induces the expression of DR6, a member of the TNF receptor family, through activation of NF-kappaB.;11753679;2002
796;CALCA;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"<span class=""gene"" id=""16222118-0-0-10"">Calcitonin</span> induces apoptosis resistance in <span class=""disease"" id=""16222118-0-43-58"">prostate cancer</span> cell lines against cytotoxic drugs via the Akt/survivin pathway.";16222118;2006
150084;IGSF5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1902;LPAR1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"We profiled gene expression of LPA receptors in androgen-dependent and androgen-insensitive <span class=""disease"" id=""16809448-2-92-107"">prostate cancer</span> cells and found that <span class=""gene"" id=""16809448-2-129-134"">LPA(1</span>) gene is differentially expressed in androgen-insensitive and LPA-responsive but not androgen-dependent and LPA-resistant cells.";16809448;2006
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Combination of proliferative and apoptotic properties prompts <span class=""disease"" id=""19593445-8-62-77"">prostate cancer</span> cells to be ""addicted"" to increased levels of phosphorylated <span class=""gene"" id=""19593445-8-139-142"">BAD</span>.";19593445;2009
11176;BAZ2A;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Finally, high <span class=""gene"" id=""25485837-6-14-19"">BAZ2A</span> levels serve as an independent predictor of biochemical recurrence in a cohort of 7,682 individuals with <span class=""disease"" id=""25485837-6-125-140"">prostate cancer</span>.";25485837;2015
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"This meta-analysis showed the evidence that <span class=""gene"" id=""21349172-8-44-49"">FGFR4</span> Gly388Arg polymorphism was associated with an increased risk of <span class=""disease"" id=""21349172-8-114-129"">prostate cancer</span> development and progression, suggesting that <span class=""gene"" id=""21349172-8-175-180"">FGFR4</span> Gly388Arg polymorphism could be a marker for <span class=""disease"" id=""21349172-8-226-241"">prostate cancer</span> development and progression.";21349172;2011
3232;HOXD3;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Further validation of candidate genes on a separate cohort of low and high grade <span class=""disease"" id=""19283074-5-81-97"">prostate cancers</span> by quantitative MethyLight analysis has allowed us to confirm DNA hypermethylation of <span class=""gene"" id=""19283074-5-184-189"">HOXD3</span> and BMP7, two genes that may play a role in the development of high grade tumours.";19283074;2009
4601;MXI1;C0376358;Malignant neoplasm of prostate;0,66;GeneticVariation;UNIPROT;"Mutation of the <span class=""gene"" id=""7773287-0-16-20"">MXI1</span> gene in <span class=""disease"" id=""7773287-0-29-44"">prostate cancer</span>.";7773287;1995
4437;MSH3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"DNA samples from 110 patients with <span class=""disease"" id=""18355840-5-35-50"">prostate cancer</span> and 110 healthy controls were analyzed by single strand conformational polymorphism and polymerase chain reaction-restriction fragment length polymorphism to determine the genotypic frequency of 5 polymorphic loci on 2 MMR genes (<span class=""gene"" id=""18355840-5-281-285"">MSH3</span> and MSH6) and p53 codon72.";18355840;2008
2678;GGT1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A population-based (245 cases and 222 controls) and family-based (159 hereditary prostate cancer families) association study was performed to test the hypothesis that sequence variants of <span class=""gene"" id=""11956079-3-188-193"">hOGG1</span> increase susceptibility to <span class=""disease"" id=""11956079-3-221-236"">prostate cancer</span>.";11956079;2002
51341;ZBTB7A;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"Notably, we found that <span class=""gene"" id=""23727861-6-23-29"">ZBTB7A</span> is genetically lost, as well as downregulated at both the mRNA and protein levels, in a subset of human advanced <span class=""disease"" id=""23727861-6-143-159"">prostate cancers</span>.";23727861;2013
51341;ZBTB7A;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"<span class=""gene"" id=""23727861-0-0-6"">Zbtb7a</span> suppresses <span class=""disease"" id=""23727861-0-18-33"">prostate cancer</span> through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.";23727861;2013
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"The results provide mechanistic support for a role of NAT1 and/or <span class=""gene"" id=""12618593-11-66-70"">NAT2</span> acetylator polymorphism(s) in human <span class=""disease"" id=""12618593-11-107-122"">prostate cancer</span> risk related to aromatic and/or heterocyclic amine carcinogens.";12618593;2003
4683;NBN;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"In vitro studies correlated <span class=""gene"" id=""25415046-8-28-31"">NBN</span> gene overexpression with <span class=""disease"" id=""25415046-8-57-60"">PCa</span> cells radioresistance.";25415046;2015
6293;VPS52;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
1012;CDH13;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis.;17288544;2007
57185;NIPAL3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
3572;IL6ST;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
4883;NPR3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
4804;NGFR;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of <span class=""gene"" id=""18056468-0-85-92"">p75 NTR</span> in <span class=""disease"" id=""18056468-0-96-111"">prostate cancer</span> cells.";18056468;2008
7431;VIM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
1289;COL5A1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
4072;EPCAM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Endocrine approaches in the therapy of prostate carcinoma.;15790600;2005
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We sought new functional mutations in <span class=""gene"" id=""12783936-3-38-42"">PON1</span> and determined whether known or new <span class=""gene"" id=""12783936-3-79-83"">PON1</span> mutations were associated with the risk for <span class=""disease"" id=""12783936-3-128-143"">prostate cancer</span> in a prospective, random, population-based sample of Finnish men and in a case-control study.";12783936;2003
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Resveratrol regulates the PTEN/AKT pathway through <span class=""gene"" id=""20729295-0-51-68"">androgen receptor</span>-dependent and -independent mechanisms in <span class=""disease"" id=""20729295-0-110-125"">prostate cancer</span> cell lines.";20729295;2011
5054;SERPINE1;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;Nucleotide variations in genes encoding plasminogen activator inhibitor-2 and serine proteinase inhibitor B10 associated with prostate cancer.;16172807;2006
29072;SETD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7422;VEGFA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The Bst U I polymorphism of the <span class=""gene"" id=""12893367-11-32-36"">VEGF</span> gene is a suitable genetic marker of <span class=""disease"" id=""12893367-11-74-89"">prostate cancer</span> but cannot be used in the prediction of the outcome of patients who have received hormonal therapy.";12893367;2003
2308;FOXO1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
8537;BCAS1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Analysis of candidate genes for prostate cancer.;15583422;2005
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"A recently identified germline mutation G84E in <span class=""gene"" id=""23292082-1-48-54"">HOXB13</span> was shown to increase the risk of <span class=""disease"" id=""23292082-1-89-104"">prostate cancer</span>.";23292082;2013
3690;ITGB3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We studied the role of integrins, primarily, the role of allele distribution of <span class=""gene"" id=""16158739-1-80-84"">GP3a</span> gene in development of <span class=""disease"" id=""16158739-1-108-124"">prostatic cancer</span> (<span class=""disease"" id=""16158739-1-126-128"">PC</span>) and assessment of its prognostic significance.";16158739;2005
8509;NDST2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Furthermore, the <span class=""gene"" id=""12622714-6-17-21"">NAT2</span> slow acetylator genotype was significantly higher among <span class=""disease"" id=""12622714-6-78-93"">prostate cancer</span> patients with locally advanced and metastatic disease (22.7%) compared with controls (8.6%) (OR = 3.14; 95% CI, 1.40-7.06; P = 0.0051).";12622714;2003
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"These results indicate that <span class=""disease"" id=""14633711-10-28-36"">Ad-ARR(2</span>)PB/h<span class=""gene"" id=""14633711-10-41-44"">NIS</span> can be used to achieve high-magnitude and tissue-specific expression of h-NIS in prostate tissue and is a promising candidate for cancer gene therapy of <span class=""disease"" id=""14633711-10-198-213"">prostate cancer</span>.";14633711;2004
4074;M6PR;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The <span class=""gene"" id=""10753955-0-4-20"">cyclooxygenase-2</span> inhibitor celecoxib induces apoptosis by blocking Akt activation in human <span class=""disease"" id=""10753955-0-95-110"">prostate cancer</span> cells independently of Bcl-2.";10753955;2000
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"A new tumor suppressor gene, <span class=""gene"" id=""9371490-4-29-33"">PTEN</span>/<span class=""gene"" id=""9371490-4-34-39"">MMAC1</span>, was isolated recently at this region of chromosome 10q23 and found to be inactivated by mutation in three <span class=""disease"" id=""9371490-4-147-162"">prostate cancer</span> cell lines.";9371490;1997
210;ALAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Genetic variation in <span class=""gene"" id=""24500903-8-21-25"">ALAD</span> may modify associations between Pb and <span class=""disease"" id=""24500903-8-65-80"">prostate cancer</span>.";24500903;2014
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.;28319090;2017
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"The <span class=""gene"" id=""12237244-1-4-21"">androgen receptor</span> (<span class=""gene"" id=""12237244-1-23-25"">AR</span>), a transcription factor that mediates the action of androgens in target tissues, is expressed in nearly all <span class=""disease"" id=""12237244-1-135-151"">prostate cancers</span>.";12237244;2003
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"New experimental therapies for <span class=""disease"" id=""12237244-12-31-46"">prostate cancer</span> are aimed to down-regulate <span class=""gene"" id=""12237244-12-74-76"">AR</span> expression and to overcome difficulties which occur because of the acquisition of agonistic properties of commonly used antiandrogens.";12237244;2003
51227;PIGP;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
8314;BAP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.;25231345;2015
6690;SPINK1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.;16421604;2006
26239;LCE2B;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
83606;GUCD1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
4502;MT2A;C0376358;Malignant neoplasm of prostate;0,33;Therapeutic;CTD_human;Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells.;17914565;2007
873;CBR1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
9817;KEAP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We integrated the RNA-Seq results with DNA-binding sites of BRD4 generated by chromatin immunoprecipitations, correlated these with gene expressions from human <span class=""disease"" id=""24763052-3-160-176"">prostate cancers</span> and identified 21 top BRD4 candidate genes among which the oxidative stress pathway genes <span class=""gene"" id=""24763052-3-267-272"">KEAP1</span>, SESN3 and HDAC6 are represented.";24763052;2015
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The prevalence of the <span class=""gene"" id=""18304461-6-22-27"">GSTM1</span> (0/0) genotype was significantly higher in <span class=""disease"" id=""18304461-6-71-86"">prostate cancer</span> patients (58.2%) than in controls (41.7%, P&lt;0.05).";18304461;2008
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"For <span class=""disease"" id=""18306354-11-4-19"">prostate cancer</span>, the best two-gene interaction included genotypes <span class=""gene"" id=""18306354-11-70-76"">SRD5A2</span> V89L GG and AKR1C3 Q5H CC with OR 1.30, 95% CI 1.01-1.66.";18306354;2008
2117;ETV3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
4824;NKX3-1;C0376358;Malignant neoplasm of prostate;0,54;Biomarker;CTD_human;Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells.;16817226;2007
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.;17136230;2007
64816;CYP3A43;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"<span class=""gene"" id=""15894682-0-0-7"">CYP3A43</span> Pro(340)Ala polymorphism and <span class=""disease"" id=""15894682-0-37-52"">prostate cancer</span> risk in African Americans and Caucasians.";15894682;2005
12;SERPINA3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Allele and genotype frequencies of a promoter single nucleotide polymorphism (SNP) in <span class=""gene"" id=""18383875-5-86-89"">ACT</span> gene were investigated in patients with benign prostate hypertrophy (BHP) or <span class=""disease"" id=""18383875-5-167-170"">PCa</span> and controls.";18383875;2008
51181;DCXR;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
29;ABR;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.;16998812;2007
5034;P4HB;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Functional variant of manganese superoxide dismutase (<span class=""gene"" id=""17646272-0-54-58"">SOD2</span> V16A) polymorphism is associated with <span class=""disease"" id=""17646272-0-97-112"">prostate cancer</span> risk in the prostate, lung, colorectal, and ovarian cancer study.";17646272;2007
2146;EZH2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.;21903722;2012
5329;PLAUR;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.;15302576;2004
1469;CST1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
2052;EPHX1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"In this study, we use <span class=""disease"" id=""20729295-7-22-37"">prostate cancer</span> cell lines to test the hypothesis that resveratrol inhibits cellular proliferation in both <span class=""gene"" id=""20729295-7-129-131"">AR</span>-dependent and -independent mechanisms.";20729295;2011
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Despite limitations due to study size, we conclude that the association between HCA intake and <span class=""disease"" id=""22564066-9-95-98"">PCa</span> risk could be modified by polymorphisms of GSTT1, <span class=""gene"" id=""22564066-9-149-154"">GSTM1</span>, and MnSOD.";22564066;2012
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We hypothesized that the functional polymorphisms in IGF-I and <span class=""gene"" id=""24586243-2-63-70"">IGFBP-3</span> may be associated with the risk of <span class=""disease"" id=""24586243-2-106-121"">prostate cancer</span> (<span class=""disease"" id=""24586243-2-123-126"">PCa</span>) in the Chinese population.";24586243;2015
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"A common polymorphism of <span class=""gene"" id=""18670643-2-25-31"">FGFR-4</span> in which arginine (Arg(388)) replaces glycine (Gly(388)) at amino acid 388 is associated with progression in human <span class=""disease"" id=""18670643-2-147-162"">prostate cancer</span>.";18670643;2008
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our results support the hypothesis that HDACi, especially in combination with androgen deprivation, is effective against <span class=""gene"" id=""18798265-10-121-139"">TMPRSS2-ERG-fusion</span> positive <span class=""disease"" id=""18798265-10-149-164"">prostate cancer</span> in vitro.";18798265;2009
7048;TGFBR2;C0376358;Malignant neoplasm of prostate;0,58;Biomarker;CTD_human;"DNA methylation of the human <span class=""gene"" id=""18381416-6-29-35"">TGFBR2</span> promoter CpG islands repressed transcription, if present, but neither methylation nor mutation were detected in 27 human <span class=""disease"" id=""18381416-6-157-173"">prostate cancers</span> analyzed.";18381416;2008
2950;GSTP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association of CYP17, <span class=""gene"" id=""15538743-0-22-27"">GSTP1</span>, and PON1 polymorphisms with the risk of <span class=""disease"" id=""15538743-0-69-84"">prostate cancer</span>.";15538743;2005
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"We found that NKX3.1 expression is down-regulated by over-expression of wild type (wt) <span class=""gene"" id=""17202838-4-87-90"">p53</span> in <span class=""disease"" id=""17202838-4-94-109"">prostate cancer</span> LNCaP cells.";17202838;2007
1509;CTSD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6041;RNASEL;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"We examined polymorphisms within ELAC2 (S217L, A541T, E622V), MSR1 (P275A, R293X, aIVS5-59c), and <span class=""gene"" id=""16114055-5-98-104"">RNASEL</span> (E265X, R462Q, D541E) in 150 European-Americans with metastatic prostate cancer and 170 <span class=""disease"" id=""16114055-5-193-208"">prostate cancer</span>-free controls using pyrosequencing assays.";16114055;2006
567;B2M;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Additional studies are warranted to explore if <span class=""gene"" id=""17404077-13-47-50"">B2M</span> is as useful marker for <span class=""disease"" id=""17404077-13-75-90"">prostate cancer</span>.";17404077;2007
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.;12644816;2003
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We genotyped 645 men with biopsy-proven <span class=""disease"" id=""17085659-3-40-55"">prostate cancer</span> (cases) and 606 males with biopsies negative for <span class=""disease"" id=""17085659-3-105-120"">prostate cancer</span> (controls) for five additional single nucleotide polymorphisms (SNP) across the <span class=""gene"" id=""17085659-3-201-205"">KLK2</span> gene and also tested for serum hK2 levels.";17085659;2007
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""17823934-0-0-6"">SRD5A2</span> and HSD3B2 polymorphisms are associated with <span class=""disease"" id=""17823934-0-52-67"">prostate cancer</span> risk and aggressiveness.";17823934;2007
84519;ACRBP;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
92105;INTS4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Since <span class=""disease"" id=""17196171-3-6-21"">prostate cancer</span> gradually progresses to an androgen-independent state despite the stress caused by various therapeutic agents, we hypothesized the stress-activated protein kinases (SAPKs) involvement in androgen-independent growth or <span class=""gene"" id=""17196171-3-240-244"">IL-6</span> secretion of <span class=""disease"" id=""17196171-3-258-273"">prostate cancer</span> cells.";17196171;2007
5328;PLAU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To evaluate the frequency of the <span class=""gene"" id=""16430655-1-33-69"">urokinase-type plasminogen activator</span> (<span class=""gene"" id=""16430655-1-71-74"">uPA</span>) gene amplification and the sensitivity of <span class=""disease"" id=""16430655-1-118-133"">prostate cancer</span> cells to <span class=""gene"" id=""16430655-1-143-146"">uPA</span> inhibition, as we previously found one hormone-refractory prostate tumour with high-level amplification of the <span class=""gene"" id=""16430655-1-258-261"">uPA</span> (alias <span class=""gene"" id=""16430655-1-269-273"">PLAU</span>) gene, and also showed that a <span class=""gene"" id=""16430655-1-304-307"">uPA</span> inhibitor, amiloride, can effectively reduce the invasion potential of the PC-3 <span class=""disease"" id=""16430655-1-388-403"">prostate cancer</span> cell line.";16430655;2006
6453;ITSN1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"<span class=""gene"" id=""1631125-0-0-17"">Androgen receptor</span> gene mutations in human <span class=""disease"" id=""1631125-0-42-57"">prostate cancer</span>.";1631125;1992
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"In summary, this is an initial description of the successful therapeutic use of <span class=""gene"" id=""16000583-7-80-87"">IGFBP-3</span> as a cancer therapy in vivo, and shows that combination treatment of <span class=""gene"" id=""16000583-7-157-164"">IGFBP-3</span> and RXR ligand has a synergistic effect on apoptosis induction leading to substantial inhibition of <span class=""disease"" id=""16000583-7-265-280"">prostate cancer</span> xenograft growth.";16000583;2005
4023;LPL;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Association of <span class=""gene"" id=""15386377-0-15-33"">lipoprotein lipase</span> gene polymorphism with risk of <span class=""disease"" id=""15386377-0-65-80"">prostate cancer</span> in a Japanese population.";15386377;2004
6541;SLC7A1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"<span class=""gene"" id=""11401523-0-0-4"">CaT1</span> expression correlates with tumor grade in <span class=""disease"" id=""11401523-0-47-62"">prostate cancer</span>.";11401523;2001
9518;GDF15;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our data suggest that the H6D variant in <span class=""gene"" id=""16775185-7-41-46"">MIC-1</span> might play a role in <span class=""disease"" id=""16775185-7-68-83"">prostate cancer</span>, but it is difficult to explain how a variant can be associated with lower risk of developing <span class=""disease"" id=""16775185-7-178-193"">prostate cancer</span> but more aggressive growth if cancer develops.";16775185;2006
6134;RPL10;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"We show here that c-Myc, which is a key mediator of ligand-independent <span class=""disease"" id=""23704919-6-71-86"">prostate cancer</span> growth, is a key ligand-independent <span class=""gene"" id=""23704919-6-123-125"">AR</span> target gene.";23704919;2013
23013;SPEN;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We identify a total of 97 SMGs, including 70 not previously implicated in <span class=""disease"" id=""29610475-6-74-89"">prostate cancer</span>, such as the ubiquitin ligase CUL3 and the transcription factor <span class=""gene"" id=""29610475-6-154-158"">SPEN</span>.";29610475;2018
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"However, we found no previous studies clarifying the nature of <span class=""gene"" id=""26468117-2-63-67"">SOD2</span> effects on <span class=""disease"" id=""26468117-2-79-94"">prostate cancer</span>.";26468117;2016
2697;GJA1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
2925;GRPR;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts.;17204703;2007
999;CDH1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Men homozygous for SEPP1-Ala234 who were also <span class=""gene"" id=""19074884-11-46-50"">SOD2</span>-Ala16+ had a higher risk of prostate cancer (OR, 1.43; 95% CI, 1.17-1.76) and aggressive <span class=""disease"" id=""19074884-11-140-155"">prostate cancer</span> (OR, 1.60; 95% CI, 1.22-2.09) than those who were <span class=""gene"" id=""19074884-11-206-210"">SOD2</span>-Val16 homozygotes (interaction, <span class=""disease"" id=""19074884-11-243-258"">prostate cancer</span> P = 0.05; aggressive <span class=""disease"" id=""19074884-11-280-295"">prostate cancer</span> P = 0.01).";19074884;2009
154;ADRB2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"The level of <span class=""gene"" id=""18454446-10-13-23"">beta(2)-AR</span> was increased by T3 in prostatic adenocarcinoma cells and reduced in <span class=""disease"" id=""18454446-10-93-108"">prostate cancer</span> patients who had received androgen ablation therapy for 3 months.";18454446;2008
6135;RPL11;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
7039;TGFA;C0376358;Malignant neoplasm of prostate;0,33;Therapeutic;CTD_human;Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.;17136230;2007
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.;17003774;2007
10499;NCOA2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"The three coactivators, <span class=""gene"" id=""12237244-11-24-29"">TIF-2</span>, SRC-1 and RAC3, are up-regulated in relapsed <span class=""disease"" id=""12237244-11-76-91"">prostate cancer</span>.";12237244;2003
55357;TBC1D2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1543;CYP1A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Associations between genetic polymorphisms of <span class=""gene"" id=""11275366-1-46-52"">CYP1A1</span>, CYP1A2, CYP2E1, GSTM1 and GSTT1 and <span class=""disease"" id=""11275366-1-90-105"">prostate cancer</span> (<span class=""disease"" id=""11275366-1-107-110"">PCa</span>) were analyzed in a case-control study of 315 individuals.";11275366;2001
5420;PODXL;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"A weak positive association was also observed between <span class=""disease"" id=""16434482-8-54-69"">prostate cancer</span> risk and <span class=""gene"" id=""16434482-8-79-84"">PODXL</span> variant 340A (in linkage disequilibrium with another variant, 587T) (OR=1.48, 95%CI=1.02-2.14, P=0.04).";16434482;2006
10928;RALBP1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
7099;TLR4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""17301271-0-0-20"">Toll-like receptor 4</span> genetic variation and advanced <span class=""disease"" id=""17301271-0-52-67"">prostate cancer</span> risk.";17301271;2007
2099;ESR1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;[Implications of estrogens and their receptors for the development and progression of prostate cancer].;16220300;2006
7367;UGT2B17;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In a case-control study of 356 patients with incident primary <span class=""disease"" id=""17826523-4-62-77"">prostate cancer</span> and 363 age-matched controls, the frequencies of HSD3B1 N367T and <span class=""gene"" id=""17826523-4-144-151"">UGT2B17</span> null polymorphisms in genomic DNA were compared between the patients and controls.";17826523;2007
54704;PDP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.;29335542;2018
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""28783165-0-0-18"">TMPRSS2-ERG fusion</span> co-opts master transcription factors and activates NOTCH signaling in primary <span class=""disease"" id=""28783165-0-97-112"">prostate cancer</span>.";28783165;2017
2932;GSK3B;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.;16421604;2006
6695;SPOCK1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Our recent microarray analysis suggested downregulation of three fibulins, FBLN1, FBLN4, and FBLN5, in <span class=""disease"" id=""17929269-6-103-118"">prostate cancer</span>, while two further ECM genes, <span class=""gene"" id=""17929269-6-149-155"">SPOCK1</span> (testican) and TENC (tenascin C), appeared upregulated or unchanged.";17929269;2008
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Associations between genetic polymorphisms of CYP1A1, CYP1A2, CYP2E1, <span class=""gene"" id=""11275366-1-70-75"">GSTM1</span> and GSTT1 and <span class=""disease"" id=""11275366-1-90-105"">prostate cancer</span> (<span class=""disease"" id=""11275366-1-107-110"">PCa</span>) were analyzed in a case-control study of 315 individuals.";11275366;2001
7099;TLR4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our findings support previous studies and suggest that inherited differences in <span class=""gene"" id=""17301271-6-80-84"">TLR4</span> influence <span class=""disease"" id=""17301271-6-95-110"">prostate cancer</span> risk.";17301271;2007
11176;BAZ2A;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"<span class=""gene"" id=""25485837-0-0-5"">BAZ2A</span> (<span class=""gene"" id=""25485837-0-7-11"">TIP5</span>) is involved in epigenetic alterations in <span class=""disease"" id=""25485837-0-54-69"">prostate cancer</span> and its overexpression predicts disease recurrence.";25485837;2015
1366;CLDN7;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results suggest that the Ala variant of <span class=""gene"" id=""17646272-9-46-50"">SOD2</span> is associated with moderately increased risk of <span class=""disease"" id=""17646272-9-99-114"">prostate cancer</span>, particularly among men with lower intakes of dietary and supplemental vitamin E.";17646272;2007
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Genetic variation in the <span class=""gene"" id=""16506214-0-25-30"">COX-2</span> gene and the association with <span class=""disease"" id=""16506214-0-61-76"">prostate cancer</span> risk.";16506214;2006
10516;FBLN5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"Expression of FBLN1 (major splice forms C and D), FBLN4, <span class=""gene"" id=""17929269-3-57-62"">FBLN5</span>, SPOCK1, and TENC was compared between 47 <span class=""disease"" id=""17929269-3-105-120"">prostate cancer</span> samples and 13 benign prostatic tissues by quantitative RT-PCR.";17929269;2008
857;CAV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We sequenced the <span class=""gene"" id=""15948133-4-17-22"">CAV-1</span> promoter region and its open reading frame in <span class=""disease"" id=""15948133-4-69-84"">prostate cancer</span> families with linkage to chromosome 7q31-33.";15948133;2005
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Niclosamide has the potential to target the IL6-<span class=""gene"" id=""25970160-13-48-53"">Stat3</span>-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced <span class=""disease"" id=""25970160-13-148-163"">prostate cancer</span>.";25970160;2015
4780;NFE2L2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Epigenetic reactivation of <span class=""gene"" id=""23441843-0-27-31"">Nrf2</span> in murine <span class=""disease"" id=""23441843-0-42-57"">prostate cancer</span> TRAMP C1 cells by natural phytochemicals Z-ligustilide and Radix angelica sinensis via promoter CpG demethylation.";23441843;2013
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Genotypes of Gly388Arg and rs2011077 polymorphisms of <span class=""gene"" id=""18756523-4-54-59"">FGFR4</span> were determined in 492 patients with <span class=""disease"" id=""18756523-4-97-112"">prostate cancer</span>, 165 patients with BPH and 179 male controls.";18756523;2008
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Despite limitations due to study size, we conclude that the association between HCA intake and <span class=""disease"" id=""22564066-9-95-98"">PCa</span> risk could be modified by polymorphisms of GSTT1, GSTM1, and <span class=""gene"" id=""22564066-9-160-165"">MnSOD</span>.";22564066;2012
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"In this study, we use <span class=""disease"" id=""20729295-7-22-37"">prostate cancer</span> cell lines to test the hypothesis that resveratrol inhibits cellular proliferation in both <span class=""gene"" id=""20729295-7-129-131"">AR</span>-dependent and -independent mechanisms.";20729295;2011
3187;HNRNPH1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
5652;PRSS8;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Androgen regulation of prostasin gene expression is mediated by sterol-regulatory element-binding proteins and SLUG.;16541421;2006
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Gene fusions between prostate-specific, androgen responsive TMPRSS2 gene and oncogenic ETS factors, such as <span class=""gene"" id=""18798265-1-108-111"">ERG</span>, occur in up to 50% of all <span class=""disease"" id=""18798265-1-139-155"">prostate cancers</span>.";18798265;2009
4610;MYCL;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Spatial genomic heterogeneity within localized, multifocal prostate cancer.;26005866;2015
2065;ERBB3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We thus assessed the effect of androgens and the bone microenvironment on the nuclear translocation of <span class=""gene"" id=""17634423-5-103-109"">ErbB-3</span> by using xenograft tumor models generated from bone-derived <span class=""disease"" id=""17634423-5-170-185"">prostate cancer</span> cell lines, MDA PCa 2b, and PC-3.";17634423;2007
596;BCL2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our data suggest that inherited <span class=""gene"" id=""16733517-5-32-37"">BCL-2</span> variants may be associated with a decrease in <span class=""disease"" id=""16733517-5-84-99"">prostate cancer</span> susceptibility.";16733517;2007
5611;DNAJC3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4780;NFE2L2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Thus, targeting the <span class=""gene"" id=""20124447-10-20-24"">Nrf2</span> pathway in <span class=""disease"" id=""20124447-10-36-51"">prostate cancer</span> cells may provide a novel strategy to enhance chemotherapy and radiotherapy responsiveness and ameliorate the growth and tumorigenicity, leading to improved clinical outcomes.";20124447;2010
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"The aim of this study was to evaluate if the hormonal therapy with BCLT can affect the <span class=""gene"" id=""17914592-2-87-91"">EGFR</span>-targeted therapy using primary cultures obtained from 22 human <span class=""disease"" id=""17914592-2-155-158"">PCa</span> tissues harvested after radical prostatectomy (RP) in patients who received (n=10) BCLT and those that did not (n=12) as neoadjuvant hormone therapy (NHT).";17914592;2007
2950;GSTP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1.;11196146;2001
3586;IL10;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association of <span class=""gene"" id=""17999153-0-15-20"">IL-10</span> polymorphisms with <span class=""disease"" id=""17999153-0-40-55"">prostate cancer</span> risk and grade of disease.";17999153;2008
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A significantly increased risk of <span class=""disease"" id=""14634453-7-34-49"">prostate cancer</span> was observed for subjects with <span class=""gene"" id=""14634453-7-81-86"">hOGG1</span>(326Cys) allele (ORadj 2.1, 95% CI 1.2-3.8).";14634453;2004
64240;ABCG5;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
8797;TNFRSF10A;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as thioredoxin domain containing 5 , <span class=""gene"" id=""17199135-3-132-186"">tumor necrosis factor receptor superfamily, member 10a</span> , ribosomal protein S19 and Janus kinase 2 upregulated in AI <span class=""disease"" id=""17199135-3-248-263"">prostate cancer</span>, could play important roles in the transition from AD to AI and could be biomarkers of prognosis.";17199135;2007
4322;MMP13;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"In summary, <span class=""gene"" id=""15138554-9-12-18"">MMP-13</span> is androgen regulated and detectable in <span class=""disease"" id=""15138554-9-59-74"">prostate cancer</span>.";15138554;2004
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.;15302576;2004
2247;FGF2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer.;12644816;2003
4322;MMP13;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We have furthermore shown that <span class=""gene"" id=""15138554-8-31-37"">MMP-13</span> expression is presented in human <span class=""disease"" id=""15138554-8-71-86"">prostate cancer</span> obtained from aspiration biopsy.";15138554;2004
632;BGLAP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The aim of this study was to realize the <span class=""gene"" id=""14666681-5-41-43"">OC</span> expression in <span class=""disease"" id=""14666681-5-58-60"">PC</span> before H/T and after H/T when HRPC developed.";14666681;2004
6928;HNF1B;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Evidence for two independent <span class=""disease"" id=""18758462-0-29-44"">prostate cancer</span> risk-associated loci in the <span class=""gene"" id=""18758462-0-73-78"">HNF1B</span> gene at 17q12.";18758462;2008
2952;GSTT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Despite limitations due to study size, we conclude that the association between HCA intake and <span class=""disease"" id=""22564066-9-95-98"">PCa</span> risk could be modified by polymorphisms of <span class=""gene"" id=""22564066-9-142-147"">GSTT1</span>, GSTM1, and MnSOD.";22564066;2012
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"Alterations in the <span class=""gene"" id=""20875869-1-19-23"">TP53</span> and MDM2 genes appear to be important in the development of many human tumors, but evidence is conflicting on associations between polymorphisms in these genes and risk of <span class=""disease"" id=""20875869-1-196-211"">prostate cancer</span> (<span class=""disease"" id=""20875869-1-213-216"">PCa</span>).";20875869;2010
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"It is known that over expression of <span class=""gene"" id=""25970160-1-36-39"">IL6</span> in <span class=""disease"" id=""25970160-1-43-58"">prostate cancer</span> cells confer enzalutamide resistance and that this may occur through constitutive Stat3 activation.";25970160;2015
3977;LIFR;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
7432;VIP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"There is little known on the involvement of <span class=""gene"" id=""19189304-1-44-73"">vasoactive intestinal peptide</span> (<span class=""gene"" id=""19189304-1-75-78"">VIP</span>) in the metastatic cascade of human <span class=""disease"" id=""19189304-1-115-130"">prostate cancer</span>, that is, cell proliferation, cell-cell adhesion, extracellular-matrix degradation, and migration/invasion.";19189304;2009
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"However, little is known about the relationships and interactions between <span class=""gene"" id=""17202838-3-74-77"">p53</span> and NKX3.1 in <span class=""disease"" id=""17202838-3-92-107"">prostate cancer</span>.";17202838;2007
64816;CYP3A43;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"In a case-control study with 490 incident <span class=""disease"" id=""15894682-4-42-57"">prostate cancer</span> cases (124 African Americans and 358 Caucasians) and 494 controls (167 African Americans and 319 Caucasians), we examined the association between <span class=""gene"" id=""15894682-4-204-211"">CYP3A43</span> Pro(340)Ala polymorphism and <span class=""disease"" id=""15894682-4-241-256"">prostate cancer</span> risk.";15894682;2005
64816;CYP3A43;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"In African Americans, there was a 2.6-fold increase in <span class=""disease"" id=""15894682-7-55-70"">prostate cancer</span> risk among individuals with the <span class=""gene"" id=""15894682-7-103-110"">CYP3A43</span>-Ala/Ala genotype (odds ratio, 2.6; 95% confidence interval, 1.0-7.0) compared with those with the <span class=""gene"" id=""15894682-7-209-216"">CYP3A43</span>-Pro/Pro genotype.";15894682;2005
2947;GSTM3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"The analysis of the frequencies from the 670 alleles indicates that men carrying two B-alleles (<span class=""gene"" id=""14968442-4-96-101"">GSTM3</span>) have increased risk for <span class=""disease"" id=""14968442-4-127-129"">PC</span> (OR = 5.50, 95% confidence interval (CI) 1.2-25.8; P = 0.016).";14968442;2004
3048;HBG2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
8409;UXT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Comparison of <span class=""gene"" id=""19318562-10-14-20"">ART-27</span> and AR staining indicated that nuclear <span class=""gene"" id=""19318562-10-60-66"">ART-27</span> expression was lost in the majority of AR-positive recurrent <span class=""disease"" id=""19318562-10-128-144"">prostate cancers</span>.";19318562;2009
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The higher activity Ala variant at <span class=""gene"" id=""17646272-5-35-39"">SOD2</span> Ex2+24T&gt;C (V16A), which has been hypothesized to suppress prostate carcinogenesis, was associated with elevation of <span class=""disease"" id=""17646272-5-156-171"">prostate cancer</span> risk in Caucasians (Val/Ala versus Val/Val: OR, 1.17; 95% CI, 0.97-1.42; Ala/Ala versus Val/Val: OR, 1.28; 95% CI, 1.03-1.60; P(trend) = 0.03).";17646272;2007
2052;EPHX1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Among men carrying the variant allele for thioredoxin reductase 2 (TXNRD2) rs4485648, <span class=""gene"" id=""21716162-6-86-116"">microsomal epoxide hydrolase 1</span> (<span class=""gene"" id=""21716162-6-118-123"">EPHX1</span>) rs17309872, or myeloperoxidase (MPO) rs11079344, an increased <span class=""disease"" id=""21716162-6-187-202"">prostate cancer</span> risk was observed with high, compared with no, petroleum oil/petroleum distillate (OR=1.9, 95% CI: 1.1-3.2, P interaction=0.01; OR=2.1, 95% CI: 1.1-4.0, P interaction=0.01), or terbufos (OR=3.0, 95% CI: 1.5-6.0, P interaction=2.0×10(-3)) use, respectively.";21716162;2012
4507;MTAP;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
5420;PODXL;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"<span class=""gene"" id=""16434482-0-0-11"">Podocalyxin</span> variants and risk of <span class=""disease"" id=""16434482-0-33-48"">prostate cancer</span> and tumor aggressiveness.";16434482;2006
43;ACHE;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"Surgical pieces of <span class=""disease"" id=""20356562-3-19-35"">prostatic cancer</span> (<span class=""disease"" id=""20356562-3-37-39"">PC</span>) and benign prostatic hyperplasia (BPH) were analyzed for <span class=""gene"" id=""20356562-3-98-102"">AChE</span> and BChE activity.";20356562;2010
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We examined whether sequence variants in the <span class=""gene"" id=""16506214-4-45-50"">COX-2</span> gene are associated with <span class=""disease"" id=""16506214-4-76-91"">prostate cancer</span> risk.";16506214;2006
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;[Implications of estrogens and their receptors for the development and progression of prostate cancer].;16220300;2006
51655;RASD1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"The ability of <span class=""disease"" id=""14633711-4-15-23"">Ad-ARR(2</span>)PB/h<span class=""gene"" id=""14633711-4-28-31"">NIS</span> to cause <span class=""gene"" id=""14633711-4-41-44"">NIS</span> expression in tumor cells was characterized by iodide uptake assay and compared with Ad-CMV/h<span class=""gene"" id=""14633711-4-138-141"">NIS</span> in which the h-NIS expression is driven by the cytomegalovirus (CMV) promoter.";14633711;2004
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;The evolving role of estrogen therapy in prostate cancer.;15046698;2004
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"These results suggest that in a European-American population, CDKN1A and <span class=""gene"" id=""12727815-11-73-79"">CDKN1B</span> variants are associated with advanced <span class=""disease"" id=""12727815-11-118-133"">prostate cancer</span>.";12727815;2003
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The <span class=""gene"" id=""12783936-13-4-8"">PON1</span> 102V allele appears to be associated with an increased risk for <span class=""disease"" id=""12783936-13-73-88"">prostate cancer</span>.";12783936;2003
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"This bicalutamide-responsive mutant <span class=""gene"" id=""16266977-10-36-38"">AR</span> will serve in the development of new therapies for androgen ablation-resistant <span class=""disease"" id=""16266977-10-118-134"">prostate cancers</span>.";16266977;2005
2068;ERCC2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"In this hospital-based case-control study, the association of <span class=""gene"" id=""17695467-3-62-65"">XPD</span> codon 312, 751 and promoter-114 polymorphisms with <span class=""disease"" id=""17695467-3-117-132"">prostate cancer</span> risk in a Taiwanese population were investigated.";17695467;2007
11214;AKAP13;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We validated ZBTB20, CELF2, PARD3, <span class=""gene"" id=""28319090-5-35-41"">AKAP13</span> and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in <span class=""disease"" id=""28319090-5-147-162"">prostate cancer</span>.";28319090;2017
2119;ETV5;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.;27783944;2016
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These findings suggest a role for the <span class=""gene"" id=""17085659-9-38-42"">KLK2</span> gene in <span class=""disease"" id=""17085659-9-51-66"">prostate cancer</span> susceptibility and imply that this role may be realized at least in part by the induction of increases in hK2 production.";17085659;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.;25970160;2015
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study demonstrated the IL6-<span class=""gene"" id=""25970160-12-32-37"">Stat3</span>-AR axis in <span class=""disease"" id=""25970160-12-49-64"">prostate cancer</span> is one of the crucial mechanisms of enzalutamide resistance.";25970160;2015
6462;SHBG;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Variant in <span class=""gene"" id=""17220347-0-11-39"">sex hormone-binding globulin</span> gene and the risk of <span class=""disease"" id=""17220347-0-61-76"">prostate cancer</span>.";17220347;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Niclosamide has the potential to target the <span class=""gene"" id=""25970160-13-44-47"">IL6</span>-Stat3-AR pathway to overcome enzalutamide resistance and inhibit migration and invasion in advanced <span class=""disease"" id=""25970160-13-148-163"">prostate cancer</span>.";25970160;2015
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"We observed non-significant association of rapid acetylator genotype <span class=""gene"" id=""16083506-6-69-73"">NAT2</span> (OR = 1.452, 95% CI: 0.54-1.87, P = 0.136) in <span class=""disease"" id=""16083506-6-120-135"">prostate cancer</span> patients.";16083506;2006
10417;SPON2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
10263;CDK2AP2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"<span class=""gene"" id=""18559593-10-0-5"">SSBP2</span> inhibits <span class=""disease"" id=""18559593-10-15-30"">prostate cancer</span> cell proliferation and seems to represent a novel <span class=""disease"" id=""18559593-10-81-96"">prostate cancer</span>-specific DNA marker, especially in high stages of human <span class=""disease"" id=""18559593-10-153-168"">prostate cancer</span>.";18559593;2008
3667;IRS1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We hypothesized that functional polymorphisms in INS, <span class=""gene"" id=""15678496-3-54-58"">IRS1</span>, IRS2, and IGF1 may be associated with <span class=""disease"" id=""15678496-3-98-113"">prostate cancer</span>.";15678496;2005
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Anti-<span class=""gene"" id=""15672864-9-5-9"">IL-6</span> antibody added to HOBIT or POB CM dose-dependently inhibited the CM-induced cell proliferation and PSA expression in these <span class=""disease"" id=""15672864-9-133-136"">CaP</span> cell lines.";15672864;2005
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The evolving role of estrogen therapy in prostate cancer.;15046698;2004
780;DDR1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
673;BRAF;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
9518;GDF15;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Morphological effects on expression of growth differentiation factor 15 (GDF15), a marker of metastasis.;23996089;2014
7110;TMF1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
124222;PAQR4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
2803;GOLGA4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"These results show that overexpression of <span class=""gene"" id=""19240160-11-42-46"">IL-6</span> increases the resistance of <span class=""disease"" id=""19240160-11-75-90"">prostate cancer</span> cells to bicalutamide via TIF2.";19240160;2009
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"In this study, we investigated the role of SIRT1 in multiple human <span class=""disease"" id=""23248098-4-67-82"">prostate cancer</span> cell lines and prostate-specific <span class=""gene"" id=""23248098-4-116-120"">PTEN</span> knockout mouse model using resveratrol.";23248098;2013
6783;SULT1E1;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3845;KRAS;C0376358;Malignant neoplasm of prostate;0,58;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
4601;MXI1;C0376358;Malignant neoplasm of prostate;0,66;GeneticVariation;UNIPROT;"<span class=""gene"" id=""7773287-6-0-4"">MXI1</span> thus displays allelic loss and mutation in some cases of <span class=""disease"" id=""7773287-6-62-77"">prostate cancer</span> that may contribute to the pathogenesis or neoplastic evolution of this common malignancy.";7773287;1995
2932;GSK3B;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress.;25246272;2015
11176;BAZ2A;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"This work identifies a new aberrant role for the epigenetic regulator <span class=""gene"" id=""25485837-7-70-75"">BAZ2A</span>, which can also serve as a useful marker for metastatic potential in <span class=""disease"" id=""25485837-7-145-160"">prostate cancer</span>.";25485837;2015
222546;RFX6;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"A <span class=""disease"" id=""24390282-0-2-17"">prostate cancer</span> susceptibility allele at 6q22 increases <span class=""gene"" id=""24390282-0-58-62"">RFX6</span> expression by modulating HOXB13 chromatin binding.";24390282;2014
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"<span class=""gene"" id=""18670643-1-0-35"">Fibroblast growth factor receptor 4</span> (<span class=""gene"" id=""18670643-1-37-43"">FGFR-4</span>) is expressed at significant levels in almost all human <span class=""disease"" id=""18670643-1-100-116"">prostate cancers</span>, and expression of its ligands is ubiquitous.";18670643;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"As a result, androgen ablation or blockade of androgen action through the <span class=""gene"" id=""15389811-2-74-91"">androgen receptor</span> (<span class=""gene"" id=""15389811-2-93-95"">AR</span>) has been the cornerstone of treatment of advanced <span class=""disease"" id=""15389811-2-147-162"">prostate cancer</span>.";15389811;2004
672;BRCA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Rare inactivating mutations in the <span class=""gene"" id=""17585057-1-35-40"">BRCA1</span> gene seem to play a limited role in <span class=""disease"" id=""17585057-1-77-92"">prostate cancer</span>.";17585057;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling.;22666205;2012
10514;MYBBP1A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2938;GSTA1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Among smokers, the frequency of the <span class=""gene"" id=""15616829-5-36-41"">GSTA1</span>*A/*B or *B/*B genotype in patients with <span class=""disease"" id=""15616829-5-82-97"">prostate cancer</span> (27.8%) showed a statistically significant increase compared with the control group frequency (18.2%; odds ratio [OR] =1.72; 95% CI, 1.01-2.94).";15616829;2005
10158;PDZK1IP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5744;PTHLH;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""16243370-1-0-35"">Parathyroid hormone-related protein</span> (<span class=""gene"" id=""16243370-1-37-42"">PTHrP</span>) increases the growth and osteolytic potential of <span class=""disease"" id=""16243370-1-93-108"">prostate cancer</span> cells, making it important to control <span class=""gene"" id=""16243370-1-147-152"">PTHrP</span> expression in these cells.";16243370;2006
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"The identification of the second mutational event in 10 (43%) tumors establishes <span class=""gene"" id=""9371490-7-81-85"">PTEN</span>/<span class=""gene"" id=""9371490-7-86-91"">MMAC1</span> as a main inactivation target of 10q loss in sporadic <span class=""disease"" id=""9371490-7-146-161"">prostate cancer</span>.";9371490;1997
2272;FHIT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Association between germline variation in the <span class=""gene"" id=""17548701-0-46-50"">FHIT</span> gene and <span class=""disease"" id=""17548701-0-60-75"">prostate cancer</span> in Caucasians and African Americans.";17548701;2007
1636;ACE;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Effects of <span class=""gene"" id=""17465223-0-11-16"">ACE I</span>/D polymorphism on <span class=""disease"" id=""17465223-0-35-50"">prostate cancer</span> risk, tumor grade and metastatis.";17465223;2007
2048;EPHB2;C0376358;Malignant neoplasm of prostate;0,4;GeneticVariation;UNIPROT;"The DU 145 <span class=""disease"" id=""15300251-4-11-26"">prostate cancer</span> cell line, originating from a brain metastasis, carries a truncating mutation of <span class=""gene"" id=""15300251-4-108-113"">EPHB2</span> and a deletion of the remaining allele.";15300251;2004
113189;CHST14;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"These results demonstrate that osteoblasts promote <span class=""disease"" id=""15672864-12-51-54"">CaP</span> growth through <span class=""gene"" id=""15672864-12-70-74"">IL-6</span>-mediated activation of the AR.";15672864;2005
7430;EZR;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6237;RRAS;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5160;PDHA1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
23671;TMEFF2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Addition of physiological concentrations of dihydrotestosterone (DHT) to <span class=""disease"" id=""23405127-5-73-88"">prostate cancer</span> cell lines increases translation of endogenous <span class=""gene"" id=""23405127-5-136-142"">TMEFF2</span> or transfected <span class=""gene"" id=""23405127-5-158-164"">TMEFF2</span>-Luciferase fusions, and this effect requires the presence of upstream open reading frames (uORFs) in the 5'-untranslated region (5'-UTR) of <span class=""gene"" id=""23405127-5-305-311"">TMEFF2</span>.";23405127;2013
28999;KLF15;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"<span class=""gene"" id=""11742035-0-0-17"">Androgen receptor</span> alterations in <span class=""disease"" id=""11742035-0-33-48"">prostate cancer</span> relapsed during a combined androgen blockade by orchiectomy and bicalutamide.";11742035;2002
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association between polymorphisms in the DNA repair genes <span class=""gene"" id=""16406883-0-58-63"">XRCC1</span> and APE1, and the risk of <span class=""disease"" id=""16406883-0-90-105"">prostate cancer</span> in white and black Americans.";16406883;2006
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results suggest that sequence variants in this gene are associated with <span class=""disease"" id=""11956079-6-78-93"">prostate cancer</span> risk, presumably through defective DNA repair function of <span class=""gene"" id=""11956079-6-152-157"">hOGG1</span>.";11956079;2002
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Here, we examined the molecular mechanisms of resveratrol and its interactive effects with <span class=""gene"" id=""17636462-2-91-96"">TRAIL</span> on apoptosis in <span class=""disease"" id=""17636462-2-113-128"">prostate cancer</span> PC-3 and DU-145 cells.";17636462;2008
51135;IRAK4;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"In this large case-control study, we tested two hypotheses: (a) sequence variants in IRAK1 and <span class=""gene"" id=""16537705-5-95-100"">IRAK4</span> are associated with <span class=""disease"" id=""16537705-5-121-136"">prostate cancer</span> risk and (b) sequence variants in IRAK1/4 and TLR1-6-10 interacts and confers a stronger risk to <span class=""disease"" id=""16537705-5-234-249"">prostate cancer</span>.";16537705;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"These cells express abundant <span class=""gene"" id=""10569618-5-29-31"">AR</span> (Nmax = 685 +/- 149 fmol./mg. protein), but the <span class=""gene"" id=""10569618-5-80-82"">AR</span> binding affinity (Kd) for DHT is only 25 nM, approximately 50-fold lower affinity than the mutated <span class=""gene"" id=""10569618-5-182-184"">AR</span> in LNCaP <span class=""disease"" id=""10569618-5-194-209"">prostate cancer</span> cells (Kd = 0.5 nM) or the wildtype <span class=""gene"" id=""10569618-5-246-248"">AR</span> in MCF-7 breast cancer cells (Kd = 0.4 nM).";10569618;2000
3952;LEP;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;"Linear trend analysis showed that quantitative increase of <span class=""gene"" id=""15042602-5-59-67"">A-allele</span> presence was associated with significantly higher risk for <span class=""disease"" id=""15042602-5-127-129"">PC</span> (P = 0.003) in heterozygous (OR = 2.11; CI, 1.20-3.71) and homozygous (OR = 2.93; CI, 1.27-6.75) genotypes.";15042602;2004
8405;SPOP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Exome sequencing identifies recurrent <span class=""gene"" id=""22610119-0-38-42"">SPOP</span>, FOXA1 and MED12 mutations in <span class=""disease"" id=""22610119-0-73-88"">prostate cancer</span>.";22610119;2012
2878;GPX3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Deletions (hemizygous and homozygous) of <span class=""gene"" id=""17804715-4-41-45"">GPx3</span> gene are frequent in <span class=""disease"" id=""17804715-4-67-82"">prostate cancer</span> samples, occurring in 39% of the samples studied.";17804715;2007
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""14754878-0-0-5"">COX-2</span> gene promoter haplotypes and <span class=""disease"" id=""14754878-0-35-50"">prostate cancer</span> risk.";14754878;2004
55256;ADI1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Expression and function of the human androgen-responsive gene <span class=""gene"" id=""17786183-0-62-66"">ADI1</span> in <span class=""disease"" id=""17786183-0-70-85"">prostate cancer</span>.";17786183;2007
54363;HAO1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
11009;IL24;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Melanoma differentiation associated gene-7, <span class=""gene"" id=""14678967-0-44-49"">mda-7</span>/<span class=""gene"" id=""14678967-0-50-64"">interleukin-24</span>, induces apoptosis in <span class=""disease"" id=""14678967-0-87-102"">prostate cancer</span> cells by promoting mitochondrial dysfunction and inducing reactive oxygen species.";14678967;2004
58508;KMT2C;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
857;CAV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Multiple lines of evidence have implicated the <span class=""gene"" id=""15948133-1-47-52"">CAV-1</span> gene in <span class=""disease"" id=""15948133-1-61-76"">prostate cancer</span> progression.";15948133;2005
3708;ITPR1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
2950;GSTP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Together with our previous in vivo observations of an ""epigenetic reprogramming gene signature"" in clinical <span class=""gene"" id=""18798265-11-108-111"">ERG</span>-positive <span class=""disease"" id=""18798265-11-121-137"">prostate cancers</span>, these studies provide mechanistic insights to <span class=""gene"" id=""18798265-11-185-188"">ERG</span>-associated tumorigenesis and suggest therapeutic paradigms to be tested in vivo.";18798265;2009
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Over-expression of <span class=""gene"" id=""20729295-3-19-21"">AR</span> and upregulation of <span class=""gene"" id=""20729295-3-42-44"">AR</span> transcriptional activity are often observed in the later stages of <span class=""disease"" id=""20729295-3-112-127"">prostate cancer</span>.";20729295;2011
655;BMP7;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Further validation of candidate genes on a separate cohort of low and high grade <span class=""disease"" id=""19283074-5-81-97"">prostate cancers</span> by quantitative MethyLight analysis has allowed us to confirm DNA hypermethylation of HOXD3 and <span class=""gene"" id=""19283074-5-194-198"">BMP7</span>, two genes that may play a role in the development of high grade tumours.";19283074;2009
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Nine single-nucleotide polymorphisms (SNPs) in <span class=""gene"" id=""17609663-5-47-51"">COX2</span> were genotyped among 1012 men in our case-control study of advanced <span class=""disease"" id=""17609663-5-120-135"">prostate cancer</span>.";17609663;2007
999;CDH1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The E-cadherin -160 C/A polymorphism and prostate cancer risk in white and black American men.;16813949;2006
8409;UXT;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"To examine <span class=""gene"" id=""19318562-9-11-17"">ART-27</span> loss in <span class=""disease"" id=""19318562-9-26-41"">prostate cancer</span> progression, immunohistochemistry was conducted on a tissue array containing samples from primary tumors of individuals who were clinically followed and later shown to have either recurrent or nonrecurrent disease.";19318562;2009
6136;RPL12;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our findings suggest that variation in <span class=""gene"" id=""17609663-12-39-43"">COX2</span> is associated with <span class=""disease"" id=""17609663-12-63-78"">prostate cancer</span> risk.";17609663;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We identify two independent susceptibility loci for <span class=""disease"" id=""26443449-4-52-67"">prostate cancer</span> at 11p15.4 (rs12791447, P=3.59 × 10(-8); PPFIBP2) and 14q23.2 (rs58262369, P=6.05 × 10(-10); <span class=""gene"" id=""26443449-4-161-165"">ESR2</span>).";26443449;2016
246778;IL27;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"We describe our findings in the effects of <span class=""gene"" id=""24028178-4-43-48"">IL-27</span> gene delivery on <span class=""disease"" id=""24028178-4-66-81"">prostate cancer</span> cells, osteoblasts, and osteoclasts at different stages of differentiation.";24028178;2014
999;CDH1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.;22581815;2012
2052;EPHX1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"In our case-control study, we assessed whether CYP1A1 and <span class=""gene"" id=""17919073-3-58-61"">mEH</span> susceptibility genotypes, tobacco use, and age factors contribute to <span class=""disease"" id=""17919073-3-131-134"">PCa</span> risk.";17919073;2008
2118;ETV4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.;27783944;2016
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"We show that the <span class=""gene"" id=""18670643-3-17-23"">FGFR-4</span> Arg(388) polymorphism, which is present in most <span class=""disease"" id=""18670643-3-72-87"">prostate cancer</span> patients, results in increased receptor stability and sustained receptor activation.";18670643;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Overall, this study demonstrates that <span class=""gene"" id=""25908785-8-38-40"">AR</span>-Vs broadly restore <span class=""gene"" id=""25908785-8-60-62"">AR</span> chromatin binding events that are otherwise suppressed during endocrine therapy, and provides pre-clinical rationale for BET inhibition as a strategy for inhibiting expression and chromatin binding of <span class=""gene"" id=""25908785-8-264-266"">AR</span>-Vs in <span class=""disease"" id=""25908785-8-273-276"">PCa</span>.";25908785;2015
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"<span class=""gene"" id=""19593445-1-0-3"">BAD</span>, a pro-apoptotic protein of the Bcl-2 family, has recently been identified as an integrator of several anti-apoptotic signaling pathways in <span class=""disease"" id=""19593445-1-144-159"">prostate cancer</span> cells.";19593445;2009
1266;CNN3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
664;BNIP3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Expression of <span class=""gene"" id=""18163427-0-14-19"">BNIP3</span> correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in <span class=""disease"" id=""18163427-0-115-130"">prostate cancer</span> and is regulated directly by hypoxia but not androgens in cell lines.";18163427;2008
3265;HRAS;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2944;GSTM1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study suggests that the CYP1A1 polymorphism and its combination with <span class=""gene"" id=""11275366-5-74-79"">GSTM1</span> may be associated with <span class=""disease"" id=""11275366-5-103-106"">PCa</span> susceptibility in the Japanese population.";11275366;2001
6376;CX3CL1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We recently defined a gene signature that was characteristic to <span class=""disease"" id=""18798265-2-64-80"">prostate cancers</span> with <span class=""gene"" id=""18798265-2-86-89"">ERG</span> activation.";18798265;2009
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"The majority of <span class=""disease"" id=""16877366-1-16-32"">prostate cancers</span> (<span class=""disease"" id=""16877366-1-34-37"">PCa</span>) that relapse after androgen deprivation therapy (androgen-independent <span class=""disease"" id=""16877366-1-109-112"">PCa</span>) continue to express <span class=""gene"" id=""16877366-1-134-151"">androgen receptor</span> (<span class=""gene"" id=""16877366-1-153-155"">AR</span>).";16877366;2006
6746;SSR2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
8854;ALDH1A2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Taken together, our findings implicate <span class=""gene"" id=""16166285-8-39-46"">ALDH1a2</span> as a candidate tumor suppressor gene in <span class=""disease"" id=""16166285-8-87-102"">prostate cancer</span> and further support a role of retinoids in the prevention or treatment of <span class=""disease"" id=""16166285-8-177-192"">prostate cancer</span>.";16166285;2005
384;ARG2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"It has been reported that <span class=""gene"" id=""23424623-3-26-37"">arginase II</span> (<span class=""gene"" id=""23424623-3-39-43"">ARG2</span>), one of two ARGs, is aberrantly expressed in <span class=""disease"" id=""23424623-3-90-105"">prostate cancer</span> cells, which convert arginine into ornithine, resulting in a lack of arginine that weakens tumor-infiltrating lymphocytes and renders them dysfunctional.";23424623;2013
8452;CUL3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We identify a total of 97 SMGs, including 70 not previously implicated in <span class=""disease"" id=""29610475-6-74-89"">prostate cancer</span>, such as the ubiquitin ligase <span class=""gene"" id=""29610475-6-120-124"">CUL3</span> and the transcription factor SPEN.";29610475;2018
8754;ADAM9;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"By decreasing <span class=""gene"" id=""17018608-11-14-19"">ADAM9</span> expression, we observed apoptotic cell death in <span class=""disease"" id=""17018608-11-68-83"">prostate cancer</span> cells.";17018608;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"We show that resveratrol inhibits <span class=""gene"" id=""20729295-8-34-36"">AR</span> transcriptional activity in both androgen-dependent and -independent <span class=""disease"" id=""20729295-8-106-121"">prostate cancer</span> cells.";20729295;2011
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"We have previously reported that one of eight endocrine therapy-resistant <span class=""disease"" id=""8827083-3-74-89"">prostate cancer</span> cases showed <span class=""gene"" id=""8827083-3-103-105"">AR</span> gene mutation [Suzuki et al: J Steroid Biochem Mol Biol 46:759-765, 1993].";8827083;1996
3092;HIP1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;;;
5896;RAG1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
3732;CD82;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;;;
3557;IL1RN;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"<span class=""gene"" id=""16106254-0-0-33"">Interleukin-1 receptor antagonist</span> haplotype associated with <span class=""disease"" id=""16106254-0-60-75"">prostate cancer</span> risk.";16106254;2005
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"<span class=""gene"" id=""23704919-0-0-17"">Androgen receptor</span> promotes ligand-independent <span class=""disease"" id=""23704919-0-46-61"">prostate cancer</span> progression through c-Myc upregulation.";23704919;2013
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We have previously shown that <span class=""disease"" id=""17718901-1-30-45"">prostate cancer</span> LNCaP cells are resistant to <span class=""gene"" id=""17718901-1-75-80"">TRAIL</span>, and downregulation of PI-3K/Akt pathway by molecular and pharmacological means sensitizes cells to undergo apoptosis by <span class=""gene"" id=""17718901-1-202-207"">TRAIL</span> and curcumin.";17718901;2011
6790;AURKA;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"The single-nucleotide polymorphism T91A (Phe31Ile) has been implicated in <span class=""gene"" id=""17898866-2-74-79"">AURKA</span> overexpression and has been suggested as a low-penetrance susceptibility allele in multiple human cancers, including <span class=""disease"" id=""17898866-2-197-212"">prostate cancer</span>.";17898866;2007
2952;GSTT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Genetic polymorphisms in cytochrome P450 (CYP) 1A1, CYP1A2, CYP2E1, glutathione S-transferase (GST) M1 and <span class=""gene"" id=""11275366-0-107-112"">GSTT1</span> and susceptibility to <span class=""disease"" id=""11275366-0-135-150"">prostate cancer</span> in the Japanese population.";11275366;2001
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These data suggest that variation of the <span class=""gene"" id=""14754878-13-41-46"">COX-2</span> promoter may influence the risk and development of <span class=""disease"" id=""14754878-13-98-113"">prostate cancer</span>.";14754878;2004
8202;NCOA3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Together, our data indicate that the CAG/CAA repeat length in the <span class=""gene"" id=""11927493-9-66-70"">AIB1</span>/<span class=""gene"" id=""11927493-9-71-76"">SRC-3</span> gene may be associated with <span class=""disease"" id=""11927493-9-105-120"">prostate cancer</span> risk in Chinese men and that the combination of CAG/CAA repeat lengths in both the <span class=""gene"" id=""11927493-9-204-208"">AIB1</span>/<span class=""gene"" id=""11927493-9-209-214"">SRC-3</span> and AR genes may provide a useful marker for clinically significant <span class=""disease"" id=""11927493-9-283-298"">prostate cancer</span>.";11927493;2002
51651;PTRH2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
114609;TIRAP;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.;16284379;2006
9080;CLDN9;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3486;IGFBP3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Genetic polymorphisms in IGF-I and <span class=""gene"" id=""24586243-0-35-42"">IGFBP-3</span> are associated with <span class=""disease"" id=""24586243-0-63-78"">prostate cancer</span> in the Chinese population.";24586243;2015
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"These properties of resveratrol strongly suggest that it could be used either alone or in combination with <span class=""gene"" id=""17636462-10-107-112"">TRAIL</span> for the prevention and/or treatment of <span class=""disease"" id=""17636462-10-152-167"">prostate cancer</span>.";17636462;2008
8743;TNFSF10;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Resveratrol either alone or in combination with <span class=""gene"" id=""17718901-8-48-53"">TRAIL</span> or Smac can be used for the prevention and/or treatment of human <span class=""disease"" id=""17718901-8-119-134"">prostate cancer</span>.";17718901;2011
857;CAV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Association of a <span class=""gene"" id=""15948133-0-17-22"">CAV-1</span> haplotype to familial aggressive <span class=""disease"" id=""15948133-0-56-71"">prostate cancer</span>.";15948133;2005
5420;PODXL;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"These results implicate <span class=""gene"" id=""16434482-9-24-29"">PODXL</span> as a candidate <span class=""disease"" id=""16434482-9-45-60"">prostate cancer</span> tumor aggressiveness gene mapping to chromosome 7q32-q33.";16434482;2006
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Our findings indicate that increased receptor stability and sustained FGFR-4 signaling occur in most human <span class=""disease"" id=""18670643-6-107-123"">prostate cancers</span> due to either the presence of a common genetic polymorphism or the expression of a protein that stabilizes <span class=""gene"" id=""18670643-6-231-237"">FGFR-4</span>.";18670643;2008
9611;NCOR1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1410;CRYAB;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Bad expression influences time to androgen escape in prostate cancer.;17542986;2007
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in <span class=""gene"" id=""18798265-0-92-95"">ERG</span>-positive <span class=""disease"" id=""18798265-0-105-120"">prostate cancer</span>.";18798265;2009
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;GeneticVariation;UNIPROT;"In preliminary screens, mutations of <span class=""gene"" id=""9072974-2-37-41"">PTEN</span> were detected in 31% (13/42) of glioblastoma cell lines and xenografts, 100% (4/4) of <span class=""disease"" id=""9072974-2-128-143"">prostate cancer</span> cell lines, 6% (4/65) of breast cancer cell lines and xenografts, and 17% (3/18) of primary glioblastomas.";9072974;1997
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Functional variant of manganese superoxide dismutase (<span class=""gene"" id=""17646272-0-54-58"">SOD2</span> V16A) polymorphism is associated with <span class=""disease"" id=""17646272-0-97-112"">prostate cancer</span> risk in the prostate, lung, colorectal, and ovarian cancer study.";17646272;2007
1474;CST6;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"<span class=""gene"" id=""19503093-6-0-4"">CST6</span> overexpression in human <span class=""disease"" id=""19503093-6-29-44"">prostate cancer</span> cells significantly reduced in vitro cell proliferation and matrigel invasion.";19503093;2009
2938;GSTA1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Human <span class=""gene"" id=""15616829-0-6-34"">glutathione S-transferase A1</span>, T1, M1, and P1 polymorphisms and susceptibility to <span class=""disease"" id=""15616829-0-87-102"">prostate cancer</span> in the Japanese population.";15616829;2005
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"A significant association was found between <span class=""gene"" id=""14634453-6-44-49"">hOGG1</span> genotypes and <span class=""disease"" id=""14634453-6-64-79"">prostate cancer</span> with a dose effect relationship (trend test p &lt;0.003).";14634453;2004
7874;USP7;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1543;CYP1A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The frequency of valine (Val)/valine (Val) genotypes for <span class=""gene"" id=""11275366-2-57-63"">CYP1A1</span> was 11.3% in cases compared with 5.5% in controls, this polymorphism thus being associated with a significantly increased risk of <span class=""disease"" id=""11275366-2-194-197"">PCa</span> (odds ratio=2.4, 95% confidence interval (CI)=1.01-5.57).";11275366;2001
57646;USP28;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
54894;RNF43;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
4152;MBD1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7514;XPO1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We evaluated the association of <span class=""disease"" id=""17646272-2-32-47"">prostate cancer</span> with genetic polymorphisms in SOD1 (CuZn-SOD; IVS3-251A&gt;G), <span class=""gene"" id=""17646272-2-108-112"">SOD2</span> [<span class=""gene"" id=""17646272-2-114-119"">MnSOD</span>; Ex2+24T&gt;C (V16A)], and SOD3 (EC-SOD; IVS1+186C&gt;T, Ex3-631C&gt;G, Ex3-516C&gt;T, and Ex3-489C&gt;T), the three main isoforms of SOD.";17646272;2007
1012;CDH13;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Multiple loci identified in a genome-wide association study of prostate cancer.;18264096;2008
5174;PDZK1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
7480;WNT10B;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk.;27415467;2017
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Controversy exists over the significance of associations between the <span class=""gene"" id=""17136762-1-69-75"">SRD5A2</span> (5alpha-reductase type 2) polymorphisms, A49T and V89L, and risk of <span class=""disease"" id=""17136762-1-144-159"">prostate cancer</span>.";17136762;2007
135112;NCOA7;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
7352;UCP3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
2346;FOLH1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"LNCaP <span class=""disease"" id=""18247401-5-6-21"">prostate cancer</span> cells were treated with 1,25-VD, followed by analysis of cell surface <span class=""gene"" id=""18247401-5-92-96"">PSMA</span> expression.";18247401;2008
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"This study was conducted to examine; (1) whether the <span class=""gene"" id=""16083506-2-53-74"">N-acetyltransferase 2</span> (<span class=""gene"" id=""16083506-2-76-80"">NAT2</span>) genotype is a risk factor for <span class=""disease"" id=""16083506-2-112-127"">prostate cancer</span>, (2) to study effect of <span class=""gene"" id=""16083506-2-152-156"">NAT2</span> genotype on modifying <span class=""disease"" id=""16083506-2-179-194"">prostate cancer</span> risk from tobacco use.";16083506;2006
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"T can nevertheless acquire DHT-like activity through an <span class=""gene"" id=""17591767-6-56-58"">AR</span> helix-10 H874Y <span class=""disease"" id=""17591767-6-74-89"">prostate cancer</span> mutation.";17591767;2007
10645;CAMKK2;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;Akt activation by Ca<sup>2+</sup>/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.;28634229;2017
6885;MAP3K7;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
23244;PDS5A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
3558;IL2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"However, no significant statistical difference was found between the polymorphism of the <span class=""gene"" id=""17115417-7-89-93"">IL-2</span> gene and <span class=""disease"" id=""17115417-7-103-118"">prostate cancer</span> in survival analysis during a 5-year follow up period (log rank test; P = 0.19).";17115417;2007
10625;IVNS1ABP;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
4023;LPL;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Our results suggest that the <span class=""gene"" id=""15386377-8-29-32"">LPL</span> Ser447stop polymorphism is a common genetic modifier for the development of <span class=""disease"" id=""15386377-8-109-124"">prostate cancer</span>, particularly that of high-grade and/or high-stage, in a Japanese population.";15386377;2004
79807;GSTCD;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
210;ALAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Using a case-only study design, we assessed potential gene-environment (G × E) interactions between lifetime occupational Pb exposure and 11 tagSNPs within <span class=""gene"" id=""24500903-5-156-160"">ALAD</span> in black (N = 260) and white (N = 343) <span class=""disease"" id=""24500903-5-200-215"">prostate cancer</span> cases.";24500903;2014
79718;TBL1XR1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
5796;PTPRK;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
1647;GADD45A;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Our results show that <span class=""gene"" id=""19190346-11-22-33"">GADD45alpha</span> is epigenetically repressed and is a potential target for treatment of <span class=""disease"" id=""19190346-11-105-120"">prostate cancer</span>.";19190346;2009
55819;RNF130;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5074;PAWR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Tumour-suppression activity of the proapoptotic regulator Par4.;15877079;2005
6091;ROBO1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.;16442593;2006
25818;KLK5;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Human <span class=""gene"" id=""16517595-0-6-25"">tissue kallikrein 5</span> is a member of a proteolytic cascade pathway involved in seminal clot liquefaction and potentially in <span class=""disease"" id=""16517595-0-128-143"">prostate cancer</span> progression.";16517595;2006
2068;ERCC2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Those who had GIA or A/A at <span class=""gene"" id=""17695467-6-28-31"">XPD</span> codon 312 showed a 1.81-fold (95% confidence interval=1.21-2.69) increased risk of <span class=""disease"" id=""17695467-6-115-130"">prostate cancer</span> compared to those with GIG.";17695467;2007
1577;CYP3A5;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"The interaction of <span class=""gene"" id=""18306354-0-19-25"">CYP3A5</span> polymorphisms along the androgen metabolism pathway in <span class=""disease"" id=""18306354-0-81-96"">prostate cancer</span>.";18306354;2008
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Overexpression of <span class=""gene"" id=""19240160-12-18-22"">IL-6</span> not only plays an important role in <span class=""disease"" id=""19240160-12-59-74"">prostate cancer</span> progression but also contributes to bicalutamide resistance.";19240160;2009
7100;TLR5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk.;16284379;2006
27173;SLC39A1;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
6038;RNASE4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Statistically significant effect modification of both HCA (DiMeIQx) and darkly browned meat intake and <span class=""disease"" id=""22564066-8-103-106"">PCa</span> risk was observed for allelic variants of <span class=""gene"" id=""22564066-8-149-154"">MnSOD</span> (rs4880) (P(interaction): 0.02).";22564066;2012
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).;25062956;2015
2950;GSTP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We found that men with the CYP17/A1A1-A1A2 genotypes, <span class=""gene"" id=""15538743-5-54-59"">GSTP1</span>/IleVal genotype, PON192/QR and PON55/LM-MM genotypes had a significantly higher risk of <span class=""disease"" id=""15538743-5-148-151"">PCa</span> compared with the others genotypes.";15538743;2005
7153;TOP2A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"This is the first study to document low-level <span class=""gene"" id=""17363613-14-46-51"">TOP2A</span> amplification in <span class=""disease"" id=""17363613-14-69-84"">prostate cancer</span> and an association with reduced survival.";17363613;2007
3417;IDH1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This study supports the hypothesis that inflammation is involved in prostate carcinogenesis and that sequence variation within the <span class=""gene"" id=""16506214-10-131-136"">COX-2</span> gene influence the risk of <span class=""disease"" id=""16506214-10-164-179"">prostate cancer</span>.";16506214;2006
1571;CYP2E1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"The results of this study indicate that DraI polymorphisms of the <span class=""gene"" id=""12771559-5-66-72"">CYP2E1</span> gene may be associated with a twofold increased risk for the development of <span class=""disease"" id=""12771559-5-149-152"">PCa</span>.";12771559;2004
23248;RPRD2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"To investigate the hypothesis that <span class=""gene"" id=""11742035-3-35-37"">AR</span> gene aberrations are involved in CAB relapse, 11 locally recurrent <span class=""disease"" id=""11742035-3-105-108"">CaP</span> samples from patients treated with orchiectomy and bicalutamide were analyzed for copy number changes and DNA sequence alterations of the <span class=""gene"" id=""11742035-3-247-249"">AR</span> gene by fluorescence in situ hybridization and single-strand conformation polymorphism, respectively.";11742035;2002
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Dietary intake of phytoestrogens, <span class=""gene"" id=""16921512-0-34-56"">estrogen receptor-beta</span> polymorphisms and the risk of <span class=""disease"" id=""16921512-0-87-102"">prostate cancer</span>.";16921512;2006
7048;TGFBR2;C0376358;Malignant neoplasm of prostate;0,58;Biomarker;CTD_human;"Methylation silencing of <span class=""gene"" id=""18381416-0-25-73"">transforming growth factor-beta receptor type II</span> in rat <span class=""disease"" id=""18381416-0-81-97"">prostate cancers</span>.";18381416;2008
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"Since these miRNAs target PTEN (<span class=""gene"" id=""21714127-6-32-62"">phosphatase and tensin homolog</span> deleted on chromosome 10), we performed Western blot to confirm up-regulation of PTEN in <span class=""disease"" id=""21714127-6-152-155"">PCa</span> cells.";21714127;2011
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Statistically significant effect modification of both HCA (DiMeIQx) and darkly browned meat intake and <span class=""disease"" id=""22564066-8-103-106"">PCa</span> risk was observed for allelic variants of <span class=""gene"" id=""22564066-8-149-154"">MnSOD</span> (rs4880) (P(interaction): 0.02).";22564066;2012
2886;GRB7;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
51084;CRYL1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Differential regulation of clusterin and its isoforms by androgens in prostate cells.;17148459;2007
9420;CYP7B1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"This is the first report showing that <span class=""gene"" id=""17639508-9-38-44"">CYP7B1</span> is overexpressed in high-grade PIN and in <span class=""disease"" id=""17639508-9-87-102"">prostate cancer</span> and that local methylation of <span class=""gene"" id=""17639508-9-133-139"">CYP7B1</span> promoter region may have significant effect on gene transcription.";17639508;2007
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;Apigenin suppresses cancer cell growth through ERbeta.;17132221;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"The higher activity Ala variant at <span class=""gene"" id=""17646272-5-35-39"">SOD2</span> Ex2+24T&gt;C (V16A), which has been hypothesized to suppress prostate carcinogenesis, was associated with elevation of <span class=""disease"" id=""17646272-5-156-171"">prostate cancer</span> risk in Caucasians (Val/Ala versus Val/Val: OR, 1.17; 95% CI, 0.97-1.42; Ala/Ala versus Val/Val: OR, 1.28; 95% CI, 1.03-1.60; P(trend) = 0.03).";17646272;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Common genetic alterations in <span class=""disease"" id=""22610119-3-30-45"">prostate cancer</span> include losses of NKX3.1 (8p21) and PTEN (10q23), gains of AR (the <span class=""gene"" id=""22610119-3-113-130"">androgen receptor</span> gene) and fusion of ETS family transcription factor genes with androgen-responsive promoters.";22610119;2012
25792;CIZ1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Quantitative methylation-specific PCR results showed that the <span class=""gene"" id=""18559593-5-62-67"">SSBP2</span> promoter was hypermethylated in 54 of 88 (61.4%) primary <span class=""disease"" id=""18559593-5-125-141"">prostate cancers</span> versus 0 of 23 (0%) in benign prostatic hyperplasia using a cutoff value of 120.";18559593;2008
9968;MED12;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Exome sequencing identifies recurrent SPOP, FOXA1 and <span class=""gene"" id=""22610119-0-54-59"">MED12</span> mutations in <span class=""disease"" id=""22610119-0-73-88"">prostate cancer</span>.";22610119;2012
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"In the comparison of genotype distributions of <span class=""gene"" id=""20875869-3-47-51"">TP53</span> codon 72 between cases and controls, the adjusted odds ratios for <span class=""disease"" id=""20875869-3-118-121"">PCa</span> associated with the Pro/Pro, Arg/Pro, and Arg/Arg genotypes were 1.00, 1.89 (95% CI = 1.20-2.97), and 2.01 (95% CI = 1.11-3.64), respectively; however, MDM2 SNP309 and C1797G did not show any significant difference between cases and controls.";20875869;2010
4353;MPO;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Among men carrying the variant allele for thioredoxin reductase 2 (TXNRD2) rs4485648, microsomal epoxide hydrolase 1 (EPHX1) rs17309872, or <span class=""gene"" id=""21716162-6-140-155"">myeloperoxidase</span> (<span class=""gene"" id=""21716162-6-157-160"">MPO</span>) rs11079344, an increased <span class=""disease"" id=""21716162-6-187-202"">prostate cancer</span> risk was observed with high, compared with no, petroleum oil/petroleum distillate (OR=1.9, 95% CI: 1.1-3.2, P interaction=0.01; OR=2.1, 95% CI: 1.1-4.0, P interaction=0.01), or terbufos (OR=3.0, 95% CI: 1.5-6.0, P interaction=2.0×10(-3)) use, respectively.";21716162;2012
55840;EAF2;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice.;20564326;2010
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Genetic expression analysis revealed RNASEL (P = 0.007) was underexpressed in <span class=""disease"" id=""27318894-6-78-81"">PCa</span> tissue, whereas <span class=""gene"" id=""27318894-6-98-102"">KLK3</span> (P = 0.041) was overexpressed.";27318894;2016
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"However, little is known about the role that sequence variation of the <span class=""gene"" id=""14754878-3-71-76"">COX-2</span> gene contributes to <span class=""disease"" id=""14754878-3-97-112"">prostate cancer</span>.";14754878;2004
6041;RNASEL;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"<span class=""gene"" id=""17020975-0-0-6"">RNASEL</span> gene polymorphisms and the risk of <span class=""disease"" id=""17020975-0-42-57"">prostate cancer</span>: a meta-analysis.";17020975;2006
54795;TRPM4;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Analysis of the effect of <span class=""gene"" id=""19593445-5-26-29"">BAD</span> on <span class=""disease"" id=""19593445-5-33-48"">prostate cancer</span> xenografts has shown that increased <span class=""gene"" id=""19593445-5-85-88"">BAD</span> expression enhances tumor growth, while knockdown of <span class=""gene"" id=""19593445-5-142-145"">BAD</span> expression by shRNA inhibits tumor growth.";19593445;2009
2052;EPHX1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"In conclusion, our study demonstrated that exon 3 of <span class=""gene"" id=""17919073-9-53-56"">mEH</span> and CYP1A1 T/C gene polymorphism are predisposing risk factors for susceptibility of sporadic <span class=""disease"" id=""17919073-9-151-154"">PCa</span> in northern India.";17919073;2008
4481;MSR1;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;Systematic replication study of reported genetic associations in prostate cancer: Strong support for genetic variation in the androgen pathway.;16998812;2007
23600;AMACR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
672;BRCA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Common variation in the <span class=""gene"" id=""17585057-0-24-29"">BRCA1</span> gene and <span class=""disease"" id=""17585057-0-39-54"">prostate cancer</span> risk.";17585057;2007
79366;HMGN5;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Neonatal exposure to estradiol/bisphenol A alters promoter methylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life.;22109888;2012
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Although the <span class=""gene"" id=""16266977-3-13-30"">androgen receptor</span> (<span class=""gene"" id=""16266977-3-32-34"">AR</span>) is suggested to play an important role in <span class=""disease"" id=""16266977-3-78-93"">prostate cancer</span> progression even after the androgen ablation, limited tissue availability for molecular studies and small numbers of human <span class=""disease"" id=""16266977-3-217-232"">prostate cancer</span> cell lines have restricted <span class=""disease"" id=""16266977-3-260-275"">prostate cancer</span> research.";16266977;2005
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"To investigate the hypothesis that <span class=""gene"" id=""11742035-3-35-37"">AR</span> gene aberrations are involved in CAB relapse, 11 locally recurrent <span class=""disease"" id=""11742035-3-105-108"">CaP</span> samples from patients treated with orchiectomy and bicalutamide were analyzed for copy number changes and DNA sequence alterations of the <span class=""gene"" id=""11742035-3-247-249"">AR</span> gene by fluorescence in situ hybridization and single-strand conformation polymorphism, respectively.";11742035;2002
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"The majority of <span class=""disease"" id=""16877366-1-16-32"">prostate cancers</span> (<span class=""disease"" id=""16877366-1-34-37"">PCa</span>) that relapse after androgen deprivation therapy (androgen-independent <span class=""disease"" id=""16877366-1-109-112"">PCa</span>) continue to express <span class=""gene"" id=""16877366-1-134-151"">androgen receptor</span> (<span class=""gene"" id=""16877366-1-153-155"">AR</span>).";16877366;2006
10333;TLR6;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the <span class=""gene"" id=""16537705-0-87-107"">toll-like receptor 6</span>-1-10 gene cluster increase <span class=""disease"" id=""16537705-0-135-150"">prostate cancer</span> risk.";16537705;2006
2264;FGFR4;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"Increased expression of fibroblast growth factors that can activate the <span class=""gene"" id=""15448004-1-72-107"">fibroblast growth factor receptor-4</span> (<span class=""gene"" id=""15448004-1-109-115"">FGFR-4</span>) occurs in a substantial fraction of human <span class=""disease"" id=""15448004-1-159-175"">prostate cancers</span> in vivo.";15448004;2005
11178;LZTS1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"These results add evidence supporting a role of <span class=""gene"" id=""12377406-9-48-53"">LZTS1</span> in <span class=""disease"" id=""12377406-9-57-72"">prostate cancer</span> risk.";12377406;2002
3284;HSD3B2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"In Caucasians, the <span class=""gene"" id=""17823934-9-19-25"">HSD3B2</span> (<span class=""gene"" id=""17823934-9-27-29"">TG</span>)n,(TA)n,(CA)n intron 3 length polymorphism is associated with both <span class=""disease"" id=""17823934-9-97-112"">prostate cancer</span> risk and aggressiveness and the SRD5A2 V89L polymorphism may modify the risk conferred by this polymorphism.";17823934;2007
196528;ARID2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In a case-control study of 207 patients with <span class=""disease"" id=""17486273-2-45-48"">PCa</span> and 235 cancer-free controls, frequency-matched by age, we genotyped three <span class=""gene"" id=""17486273-2-124-129"">XRCC1</span> polymorphisms (codons 194, 280 and 399) using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RELP) method.";17486273;2007
3716;JAK1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
5744;PTHLH;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We show that 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and its non-hypercalcemic analog, EB1089, decrease <span class=""gene"" id=""16243370-2-103-108"">PTHrP</span> mRNA and cellular protein levels in the androgen-dependent human <span class=""disease"" id=""16243370-2-174-189"">prostate cancer</span> cell line LNCaP and its androgen-independent derivative, the C4-2 cell line.";16243370;2006
2115;ETV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Recently, we identified recurrent gene fusions involving the 5' untranslated region of the androgen-regulated gene TMPRSS2 and the ETS (E26 transformation-specific) family genes ERG, <span class=""gene"" id=""17671502-1-183-187"">ETV1</span> or ETV4 in most <span class=""disease"" id=""17671502-1-204-220"">prostate cancers</span>.";17671502;2007
7263;TST;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
54897;CASZ1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
5610;EIF2AK2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"This study confirms the overall importance of the <span class=""gene"" id=""23292082-12-50-56"">HOXB13</span> G84E mutation in <span class=""disease"" id=""23292082-12-74-89"">prostate cancer</span> susceptibility.";23292082;2013
2099;ESR1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Phytoestrogen exposure, polymorphisms in COMT, CYP19, <span class=""gene"" id=""17176215-0-54-58"">ESR1</span>, and SHBG genes, and their associations with <span class=""disease"" id=""17176215-0-104-119"">prostate cancer</span> risk.";17176215;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"We show here that c-Myc, which is a key mediator of ligand-independent <span class=""disease"" id=""23704919-6-71-86"">prostate cancer</span> growth, is a key ligand-independent <span class=""gene"" id=""23704919-6-123-125"">AR</span> target gene.";23704919;2013
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We demonstrated that cultures derived from <span class=""disease"" id=""17914592-3-43-46"">PCa</span> tissues harvested after NHT presented significantly higher <span class=""gene"" id=""17914592-3-106-110"">EGFR</span> and Her2 levels compared to cultures derived from control patients.";17914592;2007
664;BNIP3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"This study investigated the role of <span class=""gene"" id=""18163427-2-36-41"">BNIP3</span> in <span class=""disease"" id=""18163427-2-45-60"">prostate cancer</span>.";18163427;2008
6757;SSX2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Inducible expression of a <span class=""disease"" id=""17929270-0-26-41"">prostate cancer</span>-testis antigen, <span class=""gene"" id=""17929270-0-58-63"">SSX-2</span>, following treatment with a DNA methylation inhibitor.";17929270;2008
4322;MMP13;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Regulation of <span class=""gene"" id=""15138554-0-14-41"">matrix metalloproteinase 13</span> expression by androgen in <span class=""disease"" id=""15138554-0-68-83"">prostate cancer</span>.";15138554;2004
23600;AMACR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Mutated human <span class=""gene"" id=""8530589-0-14-31"">androgen receptor</span> gene detected in a <span class=""disease"" id=""8530589-0-51-67"">prostatic cancer</span> patient is also activated by estradiol.";8530589;1996
7040;TGFB1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We observed an association between single nucleotide polymorphisms of <span class=""gene"" id=""18082198-14-70-75"">TGFB1</span> at C-509T and a decreased risk of aggressive <span class=""disease"" id=""18082198-14-121-136"">prostate cancer</span>.";18082198;2008
6757;SSX2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"In addition, we report that the treatment of at least two human <span class=""disease"" id=""17929270-8-64-79"">prostate cancer</span> cell lines with the DNA methylation inhibitor 5-aza-2'-deoxycytidine induced the expression of <span class=""gene"" id=""17929270-8-175-180"">SSX-2</span>.";17929270;2008
2192;FBLN1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Three <span class=""gene"" id=""17929269-14-6-10"">FBLN</span> genes are significantly downregulated in <span class=""disease"" id=""17929269-14-52-67"">prostate cancer</span>, whereas SPOCK1 is often upregulated.";17929269;2008
857;CAV1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""22159333-0-0-10"">Caveolin-1</span> as a potential high-risk <span class=""disease"" id=""22159333-0-36-51"">prostate cancer</span> biomarker.";22159333;2012
55870;ASH1L;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
2065;ERBB3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These findings suggest that the bone microenvironment and androgen status influence the subcellular localization of <span class=""gene"" id=""17634423-8-116-122"">ErbB-3</span> in <span class=""disease"" id=""17634423-8-126-141"">prostate cancer</span> cells.";17634423;2007
1588;CYP19A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We also tested a multigenic model of <span class=""disease"" id=""16424004-6-37-52"">prostate cancer</span> risk by calculating the joint effect of <span class=""gene"" id=""16424004-6-93-100"">CYP19A1</span> T201M with five other common SNPs.";16424004;2006
23197;FAF2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
7372;UMPS;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.;15999119;2005
4318;MMP9;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We demonstrate that treatment of human <span class=""disease"" id=""16606632-9-39-54"">prostate cancer</span> cell lines with zinc reduces expression of VEGF, IL-6, IL-8 and <span class=""gene"" id=""16606632-9-119-124"">MMP-9</span>.";16606632;2006
1962;EHHADH;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
3558;IL2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"This study suggests that the <span class=""gene"" id=""17115417-9-29-33"">IL-2</span> gene may be associated with susceptibility to <span class=""disease"" id=""17115417-9-80-95"">prostate cancer</span> in the Taiwan population.";17115417;2007
5444;PON1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Polymorphisms of three xenobiotic genes (CYP17, GSTP1, <span class=""gene"" id=""15538743-3-55-59"">PON1</span>) were characterized in 384 patients with untreated <span class=""disease"" id=""15538743-3-111-114"">PCa</span> and 360 age-matched control patients with benign prostatic hyperplasia (BPH).";15538743;2005
55198;APPL2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Thus, this new cell line with partial androgen responsiveness and PSA expression can serve as a functionally relevant model system of bone metastatic prostate cancer, and can be used to investigate the role of <span class=""gene"" id=""10569618-11-210-212"">AR</span> mutations in <span class=""disease"" id=""10569618-11-226-241"">prostate cancer</span> and its progression to androgen independence.";10569618;2000
1562;CYP2C18;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
3248;HPGD;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results demonstrate that osteoblasts promote <span class=""disease"" id=""15672864-12-51-54"">CaP</span> growth through <span class=""gene"" id=""15672864-12-70-74"">IL-6</span>-mediated activation of the AR.";15672864;2005
811;CALR;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
84181;CHD6;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
3913;LAMB2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4683;NBN;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"<span class=""gene"" id=""14973119-0-0-4"">NBS1</span> is a <span class=""disease"" id=""14973119-0-10-25"">prostate cancer</span> susceptibility gene.";14973119;2004
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"The growth of <span class=""disease"" id=""8827083-1-14-29"">prostate cancer</span> is androgen responsive, and <span class=""gene"" id=""8827083-1-58-75"">androgen receptor</span> (<span class=""gene"" id=""8827083-1-77-79"">AR</span>) is thought to play an important role in the development of this cancer.";8827083;1996
5296;PIK3R2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In Caucasians, the HSD3B2 (TG)n,(TA)n,(CA)n intron 3 length polymorphism is associated with both <span class=""disease"" id=""17823934-9-97-112"">prostate cancer</span> risk and aggressiveness and the <span class=""gene"" id=""17823934-9-145-151"">SRD5A2</span> V89L polymorphism may modify the risk conferred by this polymorphism.";17823934;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"This bicalutamide-responsive mutant <span class=""gene"" id=""16266977-10-36-38"">AR</span> will serve in the development of new therapies for androgen ablation-resistant <span class=""disease"" id=""16266977-10-118-134"">prostate cancers</span>.";16266977;2005
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.;15302576;2004
5290;PIK3CA;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1728;NQO1;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Our results provide suggestive findings for an association with either familial or sporadic <span class=""disease"" id=""17507624-8-92-107"">prostate cancer</span> with polymorphisms in four genes: AKR1C3, HSD17B1, <span class=""gene"" id=""17507624-8-159-163"">NQO1</span>, and GSTT1.";17507624;2007
675;BRCA2;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
467;ATF3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"These data provide new insight into the role of <span class=""gene"" id=""16516039-10-48-52"">ATF3</span> in <span class=""disease"" id=""16516039-10-56-71"">prostate cancer</span> development and/or progression.";16516039;2006
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We tested the association between a functional C748T polymorphism of the <span class=""gene"" id=""15643194-2-73-77"">KLK2</span> gene and the occurrence of <span class=""disease"" id=""15643194-2-105-108"">PCa</span>.";15643194;2005
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Human <span class=""gene"" id=""15643194-0-6-18"">kallikrein-2</span> gene polymorphism is associated with the occurrence of <span class=""disease"" id=""15643194-0-74-89"">prostate cancer</span>.";15643194;2005
467;ATF3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Forced <span class=""gene"" id=""16516039-9-7-11"">ATF3</span> over expression in a <span class=""disease"" id=""16516039-9-33-48"">prostate cancer</span> cell line induced cell proliferation and accelerated cell cycle progression from G1 to S-phase.";16516039;2006
5591;PRKDC;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.;25415046;2015
53916;RAB4B;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
56849;TCEAL7;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
1576;CYP3A4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These observations prompted the hypothesis that variant <span class=""gene"" id=""15496535-6-56-62"">CYP3A4</span> may be involved in breast and <span class=""disease"" id=""15496535-6-93-108"">prostate cancer</span>.";15496535;2004
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"It is possible that analogous to an activated/altered growth factor receptor oncogene, codon 877 mutant <span class=""gene"" id=""8187068-4-104-106"">AR</span> with altered ligand binding may provide a selective growth advantage in the genesis of a subset of advanced <span class=""disease"" id=""8187068-4-215-230"">prostate cancer</span>.";8187068;1994
4233;MET;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
7001;PRDX2;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
1950;EGF;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Epidermal growth factor promotes invasiveness of pancreatic cancer cells through NF-kappaB-mediated proteinase productions.;16340751;2006
5744;PTHLH;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results indicate that <span class=""gene"" id=""16243370-11-28-33"">PTHrP</span> gene expression is regulated by 1,25(OH)2D3 in a cell type-specific manner in <span class=""disease"" id=""16243370-11-112-127"">prostate cancer</span> cells.";16243370;2006
1786;DNMT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.;22581815;2012
23635;SSBP2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"We further examined <span class=""gene"" id=""18559593-4-20-25"">SSBP2</span> expression in primary <span class=""disease"" id=""18559593-4-48-63"">prostate cancer</span> and studied its role in cell growth.";18559593;2008
4824;NKX3-1;C0376358;Malignant neoplasm of prostate;0,54;Biomarker;CTD_human;p53 overexpression represses androgen-mediated induction of NKX3.1 in a prostate cancer cell line.;17202838;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"<span class=""gene"" id=""25908785-1-0-17"">Androgen receptor</span> (<span class=""gene"" id=""25908785-1-19-21"">AR</span>) variants (<span class=""gene"" id=""25908785-1-33-35"">AR</span>-Vs) expressed in <span class=""disease"" id=""25908785-1-53-68"">prostate cancer</span> (<span class=""disease"" id=""25908785-1-70-73"">PCa</span>) lack the <span class=""gene"" id=""25908785-1-84-86"">AR</span> ligand binding domain (LBD) and function as constitutively active transcription factors.";25908785;2015
8202;NCOA3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Expanded studies in other populations are needed to confirm this association and the combined effect of <span class=""gene"" id=""11927493-10-104-108"">AIB1</span>/<span class=""gene"" id=""11927493-10-109-114"">SRC-3</span> and other hormone-related genes in <span class=""disease"" id=""11927493-10-150-165"">prostate cancer</span> etiology.";11927493;2002
2146;EZH2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells.;17003774;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Osteoblasts induce <span class=""disease"" id=""15672864-0-19-34"">prostate cancer</span> proliferation and PSA expression through <span class=""gene"" id=""15672864-0-76-89"">interleukin-6</span>-mediated activation of the androgen receptor.";15672864;2005
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"Germline mutations in <span class=""gene"" id=""22236224-0-22-28"">HOXB13</span> and <span class=""disease"" id=""22236224-0-33-48"">prostate-cancer</span> risk.";22236224;2012
406991;MIR21;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Short interfering (si) RNA against PDCD4 attenuated resveratrol's effect on <span class=""disease"" id=""23272133-8-76-91"">prostate cancer</span> cells, and similar effects were observed following over expression of <span class=""gene"" id=""23272133-8-162-168"">miR-21</span> with pre-<span class=""gene"" id=""23272133-8-178-184"">miR-21</span> oligonucleotides.";23272133;2013
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"These results reveal a potentially critical function of <span class=""gene"" id=""16877366-8-56-58"">AR</span> in androgen-independent <span class=""disease"" id=""16877366-8-83-86"">PCa</span> that is distinct from its previously described transcriptional or nontranscriptional functions.";16877366;2006
9869;SETDB1;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1789;DNMT3B;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"These findings suggest that the <span class=""gene"" id=""16012746-11-32-38"">DNMT3b</span> polymorphisms may be associated with an increase in promoter methylation of tumor-suppressor genes related to the development of <span class=""disease"" id=""16012746-11-168-183"">prostate cancer</span>, and may thereby increase the risk of this disease.";16012746;2005
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"These results suggest that the Ala variant of <span class=""gene"" id=""17646272-9-46-50"">SOD2</span> is associated with moderately increased risk of <span class=""disease"" id=""17646272-9-99-114"">prostate cancer</span>, particularly among men with lower intakes of dietary and supplemental vitamin E.";17646272;2007
7157;TP53;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"These findings suggest that <span class=""gene"" id=""20875869-6-28-32"">TP53</span> and MDM2 polymorphisms play a role in <span class=""disease"" id=""20875869-6-71-74"">PCa</span> susceptibility in southern Chinese Han population.";20875869;2010
7099;TLR4;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To further investigate the role of <span class=""gene"" id=""17301271-3-35-39"">TLR4</span> in <span class=""disease"" id=""17301271-3-43-58"">prostate cancer</span> susceptibility, we identified six tagging single-nucleotide polymorphisms that comprehensively captured the common genetic variation of the locus and tested these polymorphisms in our case-control study of 1,012 men.";17301271;2007
7111;TMOD1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
2068;ERCC2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Our findings suggest that the heterozygous and homozygous A allele of the <span class=""gene"" id=""17695467-8-74-77"">XPD</span> codon 312 may be associated with the development of <span class=""disease"" id=""17695467-8-130-145"">prostate cancer</span> and may be a useful marker for primary prevention and anticancer intervention.";17695467;2007
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"In this study, we analyzed <span class=""gene"" id=""12533788-3-27-32"">CHEK2</span>, the upstream regulator of p53 in the DNA-damage-signaling pathway, in several groups of patients with <span class=""disease"" id=""12533788-3-136-151"">prostate cancer</span>.";12533788;2003
3572;IL6ST;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
406991;MIR21;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Similar anti-tumor effects of resveratrol were observed in DU145 and LNCaP <span class=""disease"" id=""23272133-14-75-90"">prostate cancer</span> cells which were associated with suppression of Akt and PDCD4, but independent of <span class=""gene"" id=""23272133-14-173-179"">miR-21</span>.These data suggest that resveratrol's anti-tumor actions in <span class=""disease"" id=""23272133-14-240-255"">prostate cancer</span> could be explained, in part, through inhibition of Akt/miR-21 signaling pathway.";23272133;2013
51132;RLIM;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
11176;BAZ2A;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Here we show that the gene encoding <span class=""gene"" id=""25485837-3-36-41"">BAZ2A</span> (<span class=""gene"" id=""25485837-3-43-47"">TIP5</span>), a factor previously implicated in epigenetic rRNA gene silencing, is overexpressed in <span class=""disease"" id=""25485837-3-136-151"">prostate cancer</span> and is paradoxically involved in maintaining <span class=""disease"" id=""25485837-3-197-212"">prostate cancer</span> cell growth, a feature specific to cancer cells.";25485837;2015
56924;PAK6;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"<span class=""gene"" id=""18642328-5-0-4"">PAK6</span> expression in LNCaP <span class=""disease"" id=""18642328-5-25-28"">PCa</span> cells was not directly androgen regulated, but was markedly increased when the cells were cultured for 6-8 weeks in steroid hormone depleted medium.";18642328;2008
59344;ALOXE3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
1026;CDKN1A;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;p53 Codon 72 and p21 codon 31 polymorphisms in prostate cancer.;15598783;2005
2100;ESR2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We identify two independent susceptibility loci for <span class=""disease"" id=""26443449-4-52-67"">prostate cancer</span> at 11p15.4 (rs12791447, P=3.59 × 10(-8); PPFIBP2) and 14q23.2 (rs58262369, P=6.05 × 10(-10); <span class=""gene"" id=""26443449-4-161-165"">ESR2</span>).";26443449;2016
7994;KAT6A;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
3293;HSD17B3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Therefore, the <span class=""gene"" id=""12210481-7-15-22"">HSD17B3</span> gene may be a plausible candidate gene for <span class=""disease"" id=""12210481-7-66-81"">prostate cancer</span> risk.";12210481;2002
6387;CXCL12;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""17785557-0-0-6"">CXCL12</span> G801A polymorphism is a risk factor for sporadic <span class=""disease"" id=""17785557-0-56-71"">prostate cancer</span> susceptibility.";17785557;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"To further investigate structural abnormality of the <span class=""gene"" id=""8827083-4-53-55"">AR</span> in a large number of human <span class=""disease"" id=""8827083-4-83-99"">prostate cancers</span>, exons B-H encoding DNA-and hormone-binding domains were examined by single-strand conformation polymorphism analysis of polymerase chain reaction products and direct sequencing.";8827083;1996
1545;CYP1B1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Stratification by age at onset showed that the associations of <span class=""gene"" id=""17704407-7-63-69"">CYP1B1</span> and CYP19 variants were largely confined to the younger <span class=""disease"" id=""17704407-7-126-141"">prostate cancer</span> patients.";17704407;2007
10551;AGR2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In our study, we investigated the potential association between <span class=""gene"" id=""27318894-2-64-68"">KLK3</span>, AR, RNASEL, MSR1, and ELAC2 polymorphisms, expression patterns, exposure to environmental factors, and <span class=""disease"" id=""27318894-2-173-176"">PCa</span> in a Spanish cohort.";27318894;2016
7430;EZR;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
23600;AMACR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"For single polymorphisms, the presence of Y alleles showed a significantly lower risk of <span class=""disease"" id=""16859836-5-89-104"">prostate cancer</span> in comparison with the D/D genotype in UGT2B15 (odds ratio [OR]=0.41, 95% confidence interval [CI]=1.40-4.28, p=0.0015), and the presence of A2 alleles showed a weak tendency to decrease <span class=""disease"" id=""16859836-5-292-307"">prostate cancer</span> risk in comparison with the A1/A1 genotype in <span class=""gene"" id=""16859836-5-354-359"">CYP17</span> (OR=0.69, 95% CI=0.39-1.23, p=0.21).";16859836;2007
27173;SLC39A1;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots.";16700911;2006
1577;CYP3A5;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"For <span class=""disease"" id=""18306354-10-4-19"">prostate cancer</span> patients aged below 65 years, the OR for interaction of <span class=""gene"" id=""18306354-10-76-82"">CYP3A5</span>*1/*3 or *1/*1 and AKR1C3 Q5H CC genotypes was 1.84 with 95% CI 1.03-3.28.";18306354;2008
64816;CYP3A43;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Our results suggest that the <span class=""gene"" id=""15894682-9-29-36"">CYP3A43</span>-Pro(340)Ala polymorphism contributes to <span class=""disease"" id=""15894682-9-77-92"">prostate cancer</span> risk.";15894682;2005
4846;NOS3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The <span class=""gene"" id=""16458450-1-4-37"">endothelial nitric oxide synthase</span> (<span class=""gene"" id=""16458450-1-39-44"">ecNOS</span>) has an important role in vascular development and in the carcinogenesis process of <span class=""disease"" id=""16458450-1-129-144"">prostate cancer</span> (<span class=""disease"" id=""16458450-1-146-149"">PCa</span>).";16458450;2006
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"It appears contradictory that instead of limiting expression of pro-apoptotic protein, <span class=""disease"" id=""19593445-4-87-102"">prostate cancer</span> cells choose to increase <span class=""gene"" id=""19593445-4-128-131"">BAD</span> levels while keeping it under tight phosphorylation control.";19593445;2009
3283;HSD3B1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"In a case-control study of 356 patients with incident primary <span class=""disease"" id=""17826523-4-62-77"">prostate cancer</span> and 363 age-matched controls, the frequencies of <span class=""gene"" id=""17826523-4-127-133"">HSD3B1</span> N367T and UGT2B17 null polymorphisms in genomic DNA were compared between the patients and controls.";17826523;2007
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;Dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced prostate carcinogenesis in CYP1A-humanized mice.;22581815;2012
23411;SIRT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"Here, we challenged our hypothesis that melatonin will impart antiproliferative response against <span class=""disease"" id=""21062352-5-97-100"">PCa</span> via inhibiting <span class=""gene"" id=""21062352-5-116-121"">Sirt1</span>.";21062352;2011
672;BRCA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In a study of 817 men with and without <span class=""disease"" id=""17585057-3-39-54"">prostate cancer</span> from 323 familial and early-onset <span class=""disease"" id=""17585057-3-89-104"">prostate cancer</span> families, we used family-based association tests and conditional logistic regression to investigate the association between <span class=""disease"" id=""17585057-3-229-244"">prostate cancer</span> and single nucleotide polymorphisms (SNPs) tagging common haplotype variation in a 200-kb region surrounding (and including) the <span class=""gene"" id=""17585057-3-374-379"">BRCA1</span> gene.";17585057;2007
4322;MMP13;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Using cDNA microarray as a screening tool to find androgen regulated gene in <span class=""disease"" id=""15138554-4-77-92"">prostate cancer</span>, we have found that expression of <span class=""gene"" id=""15138554-4-127-133"">MMP-13</span> is regulated by androgen in <span class=""disease"" id=""15138554-4-162-177"">prostate cancer</span> derived cell line LNCaP.";15138554;2004
1958;EGR1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Enhanced <span class=""gene"" id=""16552752-0-9-13"">EGR1</span> activity promotes the growth of <span class=""disease"" id=""16552752-0-46-61"">prostate cancer</span> cells in an androgen-depleted environment.";16552752;2006
6716;SRD5A2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Stratified analyses revealed that most of the <span class=""disease"" id=""17823934-8-46-61"">prostate cancer</span> risk associated with the intron 3 HSD3B2 short allele was confined to the <span class=""gene"" id=""17823934-8-136-142"">SRD5A2</span> 89L variant subgroup and indicated that in combination these polymorphisms may be associated with increased risk of aggressive (Gleason &gt;7) disease (Gleason &gt;7).";17823934;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"These results indicate that <span class=""gene"" id=""8827083-11-28-30"">AR</span> gene mutation scarcely occurs in the early stage of <span class=""disease"" id=""8827083-11-83-98"">prostate cancer</span> and that the mutation is found in relation to endocrine therapy resistance.";8827083;1996
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"At present, the management of non-organ confined <span class=""disease"" id=""15790600-1-49-64"">prostate cancer</span>, whether it is a recurrence or metastasis, continues to evolve based on <span class=""disease"" id=""15790600-1-137-152"">prostate cancer</span> detection using <span class=""gene"" id=""15790600-1-169-194"">prostate-specific antigen</span> and the development of medications as alternatives for the classical orchiectomy, which induced irreversible implications for quality of life.";15790600;2005
246778;IL27;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"<span class=""gene"" id=""24028178-2-0-5"">IL-27</span> is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including <span class=""disease"" id=""24028178-2-216-231"">prostate cancer</span>.";24028178;2014
10;NAT2;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"The data suggests that the <span class=""gene"" id=""16083506-8-27-31"">NAT2</span> rapid acetylator genotypes may play an important role in determining the risk of developing <span class=""disease"" id=""16083506-8-124-139"">prostate cancer</span> particularly in the tobacco users of north Indian population.";16083506;2006
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Chromosomal translocations involving the <span class=""gene"" id=""19396168-1-41-44"">ERG</span> locus are frequent events in human <span class=""disease"" id=""19396168-1-80-95"">prostate cancer</span> pathogenesis; however, the biological role of aberrant <span class=""gene"" id=""19396168-1-151-154"">ERG</span> expression is controversial.";19396168;2009
406991;MIR21;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Using microarray studies, we show that resveratrol reduced the expression of various prostate-tumor associated microRNAs (miRs) including <span class=""gene"" id=""23272133-5-138-144"">miR-21</span> in androgen-receptor negative and highly aggressive human <span class=""disease"" id=""23272133-5-203-218"">prostate cancer</span> cells, PC-3M-MM2.";23272133;2013
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Codon 877 mutation in the <span class=""gene"" id=""8827083-0-26-43"">androgen receptor</span> gene in advanced <span class=""disease"" id=""8827083-0-61-76"">prostate cancer</span>: relation to antiandrogen withdrawal syndrome.";8827083;1996
5859;QARS;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
581;BAX;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;Bad expression influences time to androgen escape in prostate cancer.;17542986;2007
56924;PAK6;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"These results indicate that <span class=""gene"" id=""18642328-9-28-32"">PAK6</span> contributes to <span class=""disease"" id=""18642328-9-48-51"">PCa</span> development and progression after androgen deprivation therapy, and that it may play roles in the regulation of motility and in stress responses.";18642328;2008
463;ZFHX3;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"In addition to more unique mutations, two somatic mutations (shortening of a polypyrimidine tract [Poly(T)n] and a deletion beginning at codon 3381 (3381del)) were each observed in multiple <span class=""disease"" id=""16637072-2-190-205"">prostate cancer</span> samples and both appear to have an impact on <span class=""gene"" id=""16637072-2-251-256"">ATBF1</span> gene function and expression.";16637072;2006
84818;IL17RC;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"<span class=""gene"" id=""17603628-1-0-7"">IL-17RC</span> (interleukin-17 receptor-like) gene codes for a transmembrane protein, the full length of which inhibits apoptosis in <span class=""disease"" id=""17603628-1-126-141"">prostate cancer</span> cells.";17603628;2007
210;ALAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Additional studies of <span class=""gene"" id=""24500903-9-22-26"">ALAD</span>, Pb, and <span class=""disease"" id=""24500903-9-36-51"">prostate cancer</span> are warranted and should include black men.Prostate 74:637-646, 2014.© 2014 Wiley Periodicals, Inc.";24500903;2014
7048;TGFBR2;C0376358;Malignant neoplasm of prostate;0,58;Biomarker;CTD_human;"In humans, marked down-regulation of <span class=""gene"" id=""18381416-5-37-43"">TGFBR2</span> protein was observed in 12 of 20 high-grade prostatic intraepithelial neoplasia and 36 of 60 <span class=""disease"" id=""18381416-5-137-153"">prostate cancers</span>.";18381416;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Interleukin-6 stimulation of growth of <span class=""disease"" id=""19011039-0-39-54"">prostate cancer</span> in vitro and in vivo through activation of the <span class=""gene"" id=""19011039-0-102-119"">androgen receptor</span>.";19011039;2009
8854;ALDH1A2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"The retinoic acid synthesis gene <span class=""gene"" id=""16166285-0-33-40"">ALDH1a2</span> is a candidate tumor suppressor in <span class=""disease"" id=""16166285-0-76-91"">prostate cancer</span>.";16166285;2005
4023;LPL;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Three single nucleotide polymorphisms (SNPs) of <span class=""gene"" id=""15386377-3-48-51"">LPL</span> designated as Ser447stop, HindIII and PvuII were genotyped by the polymerase chain reaction-restriction fragment length polymorphism method in 273 <span class=""disease"" id=""15386377-3-199-214"">prostate cancer</span> patients, 205 benign prostatic hyperplasia (BPH) patients and 230 male controls.";15386377;2004
672;BRCA1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Thus, we have identified a common, nonsynonymous substitution in the <span class=""gene"" id=""17585057-9-69-74"">BRCA1</span> gene that is associated with and linked to <span class=""disease"" id=""17585057-9-118-133"">prostate cancer</span>.";17585057;2007
2950;GSTP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Polymorphisms of three xenobiotic genes (CYP17, <span class=""gene"" id=""15538743-3-48-53"">GSTP1</span>, PON1) were characterized in 384 patients with untreated <span class=""disease"" id=""15538743-3-111-114"">PCa</span> and 360 age-matched control patients with benign prostatic hyperplasia (BPH).";15538743;2005
4968;OGG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Associations between <span class=""gene"" id=""11956079-0-21-26"">hOGG1</span> sequence variants and <span class=""disease"" id=""11956079-0-49-64"">prostate cancer</span> susceptibility.";11956079;2002
389058;SP5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"These results indicate that a codon 877 mutation in the <span class=""gene"" id=""8827083-14-56-58"">AR</span> gene in advanced <span class=""disease"" id=""8827083-14-76-91"">prostate cancer</span> evokes the antiandrogen withdrawal syndrome.";8827083;1996
1605;DAG1;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
463;ZFHX3;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Germline <span class=""gene"" id=""16637072-0-9-14"">ATBF1</span> mutations and <span class=""disease"" id=""16637072-0-29-44"">prostate cancer</span> risk.";16637072;2006
22853;LMTK2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Multiple newly identified loci associated with prostate cancer susceptibility.;18264097;2008
655;BMP7;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
7704;ZBTB16;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
472;ATM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.;25415046;2015
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"A <span class=""disease"" id=""24390282-0-2-17"">prostate cancer</span> susceptibility allele at 6q22 increases RFX6 expression by modulating <span class=""gene"" id=""24390282-0-88-94"">HOXB13</span> chromatin binding.";24390282;2014
8895;CPNE3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Multiple loci identified in a genome-wide association study of prostate cancer.;18264096;2008
8644;AKR1C3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"For <span class=""disease"" id=""18306354-10-4-19"">prostate cancer</span> patients aged below 65 years, the OR for interaction of CYP3A5*1/*3 or *1/*1 and <span class=""gene"" id=""18306354-10-101-107"">AKR1C3</span> Q5H CC genotypes was 1.84 with 95% CI 1.03-3.28.";18306354;2008
5465;PPARA;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;The Interaction between Pesticide Use and Genetic Variants Involved in Lipid Metabolism on Prostate Cancer Risk.;22919386;2012
5293;PIK3CD;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""19011039-0-0-13"">Interleukin-6</span> stimulation of growth of <span class=""disease"" id=""19011039-0-39-54"">prostate cancer</span> in vitro and in vivo through activation of the androgen receptor.";19011039;2009
79574;EPS8L3;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"The SNP rs11102001, which encodes a nonsynonymous amino acid change P356S in <span class=""gene"" id=""19223546-7-77-83"">EPS8L3</span>, is a potential candidate modifier of the effect of HCAs on <span class=""disease"" id=""19223546-7-144-159"">prostate cancer</span> risk.";19223546;2009
678;ZFP36L2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
1789;DNMT3B;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"The <span class=""gene"" id=""16012746-7-4-10"">DNMT3b</span> polymorphism frequencies in the <span class=""disease"" id=""16012746-7-43-58"">prostate cancer</span> and BPH specimens were, respectively, 20 and 26% for CC, 42 and 52% for CT, and 38 and 21% for TT.";16012746;2005
23753;SDF2L1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We hypothesized that osteoblast-derived <span class=""gene"" id=""15672864-3-40-44"">IL-6</span> in the bone microenvironment contributes to the fertile soil for <span class=""disease"" id=""15672864-3-110-113"">CaP</span> growth.";15672864;2005
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"Furthermore, resveratrol, a phytoalexin enriched in red grapes, strawberries and peanuts, has been shown to inhibit <span class=""gene"" id=""20729295-6-116-118"">AR</span> transcriptional activity in <span class=""disease"" id=""20729295-6-147-162"">prostate cancer</span> cells.";20729295;2011
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"To identify common alleles associated with <span class=""disease"" id=""18264097-3-43-58"">prostate cancer</span> risk, we conducted a genome-wide association study (GWAS) using blood DNA samples from 1,854 individuals with clinically detected <span class=""disease"" id=""18264097-3-189-204"">prostate cancer</span> diagnosed at &lt;/=60 years or with a family history of disease, and 1,894 population-screened controls with a low <span class=""gene"" id=""18264097-3-317-342"">prostate-specific antigen</span> (<span class=""gene"" id=""18264097-3-344-347"">PSA</span>) concentration (&lt;0.5 ng/ml).";18264097;2008
51322;WAC;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We validated ZBTB20, CELF2, PARD3, AKAP13 and <span class=""gene"" id=""28319090-5-46-49"">WAC</span>, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in <span class=""disease"" id=""28319090-5-147-162"">prostate cancer</span>.";28319090;2017
8754;ADAM9;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We uncovered an <span class=""gene"" id=""17018608-6-16-21"">ADAM9</span>-like protein, which is predominantly induced together with the <span class=""gene"" id=""17018608-6-85-90"">ADAM9</span> protein by a brief exposure of <span class=""disease"" id=""17018608-6-122-137"">prostate cancer</span> cells to hydrogen peroxide.";17018608;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"We show that resveratrol inhibits <span class=""gene"" id=""20729295-8-34-36"">AR</span> transcriptional activity in both androgen-dependent and -independent <span class=""disease"" id=""20729295-8-106-121"">prostate cancer</span> cells.";20729295;2011
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Niclosamide suppresses cell migration and invasion in enzalutamide resistant <span class=""disease"" id=""25970160-0-77-92"">prostate cancer</span> cells via <span class=""gene"" id=""25970160-0-103-108"">Stat3</span>-AR axis inhibition.";25970160;2015
3249;HPN;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Variants in the <span class=""gene"" id=""16783571-0-16-22"">HEPSIN</span> gene are associated with <span class=""disease"" id=""16783571-0-48-63"">prostate cancer</span> in men of European origin.";16783571;2007
467;ATF3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Immunohistochemistry and immunoblot analysis revealed <span class=""gene"" id=""16516039-6-54-58"">ATF3</span> up-regulation in <span class=""disease"" id=""16516039-6-76-91"">prostate cancer</span> in vitro and in vivo, and stimulation of expression by androgens.";16516039;2006
54361;WNT4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Here, we performed integrated in vivo and in vitro protocols that analyzed the association between Ala16Val-<span class=""gene"" id=""26468117-3-108-112"">SOD2</span> polymorphism and prostate cancer aggressiveness at the time of diagnosis and evaluated the effect of the imbalance on <span class=""disease"" id=""26468117-3-231-233"">PC</span> proliferation using the DU-145 <span class=""disease"" id=""26468117-3-265-267"">PC</span> cell line treated with paraquat and porphyrin.";26468117;2016
5290;PIK3CA;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
3603;IL16;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Multiple loci identified in a genome-wide association study of prostate cancer.;18264096;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"We confirmed that <span class=""gene"" id=""23704919-8-18-20"">AR</span> directly regulates c-Myc transcription in a ligand-independent manner, that <span class=""gene"" id=""23704919-8-97-99"">AR</span> and c-Myc suppression reduces ligand-independent <span class=""disease"" id=""23704919-8-149-164"">prostate cancer</span> cell growth, and that ectopic expression of c-Myc attenuates the anti-growth effects of <span class=""gene"" id=""23704919-8-253-255"">AR</span> suppression.";23704919;2013
5328;PLAU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Matrigel invasion assay showed that <span class=""disease"" id=""11454671-8-36-51"">prostate cancer</span> cell line PC-3, containing amplification of the <span class=""gene"" id=""11454671-8-100-103"">uPA</span> gene, was more sensitive to the urokinase inhibitor, amiloride, than DU145 or LNCaP cell lines, which do not have the amplification.";11454671;2001
246778;IL27;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"We have examined the role of a novel cytokine, <span class=""gene"" id=""24028178-1-47-61"">interleukin-27</span> (<span class=""gene"" id=""24028178-1-63-68"">IL-27</span>), in mediating interactions between <span class=""disease"" id=""24028178-1-105-120"">prostate cancer</span> and bone.";24028178;2014
7040;TGFB1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Because of the potential role of <span class=""gene"" id=""15159307-5-33-38"">TGFB1</span> variants in <span class=""disease"" id=""15159307-5-51-66"">prostate cancer</span> and progression, we hypothesized that these two <span class=""gene"" id=""15159307-5-115-120"">TGFB1</span> variants would be associated with <span class=""disease"" id=""15159307-5-155-170"">prostate cancer</span> risk, particularly later, more aggressive stage tumors.";15159307;2004
1365;CLDN3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6757;SSX2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"We identified IgG specific for NY-ESO-1, LAGE-1, NFX-2, and <span class=""gene"" id=""17929270-6-60-65"">SSX-2</span> in at least 1/98 individuals with <span class=""disease"" id=""17929270-6-100-115"">prostate cancer</span>.";17929270;2008
5595;MAPK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.;24763052;2015
3606;IL18;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"To test this hypothesis, we investigated the relationship of <span class=""gene"" id=""17688413-4-61-66"">IL-18</span> gene promoter -137 G/C and -607 C/A polymorphisms and their haplotypes with the risk of <span class=""disease"" id=""17688413-4-155-170"">prostate cancer</span>.";17688413;2007
3283;HSD3B1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"These results suggest that the <span class=""gene"" id=""17826523-9-31-37"">HSD3B1</span> N367T and UGT2B17 null polymorphisms may modify the risk of <span class=""disease"" id=""17826523-9-98-113"">prostate cancer</span>, particularly among men with a family history of the disease.";17826523;2007
5160;PDHA1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"Here, we found that genetic and pharmacological inactivation of pyruvate dehydrogenase A1 (<span class=""gene"" id=""29335542-2-91-96"">PDHA1</span>), a subunit of the pyruvate dehydrogenase complex (PDC), inhibits <span class=""disease"" id=""29335542-2-163-178"">prostate cancer</span> development in mouse and human xenograft tumor models by affecting lipid biosynthesis.";29335542;2018
55636;CHD7;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6041;RNASEL;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;"Studies revealing conflicting results on the role of <span class=""gene"" id=""17020975-1-53-59"">RNASEL</span> polymorphisms Glu265X, Arg462Gln, and Asp541Glu on <span class=""disease"" id=""17020975-1-111-126"">prostate cancer</span> risk led us to perform a meta-analysis to investigate the association of these polymorphisms and <span class=""disease"" id=""17020975-1-224-239"">prostate cancer</span> risk.";17020975;2006
2878;GPX3;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Overexpression of <span class=""gene"" id=""17804715-6-18-22"">GPx3</span> in <span class=""disease"" id=""17804715-6-26-41"">prostate cancer</span> cell lines induced the suppression of colony formation and anchorage-independent growth of PC3, LNCaP, and Du145 cells.";17804715;2007
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Collective evidence suggests that <span class=""gene"" id=""17609663-1-34-50"">cyclooxygenase 2</span> (<span class=""gene"" id=""17609663-1-52-56"">COX2</span>) plays a role in <span class=""disease"" id=""17609663-1-74-89"">prostate cancer</span> risk.";17609663;2007
2947;GSTM3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"We analyzed DNA samples from 335 (670 alleles) unrelated individuals, 185 community control subjects, and 150 <span class=""disease"" id=""14968442-3-110-125"">prostate cancer</span> (<span class=""disease"" id=""14968442-3-127-129"">PC</span>) patients, for GSTM1, <span class=""gene"" id=""14968442-3-152-157"">GSTM3</span>, and GSTT1 genotypes using polymerase chain reaction (PCR).";14968442;2004
3047;HBG1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Treatment with the bromodomain and extraterminal (BET) inhibitor JQ1 resulted in inhibition of <span class=""gene"" id=""25908785-6-95-97"">AR</span>-V chromatin binding and impaired <span class=""gene"" id=""25908785-6-131-133"">AR</span>-V driven <span class=""disease"" id=""25908785-6-143-146"">PCa</span> cell growth in vitro and in vivo.";25908785;2015
4925;NUCB2;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"Frequent inactivation of <span class=""gene"" id=""9371490-0-25-29"">PTEN</span>/<span class=""gene"" id=""9371490-0-30-35"">MMAC1</span> in primary <span class=""disease"" id=""9371490-0-47-62"">prostate cancer</span>.";9371490;1997
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Association between gene polymorphism of manganese superoxide dismutase and prostate cancer risk.;23315858;2013
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Thus, <span class=""gene"" id=""19396168-7-6-9"">ERG</span> has a distinct role in <span class=""disease"" id=""19396168-7-33-48"">prostate cancer</span> progression and cooperates with PTEN haploinsufficiency to promote progression of HGPIN to invasive adenocarcinoma.";19396168;2009
9189;ZBED1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
4804;NGFR;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of <span class=""gene"" id=""18056468-0-85-92"">p75 NTR</span> in <span class=""disease"" id=""18056468-0-96-111"">prostate cancer</span> cells.";18056468;2008
9817;KEAP1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"p38MAPK activation is involved in androgen-independent proliferation of human <span class=""disease"" id=""17196171-0-78-93"">prostate cancer</span> cells by regulating <span class=""gene"" id=""17196171-0-114-118"">IL-6</span> secretion.";17196171;2007
8785;MATN4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"For example, a recent study suggested that one cannot adequately impute the <span class=""gene"" id=""25629170-3-76-82"">HOXB13</span> G84E mutation associated with <span class=""disease"" id=""25629170-3-113-128"">prostate cancer</span> risk (carrier frequency of 0.0034 in European ancestry participants in the 1000 Genomes Project).";25629170;2015
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis.;26457646;2016
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Since <span class=""disease"" id=""17196171-3-6-21"">prostate cancer</span> gradually progresses to an androgen-independent state despite the stress caused by various therapeutic agents, we hypothesized the stress-activated protein kinases (SAPKs) involvement in androgen-independent growth or <span class=""gene"" id=""17196171-3-240-244"">IL-6</span> secretion of <span class=""disease"" id=""17196171-3-258-273"">prostate cancer</span> cells.";17196171;2007
8405;SPOP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""disease"" id=""22610119-8-0-16"">Prostate cancers</span> with mutant <span class=""gene"" id=""22610119-8-29-33"">SPOP</span> lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations.";22610119;2012
3569;IL6;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Overexpression of <span class=""gene"" id=""19240160-12-18-22"">IL-6</span> not only plays an important role in <span class=""disease"" id=""19240160-12-59-74"">prostate cancer</span> progression but also contributes to bicalutamide resistance.";19240160;2009
7184;HSP90B1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
153090;DAB2IP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Analysis of the distribution of these SNPs among 1032 <span class=""disease"" id=""18073375-7-54-69"">prostate cancer</span> patients and 571 control subjects of European descent indicated that one, rs1571801, located in the <span class=""gene"" id=""18073375-7-170-176"">DAB2IP</span> gene, which encodes a novel Ras GTPase-activating protein and putative prostate tumor suppressor, was associated with aggressive <span class=""disease"" id=""18073375-7-306-321"">prostate cancer</span> (one-sided P value = .004).";18073375;2007
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We then hypothesized that patients with <span class=""gene"" id=""18798265-4-40-43"">ERG</span>-positive <span class=""disease"" id=""18798265-4-53-69"">prostate cancers</span> may benefit from epigenetic therapy such as HDAC inhibition (HDACi), especially in combination with antiandrogens.";18798265;2009
545;ATR;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer.;25415046;2015
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;"Together, our results suggest that rs339331 affects <span class=""disease"" id=""24390282-8-52-67"">prostate cancer</span> risk by altering RFX6 expression through a functional interaction with the <span class=""disease"" id=""24390282-8-143-158"">prostate cancer</span> susceptibility gene <span class=""gene"" id=""24390282-8-179-185"">HOXB13</span>.";24390282;2014
8667;EIF3H;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"The data suggest that the expression of <span class=""gene"" id=""14997205-9-40-46"">EIF3S3</span> is increased in <span class=""disease"" id=""14997205-9-63-78"">prostate cancer</span>, and that one of the mechanisms underlying the overexpression is the amplification of the gene.";14997205;2004
60528;ELAC2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We examined polymorphisms within <span class=""gene"" id=""16114055-5-33-38"">ELAC2</span> (S217L, A541T, E622V), MSR1 (P275A, R293X, aIVS5-59c), and RNASEL (E265X, R462Q, D541E) in 150 European-Americans with metastatic prostate cancer and 170 <span class=""disease"" id=""16114055-5-193-208"">prostate cancer</span>-free controls using pyrosequencing assays.";16114055;2006
246778;IL27;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"We also examined the potential of <span class=""gene"" id=""21801027-4-34-39"">IL-27</span> gene delivery by sonoporation to treat and reduce the growth of <span class=""disease"" id=""21801027-4-104-119"">prostate cancer</span> in vivo.";21801027;2012
6581;SLC22A3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Integrative molecular concept modeling of prostate cancer progression.;17173048;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
118429;ANTXR2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
8854;ALDH1A2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"By immunohistochemistry, we observed that <span class=""gene"" id=""16166285-5-42-49"">ALDH1a2</span> was expressed in epithelia from normal prostate but not <span class=""disease"" id=""16166285-5-106-121"">prostate cancer</span>.";16166285;2005
4585;MUC4;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
101669767;SCHLAP1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"The long noncoding RNA <span class=""gene"" id=""24076601-0-23-30"">SChLAP1</span> promotes aggressive <span class=""disease"" id=""24076601-0-51-66"">prostate cancer</span> and antagonizes the SWI/SNF complex.";24076601;2014
90338;ZNF160;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Global analysis of differentially expressed genes in androgen-independent prostate cancer.;17199135;2007
1586;CYP17A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In conclusion, our results suggest that several SNPs along the androgen pathway, especially in CYP19A1 and <span class=""gene"" id=""16424004-8-107-114"">CYP17A1</span>, may influence <span class=""disease"" id=""16424004-8-130-145"">prostate cancer</span> development and progression.";16424004;2006
2690;GHR;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We have used a haplotype-based tagging approach within <span class=""disease"" id=""17220348-2-55-70"">CAncer Prostate</span> Sweden, a large retrospective case-control study of 2,863 cases and 1,737 controls to investigate if genetic variation in the <span class=""gene"" id=""17220348-2-197-200"">GHR</span> gene influences <span class=""disease"" id=""17220348-2-217-232"">prostate cancer</span> risk.";17220348;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"To study the functional importance of <span class=""gene"" id=""16877366-2-38-40"">AR</span> in these tumors, we derived androgen-independent CWR22 <span class=""disease"" id=""16877366-2-96-99"">PCa</span> xenografts in castrated mice and generated a cell line from one of these xenografts (CWR22R3).";16877366;2006
4297;KMT2A;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Our results define a new link between two critical proteins in <span class=""disease"" id=""23704919-10-63-78"">prostate cancer</span> - <span class=""gene"" id=""23704919-10-81-83"">AR</span> and c-Myc - and demonstrate the potential of <span class=""gene"" id=""23704919-10-129-131"">AR</span> and c-Myc-directed therapies to improve <span class=""disease"" id=""23704919-10-172-187"">prostate cancer</span> control.";23704919;2013
4477;MSMB;C0376358;Malignant neoplasm of prostate;0,6;Biomarker;CTD_human;Multiple newly identified loci associated with prostate cancer susceptibility.;18264097;2008
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;GeneticVariation;UNIPROT;Discovery and functional characterization of a neomorphic PTEN mutation.;26504226;2016
10439;OLFM1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
2346;FOLH1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"<span class=""gene"" id=""18247401-1-0-34"">Prostate specific membrane antigen</span> (<span class=""gene"" id=""18247401-1-36-40"">PSMA</span>) expression correlates with <span class=""disease"" id=""18247401-1-69-84"">prostate cancer</span> grade and is increased in hormone-refractory prostate cancer.";18247401;2008
4502;MT2A;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells.;17914565;2007
632;BGLAP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Expression of <span class=""gene"" id=""14666681-0-14-25"">osteocalcin</span> in <span class=""disease"" id=""14666681-0-29-44"">prostate cancer</span> before and after hormonal therapy.";14666681;2004
3490;IGFBP7;C0376358;Malignant neoplasm of prostate;0,39;Therapeutic;CTD_human;"CDNA expression array analysis revealed increased manganese superoxide dismutase (SOD-2) expression in the <span class=""gene"" id=""12592389-2-107-112"">mac25</span>/<span class=""gene"" id=""12592389-2-113-122"">IGFBP-rP1</span>-transfected M12 human <span class=""disease"" id=""12592389-2-145-160"">prostate cancer</span> cell line compared to M12 control cells.";12592389;2003
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"This is the first report on the studies of XPC and <span class=""gene"" id=""17196815-6-51-56"">XRCC1</span> Arg194Trp polymorphisms in <span class=""disease"" id=""17196815-6-84-86"">PC</span>, and our present data suggest that XPC Lys939Gln and the T-A haplotype of <span class=""gene"" id=""17196815-6-161-166"">XRCC1</span> Arg194Trp and Arg399Gln may be risk factors for <span class=""disease"" id=""17196815-6-215-217"">PC</span> in Japanese.";17196815;2007
26298;EHF;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"<span class=""gene"" id=""11742035-0-0-17"">Androgen receptor</span> alterations in <span class=""disease"" id=""11742035-0-33-48"">prostate cancer</span> relapsed during a combined androgen blockade by orchiectomy and bicalutamide.";11742035;2002
11005;SPINK5;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
101669767;SCHLAP1;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"<span class=""gene"" id=""24076601-4-0-7"">SChLAP1</span> levels independently predict poor outcomes, including metastasis and <span class=""disease"" id=""24076601-4-77-92"">prostate cancer</span>-specific mortality.";24076601;2014
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Selenium status also modifies the effect of the mitochondrial superoxide dismutase (<span class=""gene"" id=""19074884-3-84-88"">SOD2</span>) SNP Ala16Val on <span class=""disease"" id=""19074884-3-106-121"">prostate cancer</span> risk.";19074884;2009
27134;TJP3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
53353;LRP1B;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Haplotype analysis of <span class=""gene"" id=""17196815-5-22-27"">XRCC1</span> Arg194Trp (C/T) and Arg399Gln (G/A) revealed that the frequency of the T-A haplotype was significantly higher in <span class=""disease"" id=""17196815-5-141-143"">PC</span> patients.";17196815;2007
3479;IGF1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We hypothesized that the functional polymorphisms in <span class=""gene"" id=""24586243-2-53-58"">IGF-I</span> and IGFBP-3 may be associated with the risk of <span class=""disease"" id=""24586243-2-106-121"">prostate cancer</span> (<span class=""disease"" id=""24586243-2-123-126"">PCa</span>) in the Chinese population.";24586243;2015
1577;CYP3A5;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"<span class=""disease"" id=""18306354-9-0-15"">Prostate cancer</span> patients with <span class=""gene"" id=""18306354-9-30-36"">CYP3A5</span>*3/*3 and KLK -252A &gt; G GG/AG genotypes had decreased OR of 0.70 with 95% CI 0.50-0.98 for high prostate-specific antigen levels at diagnosis.";18306354;2008
316;AOX1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study.;19208208;2010
10397;NDRG1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers.;15341671;2005
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"BET bromodomain-mediated interaction between <span class=""gene"" id=""27223260-0-45-48"">ERG</span> and BRD4 promotes <span class=""disease"" id=""27223260-0-67-82"">prostate cancer</span> cell invasion.";27223260;2016
2947;GSTM3;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Our results indicate that polymorphism in the <span class=""gene"" id=""14968442-8-46-51"">GSTM3</span> may be an important biomarker for <span class=""disease"" id=""14968442-8-86-88"">PC</span> risk, especially in the definition of the genetic risk profile of populations of southern Europe.";14968442;2004
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We determined whether polymorphisms in <span class=""gene"" id=""16406883-2-39-44"">XRCC1</span> and APE1 increase the risk of <span class=""disease"" id=""16406883-2-75-90"">prostate cancer</span>.";16406883;2006
8754;ADAM9;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Oxidative stress induces <span class=""gene"" id=""17018608-0-25-30"">ADAM9</span> protein expression in human <span class=""disease"" id=""17018608-0-59-74"">prostate cancer</span> cells.";17018608;2007
6836;SURF4;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
6041;RNASEL;C0376358;Malignant neoplasm of prostate;0,5;Biomarker;CTD_human;Association between RNASEL, MSR1, and ELAC2 single nucleotide polymorphisms and gene expression in prostate cancer risk.;27318894;2016
1588;CYP19A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Individuals carrying both the <span class=""gene"" id=""16424004-7-30-37"">CYP19A1</span> and KLK3 -252A&gt;G variant alleles had a significantly increased risk for <span class=""disease"" id=""16424004-7-110-125"">prostate cancer</span> (OR, 2.87; 95% CI, 1.10-7.49; P = 0.03).";16424004;2006
3817;KLK2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We examined five variants of the <span class=""gene"" id=""17085659-2-33-37"">KLK2</span> gene to further define its relevance to <span class=""disease"" id=""17085659-2-78-93"">prostate cancer</span> susceptibility and hK2 levels.";17085659;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"To investigate the structural abnormality of the <span class=""gene"" id=""8274409-1-49-66"">androgen receptor</span> (<span class=""gene"" id=""8274409-1-68-70"">AR</span>) in human <span class=""disease"" id=""8274409-1-81-97"">prostate cancers</span>, exons B-H encoding DNA- and hormone-binding domains were examined by single-strand conformation polymorphism analysis of polymerase chain reaction products using originally designed oligoprimers.";8274409;1994
796;CALCA;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;"Since the role of Akt and inhibitors of apoptosis proteins (IAPs) in chemoresistance of advanced <span class=""disease"" id=""16222118-6-97-113"">prostate cancers</span> has been established, we tested the effect of <span class=""gene"" id=""16222118-6-160-162"">CT</span> on phospho-Akt and survivin levels in PC-3M cells.";16222118;2006
9538;EI24;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
4292;MLH1;C0376358;Malignant neoplasm of prostate;0,37;Biomarker;CTD_human;Analysis of candidate genes for prostate cancer.;15583422;2005
3717;JAK2;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as thioredoxin domain containing 5 , tumor necrosis factor receptor superfamily, member 10a , ribosomal protein S19 and <span class=""gene"" id=""17199135-3-215-229"">Janus kinase 2</span> upregulated in AI <span class=""disease"" id=""17199135-3-248-263"">prostate cancer</span>, could play important roles in the transition from AD to AI and could be biomarkers of prognosis.";17199135;2007
4437;MSH3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"To our knowledge this is the first report of the association of <span class=""gene"" id=""18355840-10-64-68"">MSH3</span> gene polymorphisms in <span class=""disease"" id=""18355840-10-91-106"">prostate cancer</span>.";18355840;2008
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"One potential therapeutic target is <span class=""gene"" id=""27223260-3-36-39"">ERG</span>, a transcription factor aberrantly up-regulated in <span class=""disease"" id=""27223260-3-91-94"">PCa</span> due to chromosomal rearrangements between androgen-regulated gene TMPRSS2 and <span class=""gene"" id=""27223260-3-173-176"">ERG</span>.";27223260;2016
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"However, supportive evidence is limited to the effect of HER-2/neu that stimulates <span class=""disease"" id=""19011039-2-83-98"">prostate cancer</span> progression through activation of the <span class=""gene"" id=""19011039-2-137-154"">androgen receptor</span>.";19011039;2009
1105;CHD1;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
1010;CDH12;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.;29662167;2018
1027;CDKN1B;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;p27(Kip1) deficiency promotes prostate carcinogenesis but does not affect the efficacy of retinoids in suppressing the neoplastic process.;20932324;2011
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"These results suggest that polymorphisms of <span class=""gene"" id=""17486273-7-44-49"">XRCC1</span> appear to influence the risk of <span class=""disease"" id=""17486273-7-82-85"">PCa</span> and may modify risks attributable to environmental exposure.";17486273;2007
55256;ADI1;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Immunohistochemistry of prostate tumor tissue microarrays showed that benign regions expressed more <span class=""gene"" id=""17786183-6-100-104"">ADI1</span> than tumors, suggesting a suppressive role for <span class=""gene"" id=""17786183-6-152-156"">ADI1</span> in <span class=""disease"" id=""17786183-6-160-175"">prostate cancer</span>.";17786183;2007
3162;HMOX1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Glycogen synthase kinase 3 regulates cell death and survival signaling in tumor cells under redox stress.;25246272;2015
2952;GSTT1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our results provide suggestive findings for an association with either familial or sporadic <span class=""disease"" id=""17507624-8-92-107"">prostate cancer</span> with polymorphisms in four genes: AKR1C3, HSD17B1, NQO1, and <span class=""gene"" id=""17507624-8-169-174"">GSTT1</span>.";17507624;2007
1557;CYP2C19;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Xenobiotic-metabolizing gene variants, pesticide use, and the risk of prostate cancer.;21716162;2012
632;BGLAP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Compared to <span class=""disease"" id=""14666681-11-12-14"">PC</span> before H/T, the expression of <span class=""gene"" id=""14666681-11-45-47"">OC</span> in HRPC increased in 5 cases (4 of Group A, 1 of Group B), did not change in 3 (2 of Group A, 1 of Group B) and decreased in 12 (4 of Group A, 8 of Group B).";14666681;2004
23411;SIRT1;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"We demonstrated that melatonin significantly inhibited <span class=""gene"" id=""21062352-6-55-60"">Sirt1</span> protein and activity in vitro in multiple human <span class=""disease"" id=""21062352-6-109-112"">PCa</span> cell lines, and melatonin-mediated <span class=""gene"" id=""21062352-6-148-153"">Sirt1</span> inhibition was accompanied with a significant decrease in the proliferative potential of <span class=""disease"" id=""21062352-6-243-246"">PCa</span> cells, but not of normal cells.";21062352;2011
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Palliative treatment for non-organ-confined <span class=""disease"" id=""12237244-3-44-59"">prostate cancer</span> aims to down-regulate the concentration of circulating androgen or to block the transcription activation function of the <span class=""gene"" id=""12237244-3-181-183"">AR</span>.";12237244;2003
11200;CHEK2;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"Mutations in <span class=""gene"" id=""12533788-0-13-18"">CHEK2</span> associated with <span class=""disease"" id=""12533788-0-35-50"">prostate cancer</span> risk.";12533788;2003
4437;MSH3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"These results suggest that the <span class=""gene"" id=""18355840-11-31-35"">MSH3</span> polymorphism may be a risk factor for <span class=""disease"" id=""18355840-11-74-89"">prostate cancer</span>.";18355840;2008
6790;AURKA;C0376358;Malignant neoplasm of prostate;0,39;Biomarker;CTD_human;"Overexpression of the centrosome-associated serine/threonine kinase <span class=""gene"" id=""17898866-1-68-83"">Aurora Kinase A</span> (<span class=""gene"" id=""17898866-1-85-90"">AURKA</span>) has been demonstrated in both advanced <span class=""disease"" id=""17898866-1-131-146"">prostate cancer</span> and high-grade prostatic intraepithelial neoplasia lesions.";17898866;2007
2078;ERG;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We provide further evidence that <span class=""gene"" id=""27223260-8-33-36"">ERG</span>-mediated invasion of <span class=""disease"" id=""27223260-8-58-61"">PCa</span> cells was significantly enhanced by an acetylation-mimicking mutation in <span class=""gene"" id=""27223260-8-135-138"">ERG</span> that augments the <span class=""gene"" id=""27223260-8-157-160"">ERG</span>-BRD4 interaction.";27223260;2016
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"<span class=""gene"" id=""23064873-0-0-6"">HOXB13</span> is a susceptibility gene for <span class=""disease"" id=""23064873-0-36-51"">prostate cancer</span>: results from the International Consortium for Prostate Cancer Genetics (ICPCG).";23064873;2013
2014;EMP3;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Analysis of candidate genes for prostate cancer.;15583422;2005
6019;RLN2;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7.;16434975;2006
3249;HPN;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"We have studied the association of 11 single nucleotide polymorphisms (SNPs) in the <span class=""gene"" id=""16783571-2-84-90"">HEPSIN</span> gene (HPN) with <span class=""disease"" id=""16783571-2-107-122"">prostate cancer</span> in men of European ancestry.";16783571;2007
4437;MSH3;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Mismatch repair gene <span class=""gene"" id=""18355840-0-21-25"">MSH3</span> polymorphism is associated with the risk of sporadic <span class=""disease"" id=""18355840-0-79-94"">prostate cancer</span>.";18355840;2008
7048;TGFBR2;C0376358;Malignant neoplasm of prostate;0,58;Biomarker;CTD_human;"The identification of methylation silencing of <span class=""gene"" id=""18381416-8-47-53"">Tgfbr2</span> in rat <span class=""disease"" id=""18381416-8-61-77"">prostate cancers</span>, in accordance with <span class=""gene"" id=""18381416-8-98-104"">TGFBR2</span> down-regulation in human <span class=""disease"" id=""18381416-8-130-146"">prostate cancers</span>, will enable us to analyze how aberrant methylation is induced in vivo and identify factors that promote and suppress the induction of aberrant methylation.";18381416;2008
2052;EPHX1;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Cytochrome P4501A1 and <span class=""gene"" id=""17919073-0-23-51"">microsomal epoxide hydrolase</span> gene polymorphisms: gene-environment interaction and risk of <span class=""disease"" id=""17919073-0-113-128"">prostate cancer</span>.";17919073;2008
6774;STAT3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Cross-talk between endocrine-disrupting chemicals and cytokine signaling through estrogen receptors.;14975756;2004
4282;MIF;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;"Macrophage migration inhibitory factor (<span class=""gene"" id=""17728788-0-40-43"">MIF</span>) gene polymorphisms are associated with increased <span class=""disease"" id=""17728788-0-94-109"">prostate cancer</span> incidence.";17728788;2008
1543;CYP1A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In our case-control study, we assessed whether <span class=""gene"" id=""17919073-3-47-53"">CYP1A1</span> and mEH susceptibility genotypes, tobacco use, and age factors contribute to <span class=""disease"" id=""17919073-3-131-134"">PCa</span> risk.";17919073;2008
7366;UGT2B15;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"For single polymorphisms, the presence of Y alleles showed a significantly lower risk of <span class=""disease"" id=""16859836-5-89-104"">prostate cancer</span> in comparison with the D/D genotype in <span class=""gene"" id=""16859836-5-144-151"">UGT2B15</span> (odds ratio [OR]=0.41, 95% confidence interval [CI]=1.40-4.28, p=0.0015), and the presence of A2 alleles showed a weak tendency to decrease <span class=""disease"" id=""16859836-5-292-307"">prostate cancer</span> risk in comparison with the A1/A1 genotype in CYP17 (OR=0.69, 95% CI=0.39-1.23, p=0.21).";16859836;2007
6948;TCN2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
472;ATM;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Loss-of-function variants in ATM confer risk of gastric cancer.;26098866;2015
2950;GSTP1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Xenobiotic metabolizing gene variants, dietary heterocyclic amine intake, and risk of prostate cancer.;19223546;2009
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"As a result, androgen ablation or blockade of androgen action through the <span class=""gene"" id=""15389811-2-74-91"">androgen receptor</span> (<span class=""gene"" id=""15389811-2-93-95"">AR</span>) has been the cornerstone of treatment of advanced <span class=""disease"" id=""15389811-2-147-162"">prostate cancer</span>.";15389811;2004
30008;EFEMP2;C0376358;Malignant neoplasm of prostate;0,32;Biomarker;CTD_human;"Our recent microarray analysis suggested downregulation of three fibulins, FBLN1, <span class=""gene"" id=""17929269-6-82-87"">FBLN4</span>, and FBLN5, in <span class=""disease"" id=""17929269-6-103-118"">prostate cancer</span>, while two further ECM genes, SPOCK1 (testican) and TENC (tenascin C), appeared upregulated or unchanged.";17929269;2008
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Identification of a new <span class=""gene"" id=""25091737-0-24-41"">androgen receptor</span> (<span class=""gene"" id=""25091737-0-43-45"">AR</span>) co-regulator BUD31 and related peptides to suppress wild-type and mutated <span class=""gene"" id=""25091737-0-121-123"">AR</span>-mediated <span class=""disease"" id=""25091737-0-133-148"">prostate cancer</span> growth via peptide screening and X-ray structure analysis.";25091737;2014
8202;NCOA3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Polymorphic CAG/CAA repeat length in the <span class=""gene"" id=""11927493-0-41-45"">AIB1</span>/<span class=""gene"" id=""11927493-0-46-51"">SRC-3</span> gene and <span class=""disease"" id=""11927493-0-61-76"">prostate cancer</span> risk: a population-based case-control study.";11927493;2002
5328;PLAU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The Matrigel invasion assay was used to study the influence of <span class=""gene"" id=""16430655-3-63-66"">uPA</span> inhibitors on the invasive potential of <span class=""disease"" id=""16430655-3-107-122"">prostate cancer</span> cell lines.";16430655;2006
8754;ADAM9;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"We found that <span class=""gene"" id=""17018608-5-14-19"">ADAM9</span> mRNA and protein expressions were elevated on exposure of human <span class=""disease"" id=""17018608-5-84-99"">prostate cancer</span> cells to stress conditions such as cell crowding, hypoxia, and hydrogen peroxide.";17018608;2007
367;AR;C0376358;Malignant neoplasm of prostate;0,7;GeneticVariation;UNIPROT;"Selection for <span class=""gene"" id=""10363963-0-14-31"">androgen receptor</span> mutations in <span class=""disease"" id=""10363963-0-45-61"">prostate cancers</span> treated with androgen antagonist.";10363963;1999
55576;STAB2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
3091;HIF1A;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer.;16205110;2006
7422;VEGFA;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab.;20052738;2010
7515;XRCC1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Our results suggest that inherited variability in DNA repair capacity, as reflected by polymorphisms in <span class=""gene"" id=""16406883-10-104-109"">XRCC1</span> and APE1, is a risk factor for <span class=""disease"" id=""16406883-10-141-156"">prostate cancer</span>.";16406883;2006
11009;IL24;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"We now demonstrate that Ad.<span class=""gene"" id=""14678967-3-27-32"">mda-7</span> selectively induces apoptosis in <span class=""disease"" id=""14678967-3-66-81"">prostate cancer</span> cells by promoting mitochondrial dysfunction and reactive oxygen species (ROS) production.";14678967;2004
56916;SMARCAD1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
6414;SELENOP;C0376358;Malignant neoplasm of prostate;0,36;Biomarker;CTD_human;"Alterations in gene expression profiles during <span class=""disease"" id=""12235003-0-47-62"">prostate cancer</span> progression: functional correlations to tumorigenicity and down-regulation of <span class=""gene"" id=""12235003-0-141-156"">selenoprotein-P</span> in mouse and human tumors.";12235003;2002
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Biomarker;CTD_human;"<span class=""gene"" id=""16877366-0-0-17"">Androgen receptor</span> remains critical for cell-cycle progression in androgen-independent CWR22 <span class=""disease"" id=""16877366-0-92-107"">prostate cancer</span> cells.";16877366;2006
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.;16984552;2007
1956;EGFR;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"The aim of this study was to evaluate if the hormonal therapy with BCLT can affect the <span class=""gene"" id=""17914592-2-87-91"">EGFR</span>-targeted therapy using primary cultures obtained from 22 human <span class=""disease"" id=""17914592-2-155-158"">PCa</span> tissues harvested after radical prostatectomy (RP) in patients who received (n=10) BCLT and those that did not (n=12) as neoadjuvant hormone therapy (NHT).";17914592;2007
138474;TAF1L;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;The long tail of oncogenic drivers in prostate cancer.;29610475;2018
5743;PTGS2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Accumulating evidence from epidemiologic studies, chemical carcinogen-induced rodent models and clinical trials indicate that <span class=""gene"" id=""16506214-3-126-131"">COX-2</span> plays a role in human carcinogenesis and is overexpressed in <span class=""disease"" id=""16506214-3-193-208"">prostate cancer</span> tissue.";16506214;2006
6528;SLC5A5;C0376358;Malignant neoplasm of prostate;0,4;Therapeutic;CTD_human;"Adenovirus-mediated expression of <span class=""gene"" id=""14633711-2-34-37"">NIS</span> that is driven by prostate-specific promoters induces generous radioiodine accumulation in <span class=""disease"" id=""14633711-2-129-144"">prostate cancer</span> cells that may be used for therapy with (131)I.";14633711;2004
5328;PLAU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Is urokinase gene 3'-UTR polymorphism associated with prostate cancer?;17192053;2007
2346;FOLH1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity.;21923190;2012
367;AR;C0376358;Malignant neoplasm of prostate;0,7;Therapeutic;CTD_human;"These results reveal a potentially critical function of <span class=""gene"" id=""16877366-8-56-58"">AR</span> in androgen-independent <span class=""disease"" id=""16877366-8-83-86"">PCa</span> that is distinct from its previously described transcriptional or nontranscriptional functions.";16877366;2006
572;BAD;C0376358;Malignant neoplasm of prostate;0,31;Biomarker;CTD_human;"Tissue culture experiments demonstrated that increased <span class=""gene"" id=""19593445-6-55-58"">BAD</span> expression stimulates proliferation of <span class=""disease"" id=""19593445-6-98-113"">prostate cancer</span> cells.";19593445;2009
27232;GNMT;C0376358;Malignant neoplasm of prostate;0,34;Biomarker;CTD_human;"Our findings suggest that <span class=""gene"" id=""17332283-13-26-30"">GNMT</span> is a tumor susceptibility gene for <span class=""disease"" id=""17332283-13-66-81"">prostate cancer</span>.";17332283;2007
10659;CELF2;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;"We validated ZBTB20, <span class=""gene"" id=""28319090-5-21-26"">CELF2</span>, PARD3, AKAP13 and WAC, which were identified by our screens in multiple cancer types, as new tumor suppressor genes in <span class=""disease"" id=""28319090-5-147-162"">prostate cancer</span>.";28319090;2017
5328;PLAU;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Matrigel invasion assays with two specific <span class=""gene"" id=""16430655-5-43-46"">uPA</span> inhibitors, B428 and p-aminobenzamidine, showed that invasion of a <span class=""disease"" id=""16430655-5-114-129"">prostate cancer</span> cell line containing <span class=""gene"" id=""16430655-5-151-154"">uPA</span> gene amplification was inhibited by these small-molecule <span class=""gene"" id=""16430655-5-212-215"">uPA</span> inhibitors, while invasion of prostate cell lines without <span class=""gene"" id=""16430655-5-274-277"">uPA</span> gene amplification were not.";16430655;2006
2048;EPHB2;C0376358;Malignant neoplasm of prostate;0,4;GeneticVariation;UNIPROT;"The <span class=""gene"" id=""16155194-1-4-9"">EphB2</span> gene was recently implicated as a <span class=""disease"" id=""16155194-1-44-59"">prostate cancer</span> (<span class=""disease"" id=""16155194-1-61-63"">PC</span>) tumour suppressor gene, with somatic inactivating mutations occurring in approximately 10% of sporadic tumours.";16155194;2006
1543;CYP1A1;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"T/C polymorphism of <span class=""gene"" id=""17919073-6-20-26"">CYP1A1</span> gene revealed significant association with the tobacco users (p &lt; 0.005) for <span class=""disease"" id=""17919073-6-104-107"">PCa</span> risk.";17919073;2008
6648;SOD2;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"In a low-selenium population, <span class=""gene"" id=""19074884-13-30-34"">SOD2</span>-Ala16+ men homozygous for SEPP1-Ala234 are at an increased risk of <span class=""disease"" id=""19074884-13-102-117"">prostate cancer</span>/aggressive <span class=""disease"" id=""19074884-13-129-144"">prostate cancer</span> especially if ever-smokers, because they are likely to produce more mitochondrial H(2)O(2) that they cannot remove, thereby promoting prostate tumor cell proliferation and migration.";19074884;2009
5728;PTEN;C0376358;Malignant neoplasm of prostate;0,8;Biomarker;CTD_human;"Here we found that PML is frequently co-deleted with <span class=""gene"" id=""29335545-2-53-57"">PTEN</span> in metastatic human <span class=""disease"" id=""29335545-2-78-93"">prostate cancer</span> (<span class=""disease"" id=""29335545-2-95-98"">CaP</span>).";29335545;2018
1387;CREBBP;C0376358;Malignant neoplasm of prostate;0,38;Biomarker;CTD_human;Integrative molecular profiling of routine clinical prostate cancer specimens.;25735316;2016
7432;VIP;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;"Taken together, these results and the presence of kappaB sites on gene promoter of cyclin D1, MMPs and, possibly, E-cadherin suggest that <span class=""gene"" id=""19189304-9-138-141"">VIP</span> may act as a cytokine in an early metastatic stage of human <span class=""disease"" id=""19189304-9-202-217"">prostate cancer</span> through the NF-kappaB/MMPs-RECK/E-cadherin system.";19189304;2009
10040;TOM1L1;C0376358;Malignant neoplasm of prostate;0,3;Biomarker;CTD_human;Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.;17013881;2007
7430;EZR;C0376358;Malignant neoplasm of prostate;0,33;Biomarker;CTD_human;Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression.;17566973;2007
56924;PAK6;C0376358;Malignant neoplasm of prostate;0,35;Biomarker;CTD_human;"Increased <span class=""gene"" id=""18642328-0-10-14"">PAK6</span> expression in <span class=""disease"" id=""18642328-0-29-44"">prostate cancer</span> and identification of <span class=""gene"" id=""18642328-0-67-71"">PAK6</span> associated proteins.";18642328;2008
354;KLK3;C0376358;Malignant neoplasm of prostate;0,4;Biomarker;CTD_human;[Dutasteride in the treatment of hormone refractory prostate cancer].;18500220;2008
10481;HOXB13;C0376358;Malignant neoplasm of prostate;0,6;GeneticVariation;UNIPROT;"These findings demonstrate that the <span class=""gene"" id=""23064873-10-36-42"">HOXB13</span> G84E mutation is present in ~5 % of <span class=""disease"" id=""23064873-10-79-94"">prostate cancer</span> families, predominantly of European descent, and confirm its association with <span class=""disease"" id=""23064873-10-173-188"">prostate cancer</span> risk.";23064873;2013
246778;IL27;C0376358;Malignant neoplasm of prostate;0,34;Therapeutic;CTD_human;"We have examined the potential of a novel cytokine, <span class=""gene"" id=""21801027-1-52-66"">interleukin-27</span> (<span class=""gene"" id=""21801027-1-68-73"">IL-27</span>), for gene therapy of <span class=""disease"" id=""21801027-1-96-111"">prostate cancer</span>.";21801027;2012